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Heart Failure
Heart failure (HF) can be defined as an abnormality of the cardiac structure or function 
leading to failure of the heart to deliver oxygen. For clinically purpose, HF can be defined 
by the inability of the heart to provide sufficient blood flow to meet the body’s need. The 
failure of the pump function of the heart causes a cascade of syndromes, symptoms and 
complaints. They can include shortness of breath, fatigue and fluid retention in the lung 
and/or body.1 
Heart failure is mainly related to people aging but is also a result of lifestyle in 
industrialized countries which results in myocardial infarction, obesity and hypertension, 
the three most important contributors for HF. Because of this increasing elderly population 
and an improved survival after myocardial infarction, the number of patients with HF is 
increasing. In the Netherlands alone, about 130,000 individuals in the adult population 
(1%) are diagnosed with HF and it is estimated that in 2025 195,000 (an increase of 50%) 
people will suffer from HF. The prevalence of HF in individuals older than 70 years is 
between 20 and 30%.2,3
Heart failure is described and characterized as a major health problem and a burden 
of epidemic proportion. It is also associated with a high re-admission and mortality 
rate.4-6 The re-admission rate of patients with HF is between 30-45% within 6 months 
after their initial admission. Forty percent of the patients that are admitted for HF die 
or are re-admitted within 1 year. About 50% of the patients will die within 5 years after 
the diagnosis. Perhaps more important is the strong negative effect that HF has on the 
quality of life.7 Moreover, patients with an HF diagnosis tend to have more depressive 
symptoms than the healthy population, but also in comparison to patients with other 
chronic diseases.8,9 
Figure 1: Costs of HF, related to increasing age. Source: RIVM rapport 260401006/20122
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HF is not only a burden for patients themselves but also for our society. Due to the 
prevalence and high re-admission rates, it is associated with a high cost for healthcare.10,11 
In 2008, 0,5% of the total Dutch healthcare budget was spend on HF (€ 500 million). With 
an estimated prevalence of 195,000 people in 2025 this amount will be about €10 billion.2 
Because HF is mainly an “aging” disease, the costs of HF are growing with an increased 
older age in the population (Figure 1).
Heart failure management and guideline adherence
In order to reduce the re-admission and mortality rates and improve the quality of 
life, many interventions and strategies have been developed over the years. One of them 
is the strong evidence of pharmacological treatment with medication as Angiotensin-
inhibitors, Beta-blockers and Aldosterone-antagonists. Another important intervention 
is the application of disease management programs (DMP’s), a multidisciplinary 
intervention designed to improve quality and cost effectiveness of care of a chronic 
disease, using a systematic approach and employing multiple treatment  modalities.12,13 
Many trials have shown a positive effect of DMP’s on the clinical outcome of HF patients 
as a result of better pharmacological and non-pharmacological care.14,15 Although the key 
characteristics of patients who benefits most of  a DMP intervention remain unclear,16 the 
European Society of Cardiology (ESC) has developed guidelines in which HF DMP’s are 
strongly recommended for all patients with HF. 
Guideline adherence 
HF disease management care is mainly provided in special HF clinics, characterized 
by a strong collaboration between HF nurses and cardiologists in a multidisciplinary 
setting. Nowadays, these HF clinics are considered as “usual care” in several European 
countries.17 HF guidelines clearly indicate that patients with systolic HF should be treated 
with specific medication, targeted to an optimal dosage. Also tailored management of the 
disease should take place (e.g., lifestyle interventions, education, recognizing signs and 
symptoms). Nevertheless, translation of these pharmacological and non-pharmacological 
guidelines into daily practice remains difficult.18-20 A possible solution to improve 
guideline adherence is the introduction of health information technology. 21
 
Health information technology
Health information (and communication) technology (HIT) includes technology 
such as electronical patient records, (EPR), computerized clinical decision support 
systems (CDSS) and telemonitoring. It can support diagnoses, treatment and follow-up 
of patients, based on guidelines and protocols and facilitate adherence to guidelines.22 
HIT provides several new opportunities in healthcare and has been promoted as having 
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tremendous promise in improving the efficiency, cost-effectiveness and quality and safety 
of care.23  However, the use of HIT is not always successful,24, 25 and implementation of 
HIT can easily fail, providing not the success on patient outcome and cost-efficiency as 
expected or promised. Developers and companies often claim cost-effectiveness and an 
improved quality of care by using HIT, but in daily practice many HIT applications do not 
fulfill these claims, leaving healthcare providers disappointed and frustrated. To retrieve 
maximum benefit of this technology it is important to understand why some HIT-
implementations are successful and others are not. A solid implementation and success of 
HIT, depends on many critical factors such as comprehensive training for users, regular 
evaluation and clear and measurable outcomes. The importancy of these factors is often 
underestimated by (future) users and management.26
Computer decision support system (CDSS)
CDSSs are able to provide support and decisions and are mainly used to provide 
software-based healthcare-related advice to assist doctors and nurses in making decisions 
and developing solutions in complex or non-routine situations.27 In healthcare, CDSSs 
are often developed to improve care for patients with chronic conditions, including HF. 
The most important reason for using CDSSs in patients with chronic conditions is the 
general belief that, specifically in this area, higher quality of care and reduction of costs in 
a growing population is achievable. When a CDSS with incorporated guidelines is directly 
linked to an electronical patient record (EPR), data such as medical history, diagnosis, 
laboratory and pharmacological treatment can be “read” by the CDSSs, thus interpreting 
the actual patient data and can give the user advice on how to treat the patient according 
to the guidelines. 
Telemonitoring
Another HIT application is telemonitoring which consist of the remote monitoring of 
patients, including the use of audio, video, and other telecommunications and electronical 
information. For HF it includes the measurement, monitoring collecting and transfer 
of clinical data related to the health status of a patient at home and guides patients in 
taking action in case of deterioration.28 Telemonitoring is considered as a promising new 
intervention for HF patients, and initial studies showed that remote monitoring of HF 
patients reduced hospitalization and mortality rates.28-30 However, other studies did not 
confirm these findings31,32 or even showed, in contradiction, that monitoring patients at a 
distance can lead to an increase of re-admissions and hospital visits. This increase of re-
admissions and hospital visits could be a result of the “need” of patients and healthcare 
providers to resolve a problematic situation, even without the presence of signs and/or 
symptoms.33 At this time it is unclear which patient with HF will benefit most from the 
of use of telemonitoring.34
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Combination of CDSS and telemonitoring in heart failure
Although both HIT applications (CDSS and telemonitoring), can be used to monitor 
patients, optimize medication (at a distance) and provide structural support and 
education,21,35,36 few hospitals have experience using this combination in HF patients. 
There are few studies on “smart” telemonitoring systems, which are able to give advice 
on how to treat patients in case of deterioration of HF.37 This systems can provide advice 
based on incoming data as weight, heart rate and/or blood pressure and answers on digital 
questions about HF symptoms. A much more advanced but also complex solution is the 
combination of telemonitoring with CDSS, incorporated in the patient’s own EPR. Now 
the advice and support are also based on the clinical variables at home such as weight, 
blood pressure and heart rate, together with the actual medication, medical history and 
diagnoses, renal function and physical condition. Besides the input of data from the 
electronic patient record, the data are completed with answers on digital health questions 
about HF symptoms from patients home situation (Figure 2). All data are transferred by 
the internet and the CDSS is able to generate a tailored advice, based on actual patient 
data and the incorporated HF guidelines. An example of the possibilities of this data-flow 
is the titration of a Beta-blocker at the patient’s home, using blood pressure, weight, EKG, 
symptoms, renal function and other medical information. The healthcare provider is now 
able to titrate this Beta-blocker to a higher dose, under safe conditions at home, making a 
visit to the outpatient clinic, solely for titration of medication, unnecessary.
Figure 2: Schematic diagram of dataflow of a telemonitoring system in combination with CDSS functionality 
for patients with heart failure.
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Difficulties in  using CDSS for heart failure care
Despite the existing evidence that using CDSS significantly improved clinical outcomes, 
widespread development, implementation and evaluation in HF clinics is lacking.38,39 
The most important reason for this lack of use seems to be a certain level of mistrust 
and resistance to CDSS. Another reason is a problematic implementation, consolidation 
and evaluation.40-42 These reasons have been described as a barrier for the use of HIT 
and therefore also for using CDSS in HF,43,44 although it is unclear to which extent these 
barriers are present. Another reason for the lack of use is that a full integration of a CDSS 
into a hospital EPR environment is rather difficult. Finally, it is unclear if using a CDSS in 
HF disease management care is cost-effective.
Objectives 
Although there have been major developments in the treatment of patients with HF in 
the last decade, more benefits could be achieved with a better and particularly structural 
application of evidence-based guidelines. A better adherence to guidelines, leading to 
improvement of outcomes, might be partly achieved by using such HITs as CDSSs and 
telemonitoring for patients with HF. It is therefore important to understand why and 
to what extent users in the field of HF experienced barriers in using HIT in their daily 
practice and to know if there is additional effect on patients’ outcomes in using CDSS 
in combination with telemonitoring in HF.  To gain more insight into practical use, 
consequences, advantages and disadvantages of using CDSS and telemonitoring in HF 
care, with a focus on user-related expectations, experiences and barriers, the following 
aims of this thesis are formulated:
1. What are the effects of telemonitoring combined with CDSS on clinical outcomes, 
adherence to guidelines, cost effectiveness and quality of life.
2. To explore the expectations, experiences, barriers and usability of telemonitoring 
and CDSS, used by HF nurses and cardiologists in the treatment of HF patients. 
3. To gain insight into different HF disease management models (one of which is 
CDSS-driven) and explore differences in and effects of  prescriber adherence of 
medication.
Study populations
Data for this thesis was collected from Dutch HF clinics, concerning both HF patients 
and HF nurses and cardiologists. To explore differences in prescriber adherence we used 
data from the COACH study,14 DEAL study45 and the HF outpatient clinic of the Martini 
Hospital Groningen, Netherlands.
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Outline of this thesis
In Chapter 2, a case study on the value of the use of telemonitoring, integrated into 
an ICT- guided disease management system in direct patient care is described. The 
outcome and expectations of the health information technology used in this case 
report was the rationale to  design the INTOUCH study,46 a multicentre randomized 
trial in the Netherlands (Chapter 3). This study was designed to investigate the effects of 
telemonitoring in addition to an ICT-guided disease management system, on the quality 
and efficiency of care of patients after worsening HF, focusing on clinical outcomes, 
adherence to guidelines, cost effectiveness and quality of life. A substantial part of this 
ICT-guided disease management system, was CDSS-driven, especially with a focus on 
prescription of HF medication. 
In Chapter 4, we describe and evaluate the primary outcome of the INTOUCH study, a 
composite endpoint of mortality, HF re-admission and quality of life. Beside this primary 
outcome we focus on the cost-efficiency of telemonitoring and CDSS. 
In Chapters 5, 6 and 7, we provide insights into the actual use of telemonitoring in 
Dutch HF outpatient clinics and focus on user-related expectations versus experiences of 
using telemonitoring. We evaluate the practical usability and acceptability of the CDSS 
used in the INTOUCH study and explore type and number of perceived barriers of HF 
nurses and cardiologists to using CDSS in the treatment of HF patients. 
In Chapter 8, we offer insight into the effect of three different HF disease management 
models on prescriber adherence of medication. One model focuses solely on education 
and counseling (COACH), while the other two focus on optimization of medication 
(DEAL and Martini Hospital). One of these models tried to achieve a better prescriber 
adherence with the help of a CDSS, the other model with the help of a dedicated physician. 
In Chapter 9 of this thesis we will discuss and reflect the major findings of this thesis and 
give recommendations for clinical practice and future perspectives in relation to the use 
of telemonitoring and CDSS in HF and their contributions to better guideline adherence.
16 Chapter 1
References 
1. Authors/Task Force Members, McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein 
K, Falk V, Filippatos G, Fonseca C, et al. ESC guidelines for the diagnosis and treatment of acute and chronic 
heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the 
european society of cardiology. developed in collaboration with the heart failure association (HFA) of the ESC. 
Eur Heart J 2012 May 19.
2. Engelfriet PM, Hoogenveen RT, Poos MJJC, Blokstra A, van Baal PHM, Verschuren WMM. Heart failure: 
Epidemiology, risk factors and future. 2012;RIVM Rapport 260401006.
3. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007 Sep;93(9):1137-46.
4. Gwadry-Sridhar FH, Flintoft V, Lee DS, Lee H, Guyatt GH. A systematic review and meta-analysis of stud-
ies comparing readmission rates and mortality rates in patients with heart failure. Arch Intern Med 2004 Nov 
22;164(21):2315-20.
5. Krumholz HM, Parent EM, Tu N, Vaccarino V, Wang Y, Radford MJ, Hennen J. Readmission after hospitali-
zation for congestive heart failure among medicare beneficiaries. Arch Intern Med 1997 Jan 13;157(1):99-104.
6. Aranda JM,Jr, Johnson JW, Conti JB. Current trends in heart failure readmission rates: Analysis of medicare 
data. Clin Cardiol 2009 Jan;32(1):47-52.
7. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, Haass M. Health related quality of 
life in patients with congestive heart failure: Comparison with other chronic diseases and relation to functional 
variables. Heart 2002 Mar;87(3):235-41.
8. Lesman-Leegte I, Jaarsma T, Sanderman R, Linssen G, van Veldhuisen DJ. Depressive symptoms are promi-
nent among elderly hospitalised heart failure patients. Eur J Heart Fail 2006 Oct;8(6):634-40.
9. Lesman-Leegte I, Jaarsma T, Coyne JC, Hillege HL, Van Veldhuisen DJ, Sanderman R. Quality of life and 
depressive symptoms in the elderly: A comparison between patients with heart failure and age- and gender-
matched community controls. J Card Fail 2009 Feb;15(1):17-23.
10. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail 2001 Jun;3(3):283-
91.
11. Lee WC, Chavez YE, Baker T, Luce BR. Economic burden of heart failure: A summary of recent literature. 
Heart Lung 2004 Nov-Dec;33(6):362-71.
12. Takeda A, Taylor SJ, Taylor RS, Khan F, Krum H, Underwood M. Clinical service organisation for heart 
failure. Cochrane Database Syst Rev 2012 Sep 12;9:CD002752.
13. Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S. Evidence-based disease management. JAMA 1997 
Nov 26;278(20):1687-92.
14. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, Sanderman R, Hoes 
AW, van Gilst WH, Lok DJ, et al. Effect of moderate or intensive disease management program on outcome in 
patients with heart failure: Coordinating study evaluating outcomes of advising and counseling in heart failure 
(COACH). Arch Intern Med 2008 Feb 11;168(3):316-24.
15. de la Porte PW, Lok DJ, van Veldhuisen DJ, van Wijngaarden J, Cornel JH, Zuithoff NP, Badings E, Hoes AW. 
Added value of a physician-and-nurse-directed heart failure clinic: Results from the deventer-alkmaar heart 
failure study. Heart 2007 Jul;93(7):819-25.
17Introduction
16. Savard LA, Thompson DR, Clark AM. A meta-review of evidence on heart failure disease management 
programs: The challenges of describing and synthesizing evidence on complex interventions. Trials 2011 Aug 
16;12:194.
17. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease 
management programs in heart failure. Am J Med 2001 Apr 1;110(5):378-84.
18. Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, Tavazzi L, 
Poole-Wilson P, Le Pen C. Adherence to guidelines is a predictor of outcome in chronic heart failure: The 
MAHLER survey. Eur Heart J 2005 Aug;26(16):1653-9.
19. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart 
D, Metra M, et al. EURObservational research programme: The heart failure pilot survey (ESC-HF pilot). Eur J 
Heart Fail 2010 Oct;12(10):1076-84.
20. de Groote P, Isnard R, Clerson P, Jondeau G, Galinier M, Assyag P, Demil N, Ducardonnet A, Thebaut 
JF, Komajda M. Improvement in the management of chronic heart failure since the publication of the up-
dated guidelines of the european society of cardiology. the impact-reco programme. Eur J Heart Fail 2009 
Jan;11(1):85-91.
21. de Vries AE, van der Wal MH, Bedijn W, de Jong RM, van Dijk RB, Hillege HL, Jaarsma T. Follow-up and 
treatment of an instable patient with heart failure using telemonitoring and a computerised disease manage-
ment system: A case report. Eur J Cardiovasc Nurs 2011 May 4.
22. Craig JC, Irwig LM, Stockler MR. Evidence-based medicine: Useful tools for decision making. Med J Aust 
2001 Mar 5;174(5):248-53.
23. Buntin MB, Burke MF, Hoaglin MC, Blumenthal D. The benefits of health information technology: A review 
of the recent literature shows predominantly positive results. Health Aff (Millwood) 2011 Mar;30(3):464-71.
24. Bates DW, Kuperman GJ, Wang S, Gandhi T, Kittler A, Volk L, Spurr C, Khorasani R, Tanasijevic M, Mid-
dleton B. Ten commandments for effective clinical decision support: Making the practice of evidence-based 
medicine a reality. J Am Med Inform Assoc 2003 Nov-Dec;10(6):523-30.
25. Trafton J, Martins S, Michel M, Lewis E, Wang D, Combs A, Scates N, Tu S, Goldstein MK. Evaluation of the 
acceptability and usability of a decision support system to encourage safe and effective use of opioid therapy for 
chronic, noncancer pain by primary care providers. Pain Med 2010 Apr;11(4):575-85.
26. Rogers EM. Diffusion of preventive innovations. Addict Behav 2002 Nov-Dec;27(6):989-93.
27. Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ, Beyene J, Sam J, Haynes RB. Ef-
fects of computerized clinical decision support systems on practitioner performance and patient outcomes: A 
systematic review. JAMA 2005 Mar 9;293(10):1223-38.
28. Riley JP, Cowie MR. Telemonitoring in heart failure. Heart 2009 Dec;95(23):1964-8.
29. Klersy C, De Silvestri A, Gabutti G, Regoli F, Auricchio A. A meta-analysis of remote monitoring of heart 
failure patients. J Am Coll Cardiol 2009 Oct 27;54(18):1683-94.
30. Inglis SC, Clark RA, Cleland JG, Cochrane Systematic Review Team. Telemonitoring in patients with heart 
failure. N Engl J Med 2011 Mar 17;364(11):1078,9; author reply 1079-80.
31. Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Bohm M, Boll H, Baumann G, Honold M, Koehler 
K, et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients 
with chronic heart failure: The telemedical interventional monitoring in heart failure study. Circulation 2011 
May 3;123(17):1873-80.
18 Chapter 1
32. Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, Phillips CO, Hodshon BV, Cooper LS, 
Krumholz HM. Telemonitoring in patients with heart failure. N Engl J Med 2010 Dec 9;363(24):2301-9.
33. van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G, Kautzner J, Aguilera RM, 
Lunati M, Yu CM, et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients 
with heart failure. Circulation 2011 Oct 18;124(16):1719-26.
34. Wootton R. Twenty years of telemedicine in chronic disease management--an evidence synthesis. J Telemed 
Telecare 2012 Jun;18(4):211-20.
35. van Wyk JT, van Wijk MA, Sturkenboom MC, Mosseveld M, Moorman PW, van der Lei J. Electronic alerts 
versus on-demand decision support to improve dyslipidemia treatment: A cluster randomized controlled trial. 
Circulation 2008 Jan 22;117(3):371-8.
36. Antonicelli R, Mazzanti I, Abbatecola AM, Parati G. Impact of home patient telemonitoring on use of beta-
blockers in congestive heart failure. Drugs Aging 2010 Oct 1;27(10):801-5.
37. Ramaekers BL, Janssen-Boyne JJ, Gorgels AP, Vrijhoef HJ. Adherence among telemonitored patients with 
heart failure to pharmacological and nonpharmacological recommendations. Telemed J E Health 2009 Jul-
Aug;15(6):517-24.
38. Kaplan B. Evaluating informatics applications--clinical decision support systems literature review. Int J Med 
Inform 2001 Nov;64(1):15-37.
39. Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and clinical decision sup-
port systems on medication safety: A systematic review. Arch Intern Med 2003 Jun 23;163(12):1409-16.
40. Varonen H, Kortteisto T, Kaila M, EBMeDS Study Group. What may help or hinder the implementation 
of computerized decision support systems (CDSSs): A focus group study with physicians. Fam Pract 2008 
Jun;25(3):162-7.
41. Short D, Frischer M, Bashford J. Barriers to the adoption of computerised decision support systems in gen-
eral practice consultations: A qualitative study of GPs’ perspectives. Int J Med Inform 2004 May;73(4):357-62.
42. Zheng K, Padman R, Johnson MP, Diamond HS. Understanding technology adoption in clinical care: Clini-
cian adoption behavior of a point-of-care reminder system. Int J Med Inform 2005 Aug;74(7-8):535-43.
43. Solberg LI. Guideline implementation: Why don’t we do it? Am Fam Physician 2002 Jan 15;65(2):176, 181-2.
44. Rousseau N, McColl E, Newton J, Grimshaw J, Eccles M. Practice based, longitudinal, qualitative interview 
study of computerised evidence based guidelines in primary care. BMJ 2003 Feb 8;326(7384):314.
45. Bruggink-Andre de la Porte PW, Lok DJ, van Wijngaarden J, Cornel JH, Pruijsers-Lamers D, van Veldhuisen 
DJ, Hoes AW. Heart failure programmes in countries with a primary care-based health care system. are addi-
tional trials necessary? design of the DEAL-HF study. Eur J Heart Fail 2005 Aug;7(5):910-20.
46. de Vries AE, de Jong RM, van der Wal MH, Jaarsma T, van Dijk RB, Hillege HL. The value of INnovative 
ICT guided disease management combined with telemonitoring in OUtpatient clinics for chronic heart failure 
patients. design and methodology of the IN TOUCH study: A multicenter randomised trial. BMC Health Serv 
Res 2011 Jul 13;11:167.
Chapter 2
ICT-guided disease management and 
telemonitoring in heart failure
Case report
Arjen E. de Vries, Martje H. L. van der Wal, Richard M. de Jong, 
Rene B. van Dijk, Hans L. Hillege, Tiny Jaarsma
Eur J Cardiovasc Nurs. 2012 Dec;11(4):432-8
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Abstract
In the last decades, the introduction of  information and communication technology in 
healthcare promised an improved quality of care while reducing work load, and resulting 
in a more cost effective system. This might be realised by the use of computer guided 
decision support systems and telemedicine. This case study describes the potential of a 
computerised disease management system in combination with telemonitoring in the 
context of heart failure. With the help of a computer guided decision support systems 
and telemedicine we were able to prevent at least two readmissions for heart failure in 
a period of 10 months and we gained more insight in patients’ behavior with regard to 
compliance with the heart failure regimen at home. Frequent contact at distance and 
the on-line availability of physiological and biological measurements at home facilitated 
patient tailored education and help the patient to react adequately to symptoms of 
deterioration. Additionally, uptitration of medication was performed without seeing the 
patient in the outpatient clinic.
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Introduction
Heart failure (HF) is not only associated with very high mortality, morbidity and re-
admission rate but also with high direct and indirect costs.1 Readmission rates usually 
vary between 25% and 50% within 6 months after the first hospitalization for HF and 
a substantial part of these readmissions occur in the first month after discharge.2-4 
Randomized studies and recent meta analyses suggest that disease management programs 
and telemonitoring can reduce readmissions for HF or cardiovascular disease by 30%5-9 
and significantly decrease mortality.10,11 
A disease management program (DMP) is defined as a multidisciplinary intervention, 
designed to improve quality and cost effectiveness of care of a chronic disease, using 
a systematic approach and employing multiple treatment modalities.12 DMP following 
treatment and lifestyle instructions as recommended by the European Society of 
Cardiology guidelines,1 showed to be more effective in improving clinical outcome than 
other programs.13 There is also evidence that remote monitoring of HF patients reduces 
readmission and mortality.11 With this remote monitoring it is possible to recognize 
early deterioration and therefore avoid unnecessary readmission, but it can also be used 
for a more efficient up-titration of HF medication (e.g. ,angiotensin converting enzyme 
(ACE) inhibitors or beta-blockers). Although studies ar not inconclusive, there is a strong 
indication that DMP’s and telemonitoring are effective, however, these components are 
not widely implemented. An important issue is not only how to successfully implement 
DMP and telemonitoring, but moreover how to identify the patient that could benefit 
from these devices. 
This case study describes a patient with severe chronic HF, who was frequently 
hospitalized for HF.  Treatment of this patient is guided by a computerised DMP program 
structured by the current guidelines with integrated remote monitoring facilities. The 
potential use, consequences and experienced benefits and barriers of this system will be 
discussed.
Case report
A 50-year old man visited the cardiologist in August 2004 because of a decrease in exercise 
capacity and shortness of breath during exercise. Echocardiography showed a large 
anterior wall defect and a left ventricular ejection fraction (LVEF) of 29%. It subsequently 
appeared that he had suffered from a large myocardial infarction in March 2004. He was 
not diagnosed at that moment, due to a lack of symptoms. He was diagnosed with HF, 
New York Heart Association class (NYHA) class II-III, and referred to the outpatient 
HF clinic for optimizing medication, education and self management. In May 2005 he 
received an implantable cardioverter defibrillator and in June 2006 he was on optimal HF 
medication and discharged from the outpatient HF clinic in a stable condition (NYHA 
class I; with a LVEF of 32%). Follow-up was performed by the cardiologist.
22 Chapter 2
In March 2008, he was readmitted to the hospital with acute HF and treated with i.v. 
diuretics and dobutamine. The most likely explanation for this deterioration of HF was 
a holiday in Greece where the patient had a high salt and fluid intake. He was in the 
hospital for sixteen days. 
After discharge he was readmitted five times within six months, once with dehydration, 
the other readmissions for worsening HF. These frequent instabilities were caused by a 
combination of factors including lack of compliance, symptoms of depression and delay 
in seeking care when symptoms of deterioration occurred. 
The patient was referred to the outpatient HF clinic again, but his situation and frequent 
readmissions caused an unstable period whereby time after time, he was readmitted 
to the hospital before he could visit the HF clinic. His last hospitalisation was critical; 
because of chronic hypotension he suffered of hypoperfusion of the brain, leading to 
cognitive dysfunction, central cyanoses, and permanent peripheral edema and ascitis. 
During this hospitalisation, his HF medication was reduced to minimal dosages due to 
symptomatic hypotension and renal dysfunction. He was diagnosed with terminal end 
stage HF, (NYHA class IV; LVEF 22%). During hospitalisation, the patient was stabilised 
and because of the frequent readmissions it was decided to monitor him immediately 
after discharge with telemonitoring integrated in a computerised DMP. With this system, 
described further below, we tried to remain a stable situation. The main purpose was 
to monitor weight and intervene early in case of deterioration, thereby trying to avoid 
readmission. Another purpose was to try to slowly up-titrate his HF medication at 
home. At discharge, the patient was classified as NYHA class III. Medication and clinical 
parameters at discharge and after 10 months are shown in Table 1.
Table 1: medication and parameters at discharge and at 10 months
At discharge At 10 months
Medication
   Carvedilol 3,125 mg twice a day 12,5 mg twice a day
   Ramipril 1,25 mg once a day 5 mg twice a day
   Hydrochlorothiazide 12,5 mg once a day 12,5 mg once a day
   Spironolactone 25 mg once a day 25 mg once a day
   Furosemide 40 mg twice a day 40 mg twice a day
   Acenocoumarol conform protocol conform protocol
   Simvastatine 40 mg once a day 40 mg once a day
Weight 85.3 kilogram 84.7 kilogram
Bloodpressure 95/45 mmHg 105/48 mmHg
Urea 6,2 mmol/l 5,7 mmol/l
Creatinine 146 µmol/l 122 µmol/l
Heart rate 72 bpm 64 bpm
23Case study
Description of the system
The system consists of a computerised disease management system located in the 
hospital, together with telemonitoring devices used in the home-setting of the patient 
measuring weight and blood pressure including a health monitor. With the health 
monitor, an interactive dialog with the patient is possible. In case of a deviation of 
predefined ranges of weight and blood pressure, the health monitor will lead the patient 
systematically through a sequential list of questions on the presence of HF symptoms 
(Table 2).  All data are send to the system in the hospital.  With these data, it is possible to 
adjust therapy to optimal levels, using integrated HF guidelines. 
For the up-titration of medication, the system advises based on renal function, blood 
pressure and heart rate. If the vital signs are within predefined ranges, an advice for the 
HF nurse is generated to further up-titrate the medication to optimal doses according to 
the HF guidelines. At the same time, the system will advise to give specific education on 
HF and the HF regimen to the patient. 
In case of serious deviated measures at home, together with HF symptoms, the HF 
nurse will be informed automatically by short message service (SMS) and E-mail. In case 
of a slight deviation of the predefined ranges without an increase of HF symptoms, the 
patient receives an automatic generated advice to take action (for example advice about 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































prescribed fluid restriction and the use of sodium). Advice about medication, derived 
from the computerised disease management system, after judgment of renal function, 
blood pressure and/or heart rate, is only given after consultation of the HF nurse. A major 
difference between a stand-alone telemonitoring system and the system described in this 
case study, is that the telemonitoring function is integrated into a computerised DMS. 
It is attached to an incorporated electronic health record and is possible to interpretate 
and give advice about type and dose of medication, laboratory tests and supplementary 
examinations. The system is also able to generate alarms for missing data and/or technical 
problems.
Follow up of the patient after discharge
The patient was discharged with the described system. In addition, the patient visited the 
HF clinic regularly for comprehensive tailored education on self-care behavior, sodium 
and fluid restriction and exercise. Psychosocial care for his depressive feelings and his fear 
for readmission was also an important issue during these visits. 
The scheduled visits for follow-up and optimisation of medication were replaced by 
remote monitor devices at home. The patients’ weight at discharge was 85 kg with an 
allowed variability of 2 kilogram. When his weight exceeded 87 kg, the health monitor 
generated a set of questions about the presence of HF symptoms. When the patient reported 
symptoms of dyspnea, sleep disorder and swollen ankles, the health monitor answered 
that the HF nurse would contact the patient by telephone within two hours. At the same 
time, an alarm was generated on a mobile phone, whereupon the HF nurse logged in 
into the computerised disease management system to evaluate the alarm. Based on up to 
date available data from the electronic health record (renal function) and telemonitoring 
devices (blood pressure and weight), the system generated the advice to double the dose 
of diuretics for a period of 3 days, monitor weight and blood pressure more intensively 
and to contact the patient the next day by telephone (Table 2). During the first initiated 
contact, within 2 hours after the alarm, the HF nurse assessed patients’ compliance and 
provided additional information on how to manage fluid intake and sodium restricted 
diet. As a result of these interventions, the weight of the patient reduced to 85 kilogram 
after 2 days, together with a decrease of dyspnea and ankle swelling. Two months later, 
there was again an increase of weight in combination with HF symptoms, with the same 
successful anticipated treatment with temporarily increase of diuretics. 
As shown in table 2, the system is able to generate alarms for weight, blood pressure 
and HF symptoms as reported by the patient in dialog with the health monitor. Beside 
correcting two periods of decompensation, it was possible with frequent control of blood 
pressure, heart rate and weight, provided by the telemonitoring devices, to up-titrate the 
HF medication in the home situation under safe conditions. The electrocardiogram and 
laboratory tests, needed for the up-titration, were performed in the outpatient clinic, 
without direct contact with cardiologist or HF nurse. The patient in this case did not visit 
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the outpatient clinic for medication consults, but the titration of the beta-blocker took 
place at the patients’ home, with the help of the telemonitoring system together with ECG 
and laboratory tests.  
Discussion 
This case report concerns a patient with severe HF, treated with a computerised DMP 
with integrated telemonitoring after a period of frequent readmissions. With this system, 
it was possible to monitor this patient at home and give advice about taking extra 
diuretics and lowering fluid intake in an early phase of deterioration. The patient in our 
case reached a stable phase of HF. Due to the described system, we were able to prevent 
at least two readmissions for HF in a period of 10 months and we gained more insight in 
patients’ behavior with regard to compliance with the HF regimen at home. Frequently 
contact by telephone gave us the opportunity to educate the patient and help him to react 
properly to symptoms of deterioration.  
With this type of system it is possible to provide a safe shifting of tasks from the 
cardiologist to the HF nurses. Even so, we belief that a reduction in costs can be achieved 
by a decrease of readmission rate and a more efficient up titration of medication at the 
patients’ home without visits to the HF clinic. In case of updated therapeutic guidelines, 
changes can be incorporated easily into the computerised system and will give the 
healthcare provider directly advice according the latest consensus texts. 
The awareness of devices at home and the knowledge that deviating or missing data 
provide alarms, had a positive effect on the compliance of the patient. In this case study, 
the patient integrated the daily measurement into his normal daily life without problems. 
Many researchers have described the benefits of telemonitoring for HF patients in 
general,10,14,15 however there are also disadvantages of this kind of remote monitoring 
systems. One often reported problem from a patient’s point of view is the permanent 
presence of “the disease” in the home environment due to the existing devices and daily 
required measurements. The feeling that the patient cannot leave home without informing 
the hospital, can also be experienced negatively. 
The combination of a computerised disease management system with intergraded 
telemonitoring is rather new in medical care and certainly not commonly used in daily 
practice. A potential indolence of patient and healthcare provider in leaving the recognition 
of signs of deterioration only by the computer can give a false sense of security and should 
be recognized In addition, healthcare providers might feel reluctant to use these systems, 
encounter difficulties to work with systems which will “think for them”, in contrast to, for 
example air traffic personnal.16  An experienced loss of autonomy can be an important 
factor for resistance of implementation of such systems. Nevertheless, decision support as 
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a substantial component of a computerised disease management program can be of great 
help to apply guidelines.17,18
Despite the expected opportunities of integrated and combined systems, there is a great 
lack of experience and evidence for widespread implementation. Therefore it is advisable 
to further investigate the effects of this type of intergraded systems. It is questionable 
whether the use of telemonitoring devices is preferable for all HF patients and whether 
all visits to the HF clinic can be replaced by remote monitoring. 
In our opinion, telemonitoring, driven by a computerised DMS, can be a useful 
supplement to face-to-face contact and a tool to prevent HF related readmissions. It can 
also be helpful in more efficient uptitration of  HF medication, without contact at the HF 
clinic. However, because of the impact and intrusion in the patient’s daily life, the use of 
telemonitoring must be considered. In this case the patient visits the outpatient clinic for 
a electrocardiogram and laboratory tests, needed for the up-titration of his medication. 
In the further development of this model we discovered that these test can perform safe 
in the own home environment. The challenge, and at the same time the difficulty, is to 
identify the right category of patients for this kind of monitoring. 
It seems recommendable to start with patients in an unstable phase of HF, just after 
an admission for HF, since many expensive readmissions occur shortly after a HF 
hospitalisation.4 Therefore, this first vulnerable period seems most appropriate to observe 
signs of early deterioration in the home situation. It is also possible to use the  system to 
up titrate medication efficiently at home in stable HF patients.19
In this case there was no special focus on cost effectiveness, but to examine whether 
this developed combined model indeed leads to a lower readmission rate for HF, lower 
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Although the value of telemonitoring in heart failure patients is increasingly studied, 
little is known about the value of the separate components of telehealth: ICT guided 
disease management and telemonitoring. The aim of this study is to investigate the value 
of telemonitoring added to ICT guided disease management (DM) on the quality and 
efficiency of care in patients with chronic heart failure (CHF) after a hospitalisation.
Methods/Design
The study is divided in two arms; a control arm (DM) and an intervention arm 
(DM+TM) in 10 hospitals in the Netherlands. In total 220 patients will be included after 
worsening of CHF (DM: N=90, DM+TM: N=130). Total follow-up will be 9 months. 
Data will be collected at inclusion and then after 2 weeks, 4.5 and 9 months. The primary 
endpoint of this study is a composite score of: 1: death from any cause during the follow-
up of the study, 2: first readmission for HF and 3: change in quality of life compared to 
baseline, assessed by the Minnesota Living with Heart failure Questionnaire. The study 
has started in December 2009 and results are expected in 2012.
Discussion
The IN TOUCH study is the first to investigate the effect of telemonitoring on top of 
ICT guided DM on the quality and efficiency of care in patients with worsening HF and 
will use a composite score as its primary endpoint. 
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Background
Heart failure (HF) is the most common hospital discharge diagnosis in elderly patients.1 
Between the age of 70 and 80 years the incidence of HF is 10 to 20%. HF is associated 
with high mortality and morbidity, readmission rates and costs.1 The readmission rates 
vary between 25% and 50% within 6 months after the first hospitalisation for HF, with a 
higher readmission rate within the first month after discharge.2,3 The costs related to HF 
contribute to 1-2% of all healthcare expenditures and are mainly the result of hospital 
stay.4-6 Because of an increasing shortage of resources, HF is a major public health problem 
and therefore, a more effective and efficient organisation of care for HF patients needs to 
be reconsidered. A first step in organising treatment and care for patients with chronic 
HF more efficiently, was the implementation of specialised outpatient HF clinics. In the 
recent European Society of Cardiology (ESC) guidelines, HF management programmes 
are strongly recommended for all patients with HF1 and HF clinics are considered as ‘usual 
care’ in several European countries.7 A widely used way to implement HF management is 
the use of specific disease management (DM) programs.
DM can be defined as an intervention, designed to manage a chronic disease and to 
reduce hospital readmissions, using a systematic approach to care and potentially 
employing multiple treatment modalities.8 Control and cost effectiveness are substantial 
components of a DM program. Randomised studies suggest that DM programs can 
reduce readmissions for HF or cardiovascular disease with 30% 7, 9,10 and significantly 
decrease mortality rates.11 Yu et al 12 described that DM for HF patients, as recommended 
by the ESC guidelines,1 are effective in reducing hospital readmissions and mortality 
rate.13 However, inconsistent findings for readmission and mortality rates have been 
found, probably due to the variety of components and practical applications of the DM 
programs.
We recently reported results of the COACH study, a study on the effect of a nurse led 
DM program on clinical outcome,14 in which the positive effects of a DM program on 
readmission were not confirmed, although there was a trend to a reduction of mortality 
in the intervention groups. The INH study 15 on the effect of DM in HF, showed that a 
DM program compared to usual care could reduce mortality but not hospitalisation rates. 
Important components of this program were patient education, optimisation of medical 
therapy, psychosocial support and an easy access to healthcare. An important aspect for 
the treatment of HF patients is the prescription of HF related medication at an optimal 
dose i.e. ACE-inhibitors, beta-blockers, and aldosteronantagonists. The up titration to 
optimal dosage is an aspect that often takes place at a HF outpatient clinic. However, data 
from the Euro Heart Failure Survey showed us that guideline adherence for HF medication 
although improving still is not optimal.16 In the IMPROVE study, dedicated HF clinics 
were associated with greater use of cardiac resynchronisation therapy and a better HF 
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education, but not with better guideline adherence to medication.17 Health information 
technology, integrated into a DM program might facilitate adherence to guidelines of 
health professionals.18 With new information and communication technology (ICT), 
healthcare providers can be supported in the diagnosis, treatment and follow up of 
HF patients by expert computerised systems, based on guidelines and protocols.19 
These systems can be used to optimise medication according to guidelines and provide 
structural support and education.20 We were the first to report promising findings on 
ICT guided DM in terms of higher doses of recommended HF medication and lower 
readmissions.21,22 Another promising ICT tool is telemonitoring. Telemonitoring is often 
used to monitor patients at home and guide patients to take action in case of deterioration, 
but it also can be used to up-titrate medication according to guidelines at distance.23 
There is support that remote monitoring of patients with HF can reduce hospitalisation 
and mortality rates,24,25 however results on clinical outcome and efficacy are inconclusive 
and limited.26-28 There are also recent study’s that where not successful in their primary 
endpoints.29,30 Furthermore, cost-effectiveness of these systems has not been thoroughly 
evaluated. It can be concluded that the overall effects of telemonitoring are inconclusive. 
To summarise, due to a growing population of patients with HF and an expected shortage 
of healthcare providers in the near future, there is a need to seek to more cost effective 
Table 1: In and exclusion criteria IN TOUCH
Inclusion criteria
Worsening HF defined as signs of fluid retention (peripheral oedema / congestion)
needing an increase of the dose of diuretics (i.v. or oral)
Evidence for structural underlying heart disease
Documented reduced left ventricular ejection fraction (LVEF) ≤45%
18 years of age 
Patients have to be able to understand content of and willing to provide informed
consent.
Exclusion criteria
History of myocardial infarction in the previous month
Life expectation less than 1 year 
Undergone cardiac invasive intervention within the last 6 months (PCI, CABG, HTX, valve replacement, 
CRT implantation)
A planned procedure for PCI, CABG, HTX, CRT implantation  or valve replacement in the following 3 
months
Evaluation for heart transplantation prior to or during the study
Weight more than 200 kilogram
The use of telemonitoring devices at home
Haemodialysis
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and efficient ways of providing optimal care for HF patients, including a better adherence 
to guidelines. ICT guided DM tools in combination with telemonitoring could be of 
important value.31,32 At the same time there is substantional data that the adaptation 
and implementation of those systems is lacking.33 The experiences with such a system 
however are fragmented. User resistance is described as a major obstacle in the adoption 
of these computerised tools. More insight in user resistance and experienced barriers in 
using ICT guided DM tools is needed to successfully implementing such tools.34
The IN TOUCH study will investigate the effect of telemonitoring in addition to an 
ICT guided DM system on the quality and efficiency of care for patients after worsening 
HF. This is the first study investigating a combination of two newly developed ICT 
interventions in a group of chronic HF patients on clinical outcome, adherence to 
guidelines, cost effectiveness and quality of life.
This study will add important information to other telemonitoring studies because of its 
strong commitment to ICT guided DM, the chosen composite endpoint, a strong focus 
on cost-effectiveness and the investigation of the influence of user aspects as resistance 
and barriers that accompany the use of modern healthcare related ICT tools.
Methods/Design
Study hypothesis
Telemonitoring added to ICT guided DM improves prognosis and quality of life in 
patients with HF compared to ICT guided DM alone.
 Aim of the study
The primary aim of this study is to assess the effect of telemonitoring on top of an ICT 
guided DM system in patients after worsening HF on the combined endpoint of death, 
readmission and quality of life, compared to patients treaded with ICT guided DM alone.
Secondary aims of the study are;
•	 To assess the effect of telemonitoring in addition to an ICT guided DM system 
compared to an ICT guided DM alone on the separate components of the combined 
endpoint (death, readmission and quality of life)
•	 To determine the cost benefit ratio of ICT guided DM with telemonitoring 
compared to ICT guided DM alone.
Study design
A multicentre, randomised study in which in total 220 HF patients (NYHA II-IV) will 
be included. Patients will be randomised to the ICT guided DM (control) arm (N=90) 
or into the ICT guided DM with telemonitoring (intervention) arm (N=130) (Figure 1).
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Study population
All patients admitted to the intensive care/coronary care unit or cardiology ward for HF 
or visiting the outpatient clinic with worsening HF who need treatment or adjustment of 
oral or intravenous diuretics, can be included in the study. Other inclusion criteria are; 
evidence of structural underlying heart disease, left ventricular ejection fraction <45% 
and age of at least 18 years. Reasons for exclusion are myocardial infarction in the past 
month, cardiac invasive intervention (percutaneous coronary intervention, coronary 
arterial bypass, valve replacement, heart transplantation, or cardiac resynchronisation 
therapy) in the past 6 months or planned in the next 3 months, weight >200 kg, actual 
haemodialysis and the use of other telemonitoring systems. (Table 1)
Primary endpoint
The primary endpoint of the study is a composite, weighted score consisting of values 
for mortality, HF readmission and change in quality of life between end of the study 
and baseline measured with the Minnesota Living with HF Questionnaire (MLHFQ), 
adapted from the A-HeFT study 35 (Table 2). A readmission for HF is defined as an 
overnight hospital stay for HF or directly related to HF. The readmissions for HF will be 
blinded adjudicated by an endpoint committee. When data on quality of life are missing, 
the worst-case score for that component of the composite endpoint will be used in the 
analysis.
Secondary endpoints
Secondary endpoints of the study are the separate components of the primary endpoint. 
Other secondary endpoints are the total number and duration of all hospital admissions, 
treatment according to the guidelines using the criteria of the Guidelines Adherence 
Indicator-3,36 number of visits to the outpatient HF clinic, patient and carer satisfaction, 
and cost-benefit ratio. 
Ethics statement
On March 2009 this study design has became ethical approval (M09.070323) given by 
the medical ethical commission (MEC) of the medical university of Groningen (UMCG). 
The study has started (first patient) in December 2009.
Incremental cost-effectiveness ratio (ICER)
Costs
A distinction will be made between intervention costs and resource utilization costs. The 
intervention costs consist of the costs of the DM system and the costs of the telemonitoring 
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devices and will be calculated as a lump-sum over the study’s follow-up period. Resource 
utilisation costs will be estimated by preparing a structured data collection form to collect 
detailed information regarding scheduled and non-scheduled outpatient clinic visits and 
hospital admissions (both HF and non-HF related), ward type (e.g. intensive/coronary 
care unit, cardiology, general internal medicine), and cardiovascular procedures/
operations. In addition, a patient questionnaire will be administered at 4.5 months and 9 
months of follow-up to collect complementary data on general practitioner visits, home 
care utilization, and nursing home admissions. Unit costs will be estimated by using the 
Dutch guidelines for cost calculations and inflated to current price levels using a general 
consumer price index. Indirect costs, such as productivity losses, will not be taken into 
account.
Quality Adjusted Life Years (QALYs)
Preference-based quality of life scores will be obtained by administering the EQ-5D to 
all patients in both the control group and the two intervention groups at baseline, 4.5 
months of follow-up, and 9 months of follow-up. QALYs will subsequently be estimated 
by calculating the area of the two trapezoids that result from linear extrapolation of the 
three quality of life scores.
Cost-effectiveness
The balance between costs and effects will be assessed by estimating the incremental cost 
per QALY gained (ICER) for the intervention group compared with the control group. 
Table 2: score system  for primary endpoint IN TOUCH
End point Score
Death (at any time during study) -3
Survival to end of study 0
First readmission for heart failure -1
No readmission for heart failure 0
Change in quality of life at 9 months
Improvement ≥ 20 units +2
Improvement by 10 until 19 units +1
No improvement by -9 until +4 units 0
Worsening by +5 until +9 units -1
Worsening by ≥ 10 units -2
Possible score -6 to +2
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The time horizon over which the costs end effects of the different treatment strategies 
will be compared is equivalent to that observed during the period of the study (i.e. no 
future projections will be made). Uncertainty surrounding the ICER will be represented 
through the use of cost-effectiveness acceptability curves, which show, for each possible 
value of λ (i.e. the societal willingness-to-pay for one additional QALY), the probability 
that the intervention will be cost-effective.
Randomisation and data collection 
Patients can be randomised during admission for HF, and in case of worsening of HF 
at the outpatient clinic. After confirmation of eligibility and written informed consent, 
patients will be included into the study. Patients will be randomised into the control 
or intervention group. Patient characteristics and clinical variables will be collected 
at baseline, and 2 weeks and 9 months after discharge. Echocardiography, ECG, and 
laboratory analysis will be performed at baseline during hospitalisation and at the end of 
the study. Quality of life as part of the primary endpoint, measured with the Minnesota 
Living with HF Questionnaire, will be collected at baseline and at 9 months. Data about 
utilisation of resources will be collected prospectively and comprise components of direct 
costs, i.e. scheduled and non-scheduled outpatient visits and hospital admissions. 
Questionnaires about self-care behaviour, anxiety, depression, compliance and medical 
technology assessment (MTA) will be completed before discharge, and at 4.5 and 9 
months (Table 3). Patients should be included preferably as soon as possible but at least 
within a period of time of 14 days after discharge or after the first visit at the HF clinic 
with worsening HF.
Table 3: Questionnaires and medical assessment used in the IN TOUCH
Questionnaires Baseline 2 weeks 4.5 months 9 months
Minnesota living with heart failure questionnaire 
(MLHFQ)
• •
Revised Heart failure Compliance • •
Disability Rating Index (VAS) • •
Hospital Anxiety and Depression scale (HADS) • •
Heart failure self-care behaviour scale( EHFScB) • •
Medical technology assessment (MTA) • •
EQ-5D • • •
Satisfaction questionnaire for patients and providers •
Medical assessment
NYHA score • • •
Echocardiography •
ECG • • •
Physical examination • • •
Laboratory tests • • •
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Control group (ICT guided disease management system without telemonitoring)
Patients in this group receive care guided by an ICT DM system. This system supports 
DM in a fully automatic way, assisting the HF nurse to optimise pharmacological and 
non-pharmacological treatment, evaluate treatment and adjust therapy to optimal 
levels, according to current HF guidelines. The patient will receive tailored education 
and counselling on the HF regimen, symptom management and improvement of the 
pharmacological and non pharmacological regimen. 
The system mainly works as a computer decision support system. Based on the input of 
data from physical examination, medical history, questionnaires and nursing assessment, 
the system provides an advice to healthcare providers according to the actual guidelines, 
including up titration of HF medication to optimal doses.
Intervention group (ICT guided disease management with telemonitoring)
Patients in the DM with telemonitoring group will be treated with the above described 
ICT guided DM system in combination with the following integrated telemonitoring 
devices that will be installed at the patients’ home;
•	 weighing scale; patients will be instructed to weigh daily.
•	 blood pressure meter; patients will be instructed to measure their blood pressure 
daily during up titration of medication. 
•	 ECG; patients have to perform an ECG twice a week during up titration of beta-
blockers. 
•	 Health monitor; an interactive monitor collects data from the weighing scale, blood 
pressure meter and ECG device and will respond to the patients’ collected data. 
Data will be directly transmitted to the DM system in the hospital. 
In case of a deviation of individualised predefined ranges of weight, blood pressure or 
heart rhythm, the health monitor will automatically generate supplementary questions 
directly to the patient to evaluate the actual health situation. This data, measurements 
and subjective patient information (predefined multiple choice questions about HF 
symptoms) will be transferred to the computerised DM in the hospital. Furthermore, 
the health monitor will generate an advice about the non-pharmacological treatment, 
for example regarding compliance with fluid and sodium restriction. When the data 
collected by the system deviates from predefined ranges, the HF nurse will be informed 
automatically by mobile phone and email. In that case, the HF nurse will contact the 
patient by phone within two hours and further discusses symptoms and treatment. If 
data are outside any reference range in combination with symptoms of deterioration, 




Group sample sizes of 130 patients for the group treated with telemonitoring and 
ICT guided DM and 90 patients treated with ICT guided DM achieve 80% power to 
detect superiority for telemonitoring using a one-sided, two-sample t-test. The margin 
of equivalence is 0.0. The true difference between the means is assumed to be 0.8. The 
significance level (alpha) of the test is 0.025. The data are drawn from populations with 
standard deviations of - 2.0 and + 2.0. These figures are based on a publication 37 in which 
the effect of the combination of isosorbidedinitrate and hydralazin was investigated 
in patient with HF. In this study a difference of 0.4 was demonstrated regarding the 
composite endpoint. Using telemonitoring, we expect to find a larger difference especially 
in the QoL domain. It has to be addressed that no information is currently available 
regarding the sensitivity of the composite endpoint in a setting of new onset or worsening 
HF patients.
Statistical analyses
The primary analysis will consist of a comparison of the composite endpoint scores 
(Table 2) between ICT guided DM in combination with telemonitoring, compared to 
ICT guided DM without telemonitoring. The test will be performed using a two-sample 
t-test, and two-sided 95% confidence intervals will be constructed to describe the 
treatment differences. An analysis of covariance will be used to test for the treatment 
effect controlling for different baseline characteristics. The results will be analysed using 
an intention-to-treat analysis including the full set of all randomised patients (primary 
efficacy population). The primary efficacy population will be analysed at endpoint for 
composite score. Secondary endpoints involving e.g. individual evaluation of deaths, 
hospitalisations, and QOL after 9 months will be analysed over the entire course of the 
study using appropriate methods. Two types of economic analyses will be performed: 
these include a cost-consequence analysis (CCA) for a disaggregated examination of 
resource costs and health outcomes associated with the alternative intervention; and 
cost-effectiveness analysis (CEA) in which the alternative intervention is examined in 
light of total cost per unit of health outcome. Thus CCA will be performed using the 
primary outcome of the study as the measure of effectiveness. For this, the annual cost per 
patient treated to postpone or prevent one patient experiencing a cardiovascular death 
or hospital admission for worsening HF within the trial will be calculated.38 For CEA, 
the incremental cost-effectiveness ratios (ICERs), in terms of cost per life year gained 
(LYG), will be estimated given that there was a significant increase in survival with DM 
and telemonitoring. CEA will not be performed in case no reduction will be observed 
in cardiovascular or all cause mortality. In case of missing data for the composite end 
point score, the worst-case scenario will be assumed for the primary analyses. Patients 
lost to follow-up will be assumed to have died (-3) and those without a quality of life 
measurement will be assigned the worst score (-2). 
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Study organisation
To include 220 patients in this study, 10 hospitals in the Netherlands are participating in 
the IN TOUCH study. The first patients are recruited in December 2009; the end of the 
study is expected to be in September 2012.
Support and monitoring
The study is supported and monitored by the Trial Coordination Centre (TCC), a 
contract research organisation for clinical trials. Both the quality of the research data and 
of the intervention will be structurally monitored according to the GCP guidelines and 
TCC standards (ISO 9000:2001)
Discussion 
In the last decades, the introduction of ICT in healthcare promised an improved 
quality of care while reducing work load, and resulting in a more cost effective system. 
This might be realised by the use of computer guided decision support systems and 
telemonitoring.20,31,32,39,40 The IN TOUCH study is the first to investigate the effect of an 
ICT guided DM system in combination with telemonitoring in patients with HF. In recent 
years there has been much research in the field of HF and DM. This has resulted in the 
implementation of DM programmes in the ESC guidelines.1 The development of these 
guidelines has enabled the creation of computer aided decision support programms.39 In 
the recent guidelines the application of ICT by DM programs is recommended. Although 
there has been progression in the development of ICT guided tools and these tools have 
become practical equipment for enhanced decision making, healthcare providers still 
experience great barriers in using and implementing them for several, often unclear 
reasons.33,34
Mortality and morbidity are important outcomes in studies in HF patients. Quality of 
life becomes a more important issue for patients and may be even more important for 
them than survival or readmissions. Therefore, a composite primary endpoint, including 
quality of life, mortality and morbidity was chosen for the IN TOUCH study. Another 
reason for this composite endpoint is that for HF a high standard of care has been 
established which makes it more difficult to investigate the added effect of new therapeutic 
options. Beside the statistical advantage of a composite endpoint, the study becomes less 
costly and results of promising new treatment may occur earlier with this selected design. 
The strength of this study is the important role of ICT guided DM, telemonitoring, the 
composite endpoint, including quality of life, a strong focus on cost effectiveness and the 
emphasis on experienced user resistance and barriers regarding ICT tools in healthcare.
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The value of telemonitoring and 
ICT-guided disease management 
in heart failure: results from the 
INTOUCH study
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It is ambiguous whether telemonitoring reduces hospitalizations and mortality in heart 
failure (HF) patients and it is unclear whether telemonitoring as an integrated approach 
with an ICT-guided-disease-management-system (DMS) improves clinical and patient-
reported-outcomes or reduces health-care cost. 
Methods
The value of Innovative ICT-guided-disease-management combined with 
Telemonitoring in OUtpatient clinics for Chronic HF patients (IN TOUCH-study) was a 
multicenter randomized controlled trial; 179 patients were included after worsening HF 
and in need of extra diuretics. Patients were randomized to ICT-guided-DMS or to ICT-
guided-DMS+telemonitoring with a follow-up of nine months. The composite endpoint 
consists of mortality, HF-readmission and change in health-related quality of life (HR-
QoL). 
Results
The mean age was 69 years; 72% male; 77% in NYHA III-IV; mean LVEF was 27%. There 
was a none significant difference in the mean score of the primary composite endpoint 
which was -0.63 in ICT-guided-DMS versus -0.73 in ICT-guided-DMS+telemonitoring; 
mean difference 0.1, 95% CI: -0.63 –0.85, p=0.31. All-cause mortality in ICT-guided-
DMS was 12% versus 15% in ICT-guided-DMS+telemonitoring (p=0.53). HF-
readmission 27% vs 29% p=0.80) and all cause readmission (48% vs 51% p=0.68) was 
not significant different between respectively the ICT-guided-DMS and ICT-guided-
DMS+telemonitoring group. HR-QoL improved in most patients and was equal in both 
groups. Incremental costs were 1360 euro in favor of ICT-guided-DMS. ICT-guided-
DMS+telemonitoring had significantly fewer HF-outpatient-clinic visits (p<0.01). 
Conclusion
ICT-guided-DMS with telemonitoring for the management of HF patients did not affect 
the primary and secondary endpoints. However, we did find a reduction in visits to the 
HF-outpatient clinic in the  ICT-guided-DMS with telemonitoring group. This reflects 




Improvements in medical care and an increase in the presence of lifestyle related-risk 
factors in the general population have resulted in a substantial increase in the prevalence 
of heart failure (HF).1 In the Netherlands, the prevalence of HF is predicted to increase 
to 50% in men and 20% in women between 2007 and 2025.2  In the elderly, HF is the 
most frequent cause for all hospital admissions.3 The costs for patients with HF is also 
increasing and was 375 million Euro in 2003, of which more than 50% related to costs for 
hospital admissions. Because of an impending shortage of resources, growing costs due 
to ageing, more expensive treatments and downwards pressure on healthcare budgets, a 
thorough review of the care for patients with HF is necessary, stressing the importance of 
patient-centered care.
Heart failure clinics and disease management
A first step in organizing treatment and care efficiently for patients with chronic HF, 
started in the 1990ties by implementing specialized HF outpatient clinics, with a strong 
collaboration between HF nurses and cardiologists4,5 In these HF outpatient clinics, 
disease management was introduced, which is a multidisciplinary intervention designed 
to improve quality and cost effectiveness of care, using a systematic approach and 
employing multiple treatment modalities.6,7 Over the last decade, these HF outpatient 
clinics became ‘care as usual’ in several European countries.8 Two randomized studies 
investigated the effect on quality of care and clinical outcomes in HF clinics in the 
Netherlands, the Coordinating Study Evaluating Outcomes of Advising and Counseling 
in HF9 (COACH) and the Deventer-Alkmaar HF Project10 (DEAL-HF). Although these 
two studies have contributed to the quality the of disease management in HF outpatient 
clinics led by specialized HF nurses, the key characteristics of patients who benefits most 
from a disease management program remain unclear.11 
Disease Management System 
A Disease Management System (DMS) can be described as a comprehensive 
coordinated system of preventive, diagnostic, and therapeutic measures intended to 
provide cost-effective and high quality healthcare for patients who have or are at risk 
for a specific chronic illness or medical condition.12,13 A DMS includes the following 
characteristics: designed for a well-defined patient population; aimed at multidisciplinary 
collaboration; includes patient education, self-management and prevention modules; 
uses recognized protocols and guidelines; divides patients in treatment regimes; and is 
driven by information and communication technology (ICT).13-15 One of the components 
of a DMS could be a computer decision support system (CDSS), can facilitate healthcare 
professionals into optimizing treatment and care for HF patients. Based on predefined 
patient profiles, treatment options and current patient medical data, the CDSS  generate 
a treatment plan specifically for that particular patient. 
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Telemonitoring
Pivotal in organizing treatment and care is the monitoring of patients with HF by means 
of regular outpatient clinic visits or assessments through telephone (tele-homecare) or 
with telemonitoring. There are many definitions used for telemonitoring but the core 
principle does not generally differ. A commonly used international definition is ‘the remote 
monitoring of patients, including the use of audio, video, and other telecommunications 
and electronic information processing technologies to monitor a patient status at a 
distance’.16 
In the Netherlands the most used definition is that telemonitoring includes the 
measurement, monitoring, collecting and transfer of clinical data, concerning the health 
status of a patient in his or her home environment, due to the use of information and 
communication technology. Cardiologists and HF nurses in the Netherlands have high 
expectations of telemonitoring at home and it is expected to improve quality of care, 
to reduce costs and to improve patients’ health-related quality of life through feelings 
of control and empowerment of the patient.17 Some studies have shown that remote 
monitoring of HF patients reduced hospitalization and mortality rates18-20 however, other 
studies have not confirmed these findings.21,22 It is still not clear whether telemonitoring, 
when delivered as an integrated approach added to an ICT-guided DMS improves clinical 
and patient reported outcomes or reduces healthcare costs.
The aim of this study is to assess the effect of telemonitoring on top of an ICT-guided 
DMS in patients after worsening HF on the combined endpoint of death, readmission 
and quality of life, compared to patients treated with ICT-guided DMS alone.
Methods
IN TOUCH Study 
Experiences with disease management systems and telemonitoring are fragmented and 
solid evidence on the effects are still lacking. In the Netherlands, at the Martini Hospital 
Groningen, an ICT-guided DMS system gave promising results23 ,and the outcome of 
this experience was the rationale for the IN TOUCH study (The value of INnovative 
ICT guided Disease Management combined with Telemonitoring in OUt patient clinics 
for Chronic Heart failure patients). This rationale and design have been described and 
published elsewhere.24 The IN TOUCH is a multicenter, randomized study designed to 
investigate the effects and costs of ICT-guided DMS, versus ICT-guided DMS combined 
with telemonitoring in HF patients on a combined endpoint of mortality, HF readmission 
and change in health-related quality of life. 
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Recruitment and procedure
Patients were recruited during a period of 25 months (December 2009 to January 2012) 
and followed for a fixed period of 9 months. All patients provided written informed 
consent. Our investigators adhered to the principles outlined in the Declaration of 
Helsinki. The medical ethics committee approved the protocol and the study was registered 
in the Dutch trial register (NTR) with the trial ID: NTR1898. Adjustment of the study 
protocol was performed December 2010 because of the impossibility of recruiting control 
sites with HF patients. Using telemonitoring for regular care was an exclusion criterion to 
participate as a control hospital in this study. However, hospitals, pre-recruited as control 
hospitals were, in the end, not willing to participate in the study with the agreement 
of not using telemonitoring for their regular HF care during the study period of 2009-
2012. For that reason, redesigning the study to a randomized intervention study without 
a control group was necessary. Another reason for adjustment of the protocol was the 
low inclusion rate of patients with a (re) admission for HF. In an attempt to improve 
the inclusion, it was decided to also include patients with deterioration for HF, treated 
with extra diuretics, visiting the outpatient HF clinic. Adjustment of the protocol was 
reported and approved by the medical ethics committee and had no consequences for 
the feasibility of the ongoing study (ABR:NL26271.042.08). The trial was prematurely 
discontinued after an extended inclusion period of 6 and respectively 3 month due to a 
poor accrual inclusion rate. 
Patient population
All patients were included if they had worsening of HF based on typical signs and 
symptoms of fluid retention. Patients were either admitted to the intensive care/ coronary 
care unit or cardiology ward or were visiting the outpatient HF clinic and needed treatment 
or adjustment with oral or intravenous diuretics. Patients were 18 years of age or older 
and all had evidence of structural underlying heart disease and documented reduced 
left ventricular ejection fraction (LVEF) ≤ 45%. Exclusion criteria were a myocardial 
infarction in the last month, cardiac invasive intervention (percutaneous coronary 
intervention, coronary arterial bypass, valve replacement, heart transplantation, or 
cardiac resynchronization therapy) in the past 6 months or planned in the next 3 months, 
actual hemodialysis, the use of other telemonitoring systems (implanted devices and/or 
external use) and the inability or unwillingness to give informed consent.
Randomization
All patients were randomized to either receiving care supported by an ICT-guided DMS 
or receiving care supported by an ICT-guided DMS system with telemonitoring  devices 
at home. Randomization was performed as soon as possible but at least within 2 weeks 
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after discharge or after the initial visit at the HF outpatient clinic with worsening of HF. 
The computer-generated randomization scheme used random permuted blocks of 2:1 
(original protocol) and 1:1 (adjusted protocol December 2010) stratified by center to 
ensure balanced assignment of patients to each group in the ten participating centers. 
Intervention strategy
Patients in both groups received tailored education and counseling on the HF symptom 
management regimen and improvement of the nonpharmacological regimen based on 
protocols and recent HF guidelines25 For the pharmacological treatment in both groups 
computer decision support (CDSS) functionality by means of a ICT-guided DMS 
system was incorporated. Based on the input of data from nursing assessment, physical 
examination, medical history, laboratory and questionnaires, the system provided advice 
to healthcare providers according to the actual ESC HF guidelines, including up titration 
of HF medication to optimal individual doses. Furthermore the CDSS gave advise in 
treatment options, for example how to react on incoming alerts of deviating values from 
patients at home by telemonitoring (e.g., increase of diuretics). The intervention group 
was provided with the same ICT-guided DMS system but also received telemonitoring 
devices at home. The telemonitoring devices used were a weighing scale, blood pressure 
equipment, an ECG device and a health monitor. The health monitor was an interactive 
monitor that generated data from the abovementioned devices and health related 
questions about the health status of the patient data, which were directly transmitted 
through the GPRS network to the DMS system located in the hospital. In case of 
deviation of predefined individual ranges of weight, blood pressure or heart rhythm, the 
health monitor at home generated supplementary questions to the patient to evaluate 
the actual health situation. At the same time, the HF nurse was informed automatically 
by mobile phone and email about any deviation of the health of the patient, according to 
the study protocol. The HF nurse contacted the patient within two hours and discussed 
the symptoms and treatment with the patient. Patients allocated to the group with ICT-
guided DMS and telemonitoring were only allowed to visit the cardiologist or HF nurse 
in the case of an absolute need for intervention. The patients in just the ICT-guided DSM 
intervention followed the normal HF routine of the individual hospitals, like any other 
HF patient, without limitations on the visits.
Follow-up and data collection
Patients were followed for a 9-month period in which data on hospitalizations 
and mortality were collected from the medical records. The change in quality of life 
between baseline and the end of the study was assessed by the Minnesota Living with 
HF Questionnaire (MLHFQ). The reason of hospital readmission or death and the date 
of the event were adjudicated by an independent endpoint committee blinded for the 
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group assignment. For the cost analyses, a distinction was made between intervention 
costs and resource utilization costs. Data on resource use for both interventions were 
also collected from medical records and questionnaires on a patient level. The cost 
of the intervention were defined as the costs of the ICT-guided DMS, the costs of the 
telemonitoring devices and handling of the alarms (personnel) were calculated as a fixed 
price over the follow-up period of the study. Resource utilization costs were calculated 
by collecting data on scheduled and non-scheduled outpatient clinic visits and hospital 
admissions (HF and non-HF-related). In addition, a patient MTA-questionnaire adapted 
from the iMTA/TiC-P26 was administered at 4.5 months and 9 months of follow-up to 
collect complementary data (e.g., GP, dietician, physiotherapist visits, home care, and 
nursing home [day care, and admissions]). Unit costs were estimated by using the 
Dutch guidelines for cost studies27 and inflated to the price level of 2012 using a general 
consumer price index (http://www.CBS.nl). The time horizon of the cost analysis was 9 
months. Indirect costs, such as productivity losses, were not calculated.
Endpoints
The primary endpoint was a composite weighted score consisting of a value for mortality, 
HF readmission and change in quality of life between baseline and end-of-study measured 
with the MLHFQ with a possible range of –6 to +2. An HF readmission was defined as 
an unplanned overnight hospital stay due to progression of HF or directly related to HF. 
The scoring system of the primary composite endpoint was adapted from the A-HeFT 
study28 (Table 1). In case of missing data for the primary composite endpoint, the worst-
Table 1: score system for primary composite endpoint
End point Score
Death (at any time during study) -3
Survival to end of study 0
First readmission for heart failure -1
No readmission for heart failure 0
Change in quality of life at 9 months
Improvement ≥ 20 units +2
Improvement by 10 until 19 units +1
No improvement by -9 until +4 units 0
Worsening by +5 until +9 units -1
Worsening by ≥ 10 units -2
Possible score -6 to +2
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case scenario was used for the analyses. Patients lost at follow-up were assumed to have 
died (-3), and patients without a quality of life score have been assigned the worst score 
for that component (-2). Secondary endpoints of the study were the separate components 
of the primary endpoint (mortality, readmission for HF and change in quality of life). 
Other major secondary endpoints were the total number and duration of all hospital 
admissions, number of visits to the outpatient HF clinic and cost analyses.
Sample size
We expected with 80% power to detect superiority for telemonitoring using a one-
sided, two-sample t-test, when 130 patients were included in the intervention group 
with telemonitoring and 90 patients in the ICT-guided DMS group. The true difference 
between the two groups was assumed to be 0.8 regarding the primary composite endpoint 
score. The largest difference between the two groups was expected to be observed in the 
quality of life domain.
Statistical Analysis
All analyses were conducted according to the intention-to-treat principle. Descriptive 
statistics were used to characterize the study population. Students’t-test and Wilcoxon 
Rank Sum tests for continuous variables and Chi square tests for categorical variables 
were performed to compare the demographic and clinical characteristics between the 
two groups. To compare the primary composite endpoint score between the group with 
ICT-guided DMS with telemonitoring and the group with ICT-guided DMS without 
telemonitoring a two-sample t-test was performed, and two-sided 95% confidence 
intervals were constructed to describe the treatment differences. Kaplan Meier curves 
were constructed for the differences in time to mortality between the two groups. 
Differences in the number of hospital readmissions were analyzed by a two samples t-test 
and visits to the outpatient clinics and the differences in length of hospital re-admissions 
between the two groups where calculated using the Wilcoxon Rank Sum test. Costs per 
category were calculated by multiplying resource use with the cost per item. Means per 
group and incremental costs were calculated based on the trial data. Bootstrap simulations 
(5000 replications of the trial data) were performed to estimate the confidence intervals 
surrounding the incremental costs (2.5th and 97.5th percentile). All analyses were 
performed using PASW version 18.0, Excel version 2003 and R version 2.15.1.
Results
During the inclusion period of 25 months in total 179 patients from 10 Dutch hospitals 
were randomized in the study. Two patients did not fulfill the inclusion criterion of 
worsening HF and were therefore not part of the analyzed population. In total, 177 HF 
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patients were analyzed, of which 80 patients were randomized into the ICT-guided DMS 
intervention and 97 patients to the ICT-guided DMS with telemonitoring intervention. 
The distribution of included patients between both intervention groups is not equal, 
due to the forced adjustment of the study protocol (as described under methods) and 
therefore a change in randomization blocks of patients from 2:1 to 1:1.
Baseline characteristics
Overall the mean age was 69 (± 12) years of age, 72% were male and the mean Left 
Ventricular Ejection Fraction was 27% (± 9).  At the time of admission, most patients 
were classified in New York Heart Association (NYHA) class III-IV (77%) of which 23% 
were in NYHA II. Twenty-four (13%) patients were included during their visit to the 
outpatient HF clinic, the others were included after a admission for HF. Of all 177 analyzed 
patients, 30% were newly diagnosed with HF (<6 months of date of HF diagnosis).  The 
other patients were diagnosed with HF for an average period of, on average 4.6 years, 
(ICT-guided DMS) and 5.4 (ICT-DMS+ telemonitoring) years (p=0.35) respectively. 
Other baseline characteristics of both groups were comparable (Table 2). There were 
no significant differences between the two groups in the use of HF medication. Total 
percentages of HF medication prescribed in the group of ICT-guided DMS was: ACE-
inhibitor 59%, Beta-blocker 69% and Aldosteron antagonist 58%. For ICT-guided DMS 
with telemonitoring this was: ACE-inhibitor 60%, Beta-blocker 64%, and Aldosteron 
antagonist 59%. 
Adherence to the intervention
Patients with telemonitoring were instructed to record their weight and blood pressure 
once a day and an ECG in the case of starting or uptitration of Beta-blockers. Adherence 
of the patients with telemonitoring (assessed by daily weighing and measuring of blood 
pressure) was 95% with a range from 87%-99% for the total study period of 9 months.
Outcomes - Primary endpoint
The mean composite endpoint score in the ICT-guided DMS group of –0.63 was not 
significant different from the endpoint score of -0.73 for the telemonitoring group; mean 
difference 0.1, 95% CI: -0.63 –0.85, p=0.31 (Table 3).  In total 8% of the patients had the 
worst possible score of –6; 7% of the patients in the ICT-guided DMS group and 9% in the 
ICT-DMS group with telemonitoring. In total 27% of the patients had the best possible 
score of +2 of which 23% were in the ICT-guided  DMS group and 28 patients (30%) 
in the ICT-DMS group with telemonitoring, with no statistical differences between the 
groups. 
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Demographics Mean ± sd
Age (yrs) 69 ± 11 69 ± 12 0.92
Male sex no. (%) 62 (75) 66 (70) 0.47
LVEF % 28 ± 9 27 ± 10 0.65
Duration of diagnosis HF, years 4.6 (5.6) 5.4 (6.5) 0.35
New diagnosis of HF no. (%) 25 (31) 29 (30) 0.64
Etiology
Ischemic no. (%) 33 (40) 39 (43) 0.96
History of  myocardial infarction no. (%) 25 (32) 35 (35) 0.72
Co-morbidities no (%)
Hypertension no. (%) 29 (35) 26 (28) 0.30
COPD no. (%) 17 (21) 21 (22) 0.67
Atrial fibrillation no. (%) 32 (40) 47 (48) 0.26
Diabetes no (%)
   IDDM 16 (19) 13 (13) 0.89
   NIDDM 13 (16) 19 (20) 0.87
Stroke 6 (8) 12 (12) 0.29
Oncology 12 (15) 12 (13) 0.61
Clinical variables
NYHA (%) 0.90
   II 18 (23) 21 (22)
   III 49 (60) 51 (54)
   IV 18 (18) 18 (19)
Heart rate 84 ± 20 81 ± 19 0.69
Weight (kg) 84 ± 18 81 ± 17 0.26
LBTB no. ( %) 16 (19) 31 (33) 0.15
SBP (mmHg) 123 ± 20 117 ± 20 0.09
DBP (mmHg) 74 ± 13 71 ± 11 0.07
Cardiovascular interventions no. (%)
CABG no. (%) 15 (19) 22 (23) 0.52
PCI no. (%) 13 (16) 18 (19) 0.69
ICD no. (%) 10 (11) 16 (18) 0.24
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Outcomes - Secondary endpoints
      Mortality 
All cause mortality in the ICT-guided DMS group was 12% (n=10) and in the ICT-
guided DMS group with telemonitoring 15% (n=14), p=0.53 (Table 3). The analyses of 
time to death showed a hazard ratio (HR) of 1.28 (95% CI 0.55-2.96, p=0.56). During the 
9 months of follow-up, the total number of days lost to death was 156 days with a range 
of 114 to 206 for the ICT-guided DMS group and 128 days (84-217) for the ICT-guided 
DMS group with telemonitoring (p=0.52). Kaplan Meier Survival analysis did not show 
a statistically significant difference between the two interventions (log rank χ2=0.025, 
p=0.88).
      Readmission for HF
Of all patients, 28% were readmitted for HF at least once during the 9 month follow-up 
period: 29% (n=24) in the ICT DMS group versus 28% (n=26) in the ICT DMS group 
with telemonitoring group (p=0.80). (Table 3). The mean number of readmission days 









Hemoglobin, mmol/L 8.4 ± 0.98 8.2 ± 1.16 0.26
Sodium, mmol/L 141 ± 2.95 141 ± 4.2 0.99
Creatinine, µmol/L 138 ± 67.6 140 ± 77.7 0.83
Nt-pro BNP, ng/l (range) 5380 (483-24799) 3646 (591-
23800)
0.27
Mean eGFR – ml/min/1.732 66.3 ± 26.6 65.3 ± 29.8 0.90
Medication (total % of use )
Diuretica 88 87 0.51
ACE-inhibitor 59 60 0.73
Angiotensin renine blocker 27 24 0.15
Beta blocker 69 64 0.75
Aldosteron antagonist 58 59 0.41
Note: DMS = disease management system; TM = telemonitoring; yrs = years; LVEF = left ventricular ejection 
fraction; HF = heart failure; IDDM = insulin dependent diabetes mellitus; NIDDM = non-insulin dependent 
diabetes mellitus; NYHA = New York Heart Association; LBTB = Left Bundle Branch Block; SBP = systolic 
blood pressure; DBP = diastolic blood pressure; CABG = Coronary Artery Bypass Graft; PCI = Percutaneous 
Coronary Intervention; ICD = internal cardiac defibrillator; NT-pro-BNP = N-terminal prohormone of brain 
natriuretic peptide; eGFR = estimated globular filtration rate: ACE-inhibitor =  Angiotensine Converting En-
zyme inhibitor
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      All cause readmission
In total 48% percent (n=40) of the patients included in the ICT-guided DMS group were 
admitted to hospital at least once for all-cause reasons with a median  of 6.5, IQR 25-75% 
4, 6, 21. For the patients using telemonitoring this was 51% (n=48) with a median of 10.5 
days, IQR 25-75% 3, 10, 19 (Table 4). 
      Health-related quality of life
The MLHFQ was similar in the two groups at baseline (49 ± 22 versus 48 ± 21, p=0.20). 
At 9 months the mean change in score on quality of life was -14.6 units in the ICT DMS 
group versus -14.0 units in the telemonitoring group; mean difference -0.6, 95% CI: -8.7 
-7.4, p=0.87 (Table 3). Most patients had improved quality of life during the 9 month 
follow-up: in total, 39% (n=51) of patients improved with ≥ 20 units of which 34% was 
in the ICT-guided DMS group and 44% was in the telemonitoring group. In total 16% 
(n=21) patients improved between 10 and 19 units. (23% in the ICT DMS group vs 10% 
in the telemonitoring group). In total 46% did not improve and even had a worse quality 
of life at the end of the study. In total 24% (n=31) patients had no improvement (-9 to 
+4) ( 21% in the ICT DMS group vs 26% in the telemonitoring group) and 17% (n=22) 
of the patients (18% in the ICT DMS group vs 16% in the telemonitoring group) had 
worsening quality of life (≥ +5 units). Regarding the physical and emotional sub scores of 
the MLHFQ, no significant differences were seen between both groups.
      Outpatient clinic visits
Patients in the ICT-guided DMS group were supposed to have regular contact with the 
outpatient HF clinic during the 9 months, in line with the normal follow-up of HF patients 
in each of the participating hospitals according to the HF ESC guidelines.29 Patients in the 
telemonitoring group were not scheduled for regular follow-up during these 9 months, 
except for worsening of HF that could not be managed at home. The median number 












    Composite endpoint score, mean -0.63 -0. 73 ± 0.10 (-0.63-0.85) 0.31
Secondary endpoints
    Mortality % (n) 12 (10) 15 (14) -4  (-14 – 6) 0.53
    Re-admission HF % (n) 29 (24) 28 (26) -2 (-12 - 15) 0.80
    Change in quality of life, mean -14.63 -13.97 -0.66 (-8.68-7.36) 0.87
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of contacts times with the HF outpatient clinic was 5 for the ICT-guided DMS group 
versus 2 times for the telemonitoring group (p< 0.01) (Table 4). To any outpatient clinic a 
median of 6 versus 5 visits was observed (p=0.47) (Table 4). 
      Cost analysis
Results showed a mean total costs of € 5006 per patient for the ICT-guided DMS group 
and € 6366 per patient for the telemonitoring group (Table 4). Incremental costs were 
€ 1360 in favor of patients in the ICT-guided DMS group. In this scenario the costs 
for outpatient visits were €530 for telemonitoring vs. € 603 for the ICT-guided DMS. 
Hospital admissions were € 3213 for DMS and € 2427 for telemonitoring. In both groups, 
the highest proportion of costs consisted of costs for admissions to a hospital ward. 
Costs incurred outside the hospital (GP, dietician, physiotherapist visits, home care and 
nursing home [day care, and admissions]) amounted to €1152  in the ICT-guided DSM 
strategy and €1642 in the telemonitoring strategy. The major cost driver in this category 
was nursing home admissions. The handling of the incoming telemonitoring data (alerts, 
viewing the ICT-guided DMS, making telephone calls to patients, reporting the action/
intervention and performing follow-up) was estimated at 12 hours for each patient for the 
total study period, which was calculated to be  €364 based on nurses salary. The cost data 







Number of patients with hospitalizations % (no.)
    All-cause hospitalization 48 (40) 51 (48) 0.68
      Cardiovascular-related hospitalizations 18 (15) 17 (16) 0.86
         Heart failure-related hospitalizations 29 (24) 28 (26) 0.80
Number of hospitalizations
   All cause 79 98
     Cardiovascular-related 24 18
       Heart failure-related 37 39
Number of days readmitted, median
      All- cause 6.5 10.5 0.95
         IQR 25-50-75% 4-6-21 3-10-19
     Heart failure-related 8 11.5 0.80
        IQR 25-50-75% 5-8-21 5-11-28
Number of visits to outpatient clinics,  median
     All- cause 7 6.5 0.47
         IQR 25-50-75% 4-7-12 4-6-9
      Heart failure-related 9 7 0.01
         IQR 25-50-75% 5-9-13 5-7-9
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for hospital admissions were highly skewed due to one patient with an extreme admission 
duration (126 days of rehabilitation) Therefore, were performed this analyse whereby for 
this patient the mean of admission duration was replaced with the group mean value.
Post-hoc analysis
In order to examine if patients with lower HF related readmission rates we performed 
a post-hoc analyses on a group of patients with none or only one readmission for HF 
(n=161). For the ICT-guided DMS group all cause mortality was 10% (n=8) vs. 13% 
(n=11) for the telemonitoring group (p=0.60). Readmission for HF was 23% (n=18) vs. 
19% (n=16) p=0.50, respectively. The score of change in quality of life in the ICT-guided 
DMS group was -14.5 vs. 15.1 (p=089).
Discussion
In this study on the effects of ICT-guided DMS compared to ICT-guided DMS with 
telemonitoring, no additional effect of ICT-guided DMS with telemonitoring were found 
compared to ICT-guided DMS on the composite endpoint score; all cause mortality, 
readmission for heart failure and QoL. We expected to find a difference of 0.8, however we 
found a difference of only 0.1. One of the explanations for the absence of an effect could 
be that patients in this population (both groups) were relatively “healthy” compared to 
other HF studies,30 making a significant or clinical difference for further improvement 
in outcome rather difficult. Furthermore, only 16 patients had more than 1 readmission 
for HF (9%), and a relative large group of included patients (30%) was newly diagnosed 
with HF and therefore did not have a history of frequent re-admissions, Frequent 
readmissions are known as unfavorable for outcome. The mortality rate was rather low 
(12%) and almost all patients (96%) received scheduled visits to the HF clinic, indicating 
that there was no need for acute care because of worsening of HF. Furthermore, although 
in both groups the QoL increased equally, no differences in the changed score between 
Table 5: Bootstrap simulations (5000 replications of the trial data) to estimate the confidence intervals 
surrounding the incremental costs ( 2.5th and 97.5th percentile)of the interventions 
(*software.**software,  telemonitoring devices and the handling of incoming data)
ICT-DMS ICT-DMS with 
telemonitoring
Difference CI 95%
Intervention costs €37* €1766** €1729 constant
Re-admission costs €3213 €2427 €786 - 2875 +1525
Out-of-hospital care costs €1152 €1642 €490 -1297 +2880
Outpatient clinic costs €603 €530 €73 - 261 +110
Total €5006 €6366 €1360 - 2263 +5221
59Outcome INTOUCH
baseline and 9 months was seen between the two groups. Moreover, it might be possible 
that the effect of the intervention was not large enough to be able to discriminate since the 
differences in treatment modalities was moderate;  daily measurements of weight, blood 
pressure and an EKG in case of titration of Betablocker.
To find an effect for telemonitoring on mortality, readmissions and, quality of life 
probably requires a more defined and coherent group of patients that could benefit 
from this new intervention.31 It seems reasonable to assume that other variables, such 
as age, socioeconomic demographics like living alone or the severity of the disease in 
terms of frequent readmissions before starting with telemonitoring might affect the 
benefit of telemonitoring, perhaps more than we initially calculated and defined in the 
study protocol.32 However, previous studies do not show specific profiles of patients are 
known who could benefit more from telemonitoring, with the exception for patients 
with depressive symptoms.31 In post hoc analyses, we could not find specific patient 
characteristics that played a role in their benefiting from telemonitoring. To find out 
if patients with more than one readmission influenced the outcome on the primary 
endpoint negatively, we performed analyses on the group of patients with none or only 
one re-admission for HF. This analysis did not provide new insight. Recently Richard 
Wootton, editor of the Journal of Telemedicine and Telecare, propose to focus future 
telemonitoring studies on patients’ characteristics and comparable endpoints, like long 
term follow-up, quality of life, costs to society, emergency department visits, and days in 
hospital.33 
It was set out in the study protocol that for starting and titration of HF medication during 
the follow-up period in both groups the CDSS functionality in the ICT-guided DMS 
had to be used. The adherence of using ICT-guided DMS was experienced as difficult, 
especially regarding the use of the CDSS functionality for up-titrating HF medication, 
which might be reflected by the relatively low percentage of prescribed ACE-inhibitor 
use at the end of the follow-up period. Although the percentage of Beta-blockers and 
Aldosteron antagonists are conform the observed percentages in the EURO Heart survey 
II study,34 the percentage of ACE-inhibitors at the end of the study (59% vs. 68%) is much 
lower than the observed 80%. The main reason for the lack of use of the CDSS was that 
the usability and acceptability were considered poor, primarily due to organization- 
and system-related barriers, which are known as major obstacles in applying CDSS in 
healthcare.35,36 A known personal-related barrier to use a CDSS is a lack of trust, this 
was also observed  in some participating hospitals where HF nurses were not allowed to 
titrate medication themselves due to the hesitations of the cardiologists. Finally, the lack 
of use was also attributed to the fact that the CDSS was not integrated into the existing 
electronic patient record  and therefore caused additional work. 
Despite the fact that we could not find a difference in outcome in favor of the 
telemonitoring group, we did find that telemonitoring and ICT-guided DMS seem 
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safe to use for HF patients. The number of HF-related visits to the outpatient clinic 
was substantially lower (partly protocol-driven) compared to patients who did not use 
telemonitoring, but the outcome in terms of readmission and mortality was similar 
in both groups. Importantly in this context is the overall patient adherence of using 
telemonitoring at home which was very high (the telemonitoring devices were used in 
95% of cases, according to the protocol). Compared to other studies21,22 in which patient 
adherence of using telemonitoring was overall not higher than 30-40%, this clearly 
indicates that the devices used for this study, in combination with the protocol of daily 
measurements, were well accepted by patients and therefore suitable to implement 
regular care. 
Practical implications
Taking into consideration the advances and possibilities of telemonitoring and the 
limited additional costs, an intervention with telemonitoring might be an option for 
caregivers. This could be in situations where patients do not have direct or difficult 
access to a HF outpatient clinic (e.g., primary care, long distance to travel, the inability 
of a patient to visit the HF outpatient clinic) or in case of preventing regular visits to the 
outpatients clinic just for uptitration of medication or assessment of physical condition. 
From this same perspective, given the comparability of both interventions in terms of an 
effect on outcome, a change in standard HF practice, could therefore be based on costs, 
availability of human recourses, usability and trust of patients and healthcare providers 
instead of focusing ‘only’ on reduction of mortality and/or re-admission. Telemonitoring 
could be a significant tool for re-organizing HF care to be more efficient, a necessity due 
to the understaffed care of a growing and aging population.  
Limitations
Despite an extended inclusion period of 9 months in combination with an adjustment 
of the study protocol to include patients with a deterioration of HF from the outpatient 
HF clinic, we were not able to include the number of patients needed as calculated. This 
could have influenced the outcome in terms of a lack of sample strength. However, the 
calculated p-values did not show a trend or ‘near’ significance. In addition there were no 
numerical differences between both groups indicating that a larger population would not 
make a difference. Additionally we calculated based on the figures of inclusion and results 
how many patients would be needed to probably cause an effect (HH). In the design of 
the study, a cost effectiveness analysis (CEA) and or cost consequence analysis (CCA) 
was planned. However, since no difference in primary and secondary clinical endpoints 
was found, the planned analyses were not performed. To account for this, we performed 
a cost minimization analysis. Finally, we have no information on how many patients were 
eligible for this study because this was not part of the protocol.
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Conclusions
ICT-guided disease management in combination with telemonitoring, used in the 
follow-up of HF patients, did not affect the primary (composite) endpoint of mortality, HF 
readmission and quality of life, nor the separated individual outcomes of this composite 
endpoint. However, we demonstrated that telemonitoring  is safe and can reduce visits 
to the HF outpatient clinic, keeping HF care accessible. Costs however were still Euro 
1360,- higher with TM. The adherence of patients in using telemonitoring was very high, 
indicating that the devices used for this study, in combination with daily measurements, 
were well accepted by patients and therefore acceptable when implementing regular care. 
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Computer decision support systems (CDSS) can contribute to more effective 
implementation of recommended guidelines and prescription of optimal dosage of 
heart failure medication. However, a widely spread implementation of CDSS in heart 
failure (HF) is lacking. The IN TOUCH study, a study on the effect of ICT-guided 
disease management in HF, incorporated a CDSS to improve guideline adherence of 
HF medication. During that study, minimal use of the offered CDSS was observed. The 
objective of our study was to explore the usability and acceptability of the implemented 
HF CDSS and to gain insight into barriers experienced by HF nurses in using a CDSS to 
start or up-titrate HF medication. 
Methods
A descriptive design was used with both quantitative (SUS questionnaire) and qualitative 
(interviews) data collection. The system usability scale (SUS) was developed and regularly 
used to measure the percieved ease-of-use of a CDSS. 
Results
In total, 9 HF clinics participated in this study. 27 SUS questionnaires from 27 
respondents were received (mean age 46 years). Of the 27 respondents, 15 participated 
in the interview procedure. The total score on the SUS questionnaire was 48 (SD 16) 
points. In the interviews, organizational, system-related and personal barriers were 
found. 60% of respondents admitted not using the CDSS because it was not integrated 
into the current electronic patient record, and 40% stated that they were not allowed to 
use it by their supervisor (cardiologist). 47% stated that using the CDSS was too time 
consuming, was “awkward” and not “user friendly”, was not sophisticated enough, and 
that the advice of the CDSS did not correspond to daily practice. Finally, 27% stated they 
did not need a CDSS, experienced a lack of trust, or did not have enough knowledge to 
make appropriate use of it. 
Conclusions
The usability of the CDSS was considered very low; the average score on the SUS was 68 
points. Acceptance of the CDSS was also low mainly because of organizational, personal, 
and system-related barriers. The overall impression of the CDSS by respondents was that 
it needed more development. Therefore it was clear that success, in terms of optimal use 
of the CDSS related to start and up-titrate of HF medication, was not achieved.
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Introduction 
The prevalence of heart failure (HF) increases with age and as a result of lifestyle-
related risk factors such as myocardial infarction and hypertension. It is associated with 
a high re-admission and mortality rate.1  Many interventions have been developed in 
order to reduce these rates, for example, the structural prescription and usage of HF 
medication. This evidence-based prescription of medication plays a substantial role in the 
recent HF guidelines.2,3 However, healthcare providers still experience difficulties when 
implementing those guidelines in daily practice, especially in structural prescription and 
up-titration of HF medication.4 To encourage a better implementation of the recommended 
guidelines, computerized clinical decision support systems (CDSSs) as part of a disease 
management program could be used. These systems can provide advice and support in 
prescribing the optimal doses of medication.5 Based on the existing literature, a CDSS can 
provide software-based healthcare-related advice to assist healthcare providers in making 
decisions and developing solutions. Using a CDSS can significantly improve clinical 
outcomes and quality of care.6-9 
Despite the evidence for the effectiveness of CDSS, widely spread development, 
implementation, and evaluation of CDSSs in HF clinics are lacking.10,11 Mistrust and user 
resistance to CDSSs,12,13 have been described as major barriers for their implementation and 
use.13-16 Other barriers for using a CDSS include the lack of integration of the system into 
clinical workflow. Working with a CDSS, especially in the beginning, may be considered 
“too time consuming”.17 In the IN TOUCH study, which was designed to investigate the 
effects of telemonitoring, in addition to an information and communication (ICT) guided 
disease management system,18 a CDSS was incorporated to improve guideline adherence 
of HF medication (start and up-titration). 
During the monitoring visits of the IN TOUCH study (December 2009 to September 
2012) and analyses of the first raw data, we observed minimal use of the CDSS functionality. 
To judge a CDSS useful, it must be effective in many ways.19 Various factors—human, 
organizational, technological—will have an influence on the success or failure of the 
implementation and use of a CDSS.17 One of the outcome measures in this ‘judgment’ is 
the usability and acceptability of a CDSS.20 For this study, we defined usability as “ease-of-
use”, ie, the extent to which users found the CDSS easy to use. Ease-of-use is critical for 
the adoption of a CDSS.20 We defined acceptability as the extent to which users approved 
of or accepted the CDSS. To gain more insight into the usability and acceptability of the 
CDSS offered in the INTOUCH study, our objectives consisted of the following:
1. To explore the usability and acceptability of the HF CDSS.




Description of the system and incorporated CDSS functionality
A descriptive design was used with both quantitative (questionnaire) and qualitative 
(interviews) data collection. The qualitative data were analyzed according to a directed 
approach to content analysis.21 
CDSS
The CDSS that was evaluated was part of CardioConsult HF®, a computerized disease 
management system specifically developed and built for HF clinics in the Netherlands 
by Curit BV. For the up-titration of medication, the actual CDSS functionality provides 
advice based on the HF guidelines, guided by the actual HF medication, renal function, 
blood pressure, and heart rate of the HF patients. If vital signs (eg, blood pressure, renal 
function, and heart rate) of the HF patients are within predefined ranges, advice for 
the HF nurse is generated to start or further up-titrate the medication to an optimal 
dose. CardioConsult HF® is implemented as a stand-alone application and therefore not 
integrated into the hospital’s own electronic patient record (EPR) environment, except 
for the interchange between the CDSS and the hospital EPR for renal function, blood 
pressure, and heart rate, which is needed for the CDSS to advise on medication. Benefits 
of the CardioConsult HF® are that clinical content can be updated instantly and that the 
system is able to generate alarms and reminders for missing data. 
Data collection
System Usability Scale (SUS)
To measure the usability (“ease-of-use”) of the CDSS, we used the System Usability 
Scale (SUS).22 While SUS was intended to measure only the perceived ease-of-use as a 
dependent variable (a single dimension), recent research shows that it provides a global 
measure of system usability and subscales of usability and learnability. The usability of 
a CDSS is multilevel in principle. It provides not only insight into the characteristics 
of a CDSS, but also to individual familiarity with the CDSS. The SUS was developed by 
International Business Machines (IBM) and has been used in more than 500 evaluations 
of usability of health information technology.22 It has proven to be a reliable and valid 
instrument for measuring system usability. The SUS is a 10-item questionnaire with 5 
response options ranging from 1 (“strongly disagree”) to 5 (“strongly agree”). The average 
SUS score from all 500 studies is 68 points.22 Items 4 and 10 of the questionnaire provide 
the learnability dimension, and the other 8 items provide the usability dimension. In 
our study, Cronbach’s alpha was .80 for the total scale. Cronbach’s alpha for the subscales 
learnability was .65 and for usability .82.
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Interviews
To describe the specific barriers for the minimal use of the CDSS function to start or 
up-titrate HF medication by HF nurses, semi-structured interviews were conducted and 
analyzed using content analyses.21 Nurses working in the 9 HF clinics in the IN TOUCH 
study who considered themselves as having the most experience with working with the 
CDSS were invited to participate and received written and verbal information. Those 
who were willing to participate in the interview procedure were approached by telephone 
by an interviewer who was independent of the study. Before the start of the interview, 
participants were further instructed about the procedure and anonymity. The interview 
guide, which was completed in approximately 15 minutes, included the following three 
questions: 1) “Can you tell or explain why you barely used or did not use the CDSS 
functionality of the offered system?”, 2) “In your opinion, what should change or should 
happen to result in more frequent usage of the system, specifically for starting or up-
titrating medication?”, and 3) “Do you have any further questions or comments regarding 
the previous two questions?” Additional questions (e.g. “Can you give an example?”, “Can 
you explain?”, “Can you elaborate?”) were asked to encourage participants to elaborate on 
their thoughts and responses.
Analysis
The quantitative data were analyzed using descriptive statistics. Data were presented 
by mean and SD or as percentages in the case of categorical data. Qualitative data on 
specific barriers for barely using or not using the CDSS were presented by describing, per 
category, the number of respondents that reported that specific barrier. Furthermore, the 
two most relevant reported barriers per category were presented. Statistical analyses were 
performed using PASW version 18.0 and ATLAS.ti version 7 for Windows. 
The complete interviews were recorded on tape and transcribed according to the 
verbatim method. Data were scored and categorized into system-related, organization-
related, and person-related barriers by 2 independent observers. These three categories 
were predefined and formulated on a practical and a theoretical concept,12,17 based on 
the assumption that the assessed barriers for not using the CDSS could be categorized 
into one of these three categories. Respondents were not informed beforehand about 
these three predefined categories. All text from the audio tape that was recorded and 
transcribed verbatim was coded using the predetermined categories whenever possible. 
Text that could not be coded into one of the three categories was coded with another 
label, called “other barrier”. In case of inconsistency in categorizing data into the three 
different categories by the 2 independent observers, a third observer was consulted. After 
this procedure, the tapes were erased; as a result, data could not be linked to respondent 
or clinic characteristics afterwards, in order to ensure anonymity. 
To control for the results of the observers and to obtain possibly new constructs and/
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or information, ATLAS.ti 7 software was used. This qualitative or nominal statistical 
software, designed for coding and analyzing qualitative data, did not give new insights 
other than what we already obtained as a result of the independent observers from the 
verbatim interviews. 
Results
In total, 27 SUS questionnaires were sent out to the HF nurses of the 9 HF clinics in 
the Netherlands who participated in the IN TOUCH study, with a total response rate of 
100%. Of the 27 participants, 15 regarded themselves as eligible for participating in the 
interview because they considered themselves as “most experienced” in working with the 
CDSS during the 9-month study period. All 15 respondents were willing to participate in 
the interviews, resulting in a 100% response.
Basic characteristics of the sample
The 27 respondents had a mean age of 46 (SD 10) and all were female. The mean years of 
work experience in the current position was 8 (SD 4) years, and the respondents worked 
with HF patients for an average of 26 (SD 8) hours a week. The mean experience in years 
of working with computers was 18 (SD 5) years. Respondents reported having at least 14 
(SD 3) years of experiences using email and Internet (Table 1). 
SUS
The total mean score of all 27 respondents on the SUS questionnaire (all 10 items) was 
48 points (SD 16) (Figure 1). The score of the subscale learnability was 5.6 (SD 1.5), with 
a theoretical range from 2 to 10 points, indicating a neutral opinion on the learnability of 
the CDSS. For the scores of the individual SUS questions, refer to Table 2.
Table 1: Summary of baseline characteristics (N = 27) 
Characteristic (SD)
    Age (mean), years 46 (10)
    Female gender (%) 96
    Years of experience in current position (mean) 8 (4)
    Working hours per week with HF patients (mean) 26 (8)
 Experience with computers (years) 18 (5)
    Email 15 (3)
    Internet 14 (3)
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Interviews
The various types of reported barriers were categorized into three predefined 
categories: organizational, system, and personal. The categories are known to influence 
the acceptability of a CDSS. To assess barriers related to the use of the CDSS, we first 
asked respondents: “Can you tell or explain why you barely used or did not use the CDSS 
functionality of the offered system?
Organization-related barriers
Fourteen of the 15 participants reported that not using the offered CDSS was directly 
related to the organization of their work. The average number of the quoted organization- 
related barriers was two. The reported barriers were: “the CDSS was not integrated into 
the existing EPR (Electronic Patient Record)” (n = 9), “no permission, or unwillingness 
to use the CDSS by the cardiologist” (n = 6), “the CDSS does not match the routine of our 
organization” (n = 3), “we use a different protocol for up-titration of medication” (n = 2), 
and “in the case of actually purchasing the system, it is too expensive” (n = 1).
System-related barriers
Of the 15 participants, 12 reported one or more system-related barriers for not using 
the offered CDSS. The average number of the quoted system-related barriers was two. 
The reported barriers of the participants were: “using the CDSS is too time consuming” 
(n = 7), “medication advice from the CDSS does not correspond with daily practice” (n 
= 7), “I find it awkward to use” (n = 7), “I find it not sophisticated enough” (n = 7), “the 
CDSS is inflexible” (n = 4), “it is not user-friendly” (n = 4), “the CDSS does not have any 
additional value” (n = 3), and “occurrence of system errors” (n = 1). 
Table 2: The 10 items the SUS questionnaire (N = 27; 5 response options ranging from 1(strongly disagree) to 
5 (strongly agree)
SUS items Mean SD
1. I think that I would like to use this system frequently. 2.1 1.1
2. I found the system unnecessarily complex. 3.5 1.1
3. I thought the system was easy to use. 2.6 1.1
4. I think that I would need the support of a technical person to be able to use this system. 1.9 0.9
5. I found the various functions in this system were well integrated. 2.6 0.9
6. I thought there was too much inconsistency in this system. 3.1 0.9
7. I would imagine that most people would learn to use this system very quickly. 3.0 1
8. I found the system very cumbersome to use. 2.5 1.1
9. I felt very confident using the system. 2.8 1.1
10. I needed to learn a lot of things before I could get going with this system. 2.4 0.9
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Person-related barriers
In total, 8 of the interviewed participants reported that not using the CDSS was person 
related. The average number of the quoted person-related barriers was one. Specifically, 4 
participants reported that they had “enough knowledge and experience”’ themselves and 
therefore did not find it necessary to use the CDSS to up-titrate medication, regardless of 
the added value of the system. Other barriers were “lack of trust in the CDSS” (n = 2), and 
“not enough knowledge to use the CDSS” (n = 2). “Negative previous experience with the 
system”, “dislike of the system”, and “lack of routine in using the system” were barriers that 
were reported by 1 respondent. Furthermore, 2 respondents reported that their patients 
were already on optimal medication. In summary, Table 3 presents the two most reported 
barriers per category.
The second question in the interviews was: “What should change or should happen 
to result in more frequent usage of the system, specifically for starting or up-titrating 
medication?”
The majority of the responders pointed out that the barriers (organization- and system-
related) would have to change for them to overcome their resistance to working with the 
offered CDSS. The most frequent desired change was a full integration of the CDSS into 
their own hospital environment (EPR), a further development of the system to provide 
more sophisticated functionality, such as reminders and alerts, and an adequate up-to-
date medication protocol that corresponds to daily practice. There was no recommended 
change regarding the barriers experienced in the person-related category.
Figure 1: All individual total SUS scores and mean scores (thin line = 48 points; the fat line = 68 points and 
indicates the average score of the 500 control studies).
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Discussion
One of the motivating factors for executing this study was the observed lack of use of 
the CDSS during the IN TOUCH study. Specifically, the functionality for starting and 
up-titration of HF medication was barely used. This is an interesting but also remarkable 
observation because the use of the medication titration module was a compulsory part of 
the IN TOUCH study protocol and because it was introduced primarily to help the HF 
nurses in applying a better guideline adherence to HF medication, as shown in earlier 
studies.5,6 It is extraordinary that even a strict study protocol for using the intentional 
“helpful” software tool did not lead to a higher usage in the group of nurses of the IN 
TOUCH study.
Principal findings
The users of the CDSS in this study qualified the overall usability or ease-of-use of the 
CDSS as low (48 points). Results of 500 earlier studies using the SUS questionnaire to 
measure the usability of a software tool22 showed that an SUS score below 68 points can 
be considered as “below average”. 
Furthermore, the acceptability of the CDSS was considered poor. Earlier research has 
shown that organizational, system-related, and human factors (ie, person-related factors) 
are frequently identified as the main cause of the failure of health information technology 
(HIT) implementations and that these factors are significant barriers in the acceptability 
of a system.12 The results of these earlier studies are similar to the findings of our study; 
participants quoted organization-, system-, and person-related barriers as reasons for not 
using CDSS.
Table 3: The most reported barriers for not using the CDSS per construct
System related % (n)
“using the CDSS is too time consuming” 47 (7)
“medication advice from the CDSS does not correspond with daily practice”
“I find it awkward to use”
”I find it not sophisticated enough”
Organization related
“the CDSS was not integrated into the existing EPR” 60 (9)
“no permission or unwillingness to use the CDSS by the cardiologist” 40 (6)
Person related
“I have enough skills myself, therefore I find it not necessary to use the CDSS” 27 (4)
“lack of trust in the CDSS”
“not enough knowledge to use the CDSS’” 13 (2)
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Barriers regarding acceptability
Our results showed that the lack of integration of the system within the hospital EPR 
environment was the most frequently cited organization-related barrier for not using 
the CDSS. Another important barrier for not using the CDSS was a lack of cooperation 
and unwillingness to work with the CDSS by the cardiologists involved. Approximately 
half of the nurse participants indicated that they were willing to start and up-titrate 
medication with the CDSS, but they were not allowed by the cardiologists in charge of the 
HF clinics to titrate medication with the help of the CDSS. Because we did not interview 
the cardiologists, we cannot elaborate clearly on this statement by the nurses. However, 
it is possible that the perception of a loss of experienced autonomy, unwillingness to rely 
on a computer-guided protocol, and a lack of trust in the offered CDSS might play a 
role.12,23 In this context, we also observed that users stated that the CDSS did not fit into 
the usual routine of their organization due to a different protocol for up-titration of HF 
medication. Not developing clinic-specific protocols that reflect the actual procedure in 
daily practice is a known obstacle for the introduction and use of HIT.24,25
The four most frequently named system-related barriers were mainly caused by the 
“immaturity” of the tested CDSS, ie, it was still too rudimentary. This clearly indicates 
that there is much more to be developed for this specific CDSS in the field of both general 
(eg, layout) and professional HF functionality (eg, medication protocols). The “time 
consuming” and “awkward” nature of the CDSS are two of the four most quoted (system-
related) barriers. The system was also described as “inflexible” and “incomplete” because 
a number of treatment protocols were missing. The reason “not sophisticated enough” is 
directed at a lack of sufficient alerts and reminders.
Regarding person-related barriers, several nurses indicated that they had personal 
barriers for not using the CDSS effectively. This is particularly evident in the case of users 
who classified themselves as “not having sufficient skills for properly titrating”. Others 
stated that they did not need a CDSS for titration and were very capable themselves of 
optimizing medication without the help of a CDSS. However, recent research on optimal 
medication in HF shows that a substantial number of HF patients do not receive optimal 
medication.26,27
To interpret the results of this study appropriately, it is important to address a number 
of factors that may have caused this lack of usage of the CDSS and consequently the 
outcome of this study. First, despite the CDSS being offered in the IN TOUCH study, it is 
known that HF nurses in the Netherlands do not have much experience in working with 
CDSSs. Second, this CDSS was specifically introduced and used within the framework 
of the IN TOUCH study, and due to a low inclusion ratio, experiences and routine in 
working with the CDSS in daily practice remained low. Third, because the CDSS was 
introduced as a research tool, integration in the hospital EPR was not possible and the 
system should be considered as a “stand-alone” program. Stand-alone programs are often 
designed and desired for “personal additional value” and therefore have limited technical 
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support across hospitals. A significant drawback of these additional stand-alone, patient-
related programs is the storage of various data sources into different systems. Double 
registrations are experienced as ineffective and characterized by low user acceptability 
and result in an increase in errors. The participating hospitals were permitted to use this 
CDSS for other HF patients outside the study, but this rarely happened. We conclude, 
therefore, that the users experienced little pleasure and/or benefit in working with the 
CDSS. It is obvious that if a new software tool is used, it will be judged critically on 
complexity and/or time saving and routine.28
Limitations
In this study, we assessed the usability and acceptability of only one CDSS in a specific, 
limited group of users. The generalizability of this study, therefore, may be questionable. 
However, the outcome is quite similar to that of other studies.  
Implications and future research
It is important to understand why users classify a system as lacking “ease-of-use” or rate 
it low in “acceptability”; these practical experiences provide useful information on how to 
implement CDSS in daily practice and to develop and improve the system to a higher level 
or generation. In a recent review, Gagnon et al17 pointed out a number of interventions 
and strategies that could potentially overcome this HIT implementation failure. The 
most important factors for a successful adoption were: training for users varying from 
general instruction to intensive training, the usage of “super users”, a realistic perception 
of the benefits of the innovation (e.g., the possibilities of a CDSS, but maybe even more 
important, the impossibilities of a CDSS). “Ease-of-use” was the second most cited 
facilitator for a successful adoption. Interestingly, sociodemographic characteristics such 
as age, gender, experience, etc., were seldom considered as HIT adoption factors. Because 
the results of our study are, in principle, comparable with studies in other domains, it is 
therefore reasonable to assume that these interventions and strategies could improve the 
usability and acceptability of an HF CDSS as investigated in our study. 
An often cited principle for successful usage of health information technology in this 
context is “KISS”, meaning “Keep It Simple Stupid” (or more kindly, “Keep It Short and 
Simple”). This principle was used in the 1970s when computer programmers preferred to 
avoid large, time-consuming, and complex computer programs. These days, the “KISS” 
philosophy is still popular and used to introduce simple, easy-to-use, and understandable 
new technology in healthcare.29 To help the introduction of health information technology 
and so the usage of CDSSs, it is important, aside from further technical development of 
CDSS, to focus in further research not only on successful implementation strategies but 
also on the barriers encountered, in order to find the most effective way of using CDSSs. 
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Conclusions
The main conclusion of this study is that the usability and the acceptability of the offered 
CDSS in HF clinics were considered poor, mainly due to organization- and system-related 
barriers. These findings were largely attributed to the “immaturity” of the CDSS itself and 
the fact that the CDSS was not integrated into the existing EPR environment.
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Although telemonitoring is increasingly used in heart failure care, data on expectations, 
experiences, and organizational implications concerning telemonitoring are rarely 
addressed, and the optimal profile of patients who can benefit from telemonitoring has 
yet to be defined. Our objective was to assess the actual status of use of telemonitoring 
and to describe the expectations, experiences, and organizational aspects involved in 
working with telemonitoring in heart failure in the Netherlands.
Methods
In collaboration with the Netherlands Organization for Applied Scientific Research 
(TNO), a 19-item survey was sent to all heart failure clinics in the Netherlands.
Results
In total, 31 out of 86 (36%) heart failure clinics were using telemonitoring and 12 heart 
failure clinics (14%) planned to use telemonitoring within one year. The number of heart 
failure patients receiving telemonitoring generally varied between 10 and 50; although 
in two clinics more than 75 patients used telemonitoring. The main goals for using 
telemonitoring are “monitoring physical condition”, “monitoring signs of deterioration” 
(n=39, 91%), “monitoring treatment” (n=32, 74%), “adjusting medication” (n=24, 56%), 
and “educating patients” (n=33, 77%). Most patients using telemonitoring were in the 
New York Heart Association (NYHA) functional classes II (n=19, 61%) and III (n=27, 
87%) and were offered the use of the telemonitoring system “as long as needed” or 
without a time limit. However, the expectations of the use of telemonitoring were not 
met after implementation. Eight of the 11 items about expectations versus experiences 
were significantly decreased (P<.001). Health care professionals experienced the most 
changes related to the use of telemonitoring in their work, in particular with respect to 
“keeping up with current development” (before 7.2, after 6.8, P= .15), “being innovative” 
(before 7.0, after 6.1, P= .003), and “better guideline adherence” (before 6.3, after 5.3, P= 
.005). Strikingly, 20 out of 31 heart failure clinics stated that they were considering using 
a different telemonitoring system than the system used at the time.
Conclusion
One third of all heart failure clinics surveyed were using telemonitoring as part of 
their care without any transparent, predefined criteria of user requirements. Prior 




Telemonitoring in heart failure care is used to monitor patients’ symptoms at home and 
to guide patients in taking action in case of deterioration. Telemonitoring is considered a 
promising new intervention for heart failure patients, and a study on the use, perceptions, 
and experiences has been published recently.1,2 However, current evidence regarding 
the effectiveness of telemonitoring in the care of heart failure patients is conflicting.3 
There are many definitions used for telemonitoring, but the core principle does not 
generally differ. A commonly used international definition is “the remote monitoring of 
patients, including the use of audio, video, and other telecommunications and electronic 
information processing technologies to monitor patient status at a distance”.4 In the 
Netherlands, the most used definition is that telemonitoring includes the measurement, 
monitoring, collecting, and transfer of clinical data concerning the health status of 
a patient in his or her home environment, using information and communication 
technology. Initial studies showed that remote monitoring of heart failure patients 
reduced hospitalization and mortality rates.5-8 However, recent studies performed on a 
larger scale did not confirm these findings.9,10 Questions remain regarding the optimal 
patient profile for using telemonitoring, the technical aspects of the telemonitoring 
systems, the intensity and frequency of providing data, and the cost-effectiveness of the 
various telemonitoring systems used.11,12 Furthermore, expectations and consequences of 
telemonitoring for the organization of care, logistic processes, and the work of health care 
providers are rarely studied, and thus unclear. However, these aspects of telemonitoring 
are vital for the consideration and acceptance of these systems in future practice.13
Despite the inconclusive evidence for the use of telemonitoring in heart failure, 
telemonitoring is considered to be a promising development,7 and there are increasing 
efforts to introduce telemonitoring in outpatient heart failure clinics. In some countries, 
including the Netherlands, health care insurance companies reimburse telemonitoring 
for heart failure patients. The present study was designed to assess the perspectives and 
expectations for both heart failure nurses and cardiologists working in a heart failure 
team with telemonitoring.
To this end, the following research questions were posed: 1) What are the perceptions and 
expectations of cardiologists and heart failure nurses with respect to the implementation 
of telemonitoring in heart failure patients? and 2) What are their experiences with the 
implementation of telemonitoring? In this study, we did not focus on possible differences 





Participants in the study consisted of cardiologists and heart failure nurses working 
in heart failure outpatient clinics in the Netherlands. Out of all 118 Dutch heart failure 
clinics, 109 clinics received a questionnaire in March 2011, addressed to the cardiologists 
and heart failure nurses working in the heart failure outpatient clinic. Nine heart failure 
clinics were excluded and did not receive a questionnaire due to their participation in the 
IN TOUCH study, a study evaluating the added value of information and communication 
technology-guided disease management combined with telemonitoring for heart failure 
patients.14 Participants were requested to return the questionnaire within 12 weeks. We 
sent out two reminders.
Instrument
In collaboration with the Netherlands Organization for Applied Scientific Research 
(TNO), a 19-item questionnaire on telemonitoring was specifically developed for 
this study, based on the two research questions. For this questionnaire we defined 
telemonitoring as: “The remote, Internet-based monitoring and mentoring of heart 
failure patients on weight, blood pressure, heart rate, and signs and symptoms that 
disclose the actual condition of the heart failure patient. The devices are used by the 
patients in their own home environment and the generated data are transferred by the 
Internet”. The use of telemonitoring by means of telephone, telephone support, telephone 
follow-up, or by means of implantable devices was not included in this study because our 
focus was to investigate expectations and experiences of using telemonitoring devices 
that required an active user interaction (eg, direct handling of deviated values, generated 
alerts, and complaints). The technology and handling for users between implanted 
devices and external devices, such as weight scales and/or blood pressure measurements, 
are essentially different. Based on the research questions, items for the questionnaire were 
developed with the input of 10 cardiologists and 10 heart failure nurses, resulting in a 
questionnaire consisting of 3 domains: 1) availability of telemonitoring, 2) experiences 
with telemonitoring, and 3) organization of telemonitoring. The questionnaire consisted 
of both multiple choice and “agree/disagree” questions. For data regarding the motivation 
for and importance of using telemonitoring, as well as the experiences with using 
telemonitoring, we asked respondents to rate 11 items on a 10-point scale. On this scale, 
0 counted as “not important”’ and 10 as “very important”.
These 11 items were based on practical considerations related to the start-up of 
telemonitoring. Aside from addressing the practical considerations of health care 
workers in our study, these same 11 items are frequently used by sales representatives to 
convince future users of the added value of working with telemonitoring. The 11 different 
items could be combined into 3 groups: 1) direct patient care (better self-management, 
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improving quality of care, and reduction of (re) admission); 2) telemonitoring system–
related aspects (current development, innovation, and better guideline adherence); and 
3) organizational aspects (treating more patients, fulfilling hospital policy, reducing 
workload, lowering heart failure related costs, and fulfilling health care insurance policy).
Validation Process of the Questionnaire
To test the questionnaire, a group of 30 pilot responders, representing the future research 
population, completed the questionnaire. Internal consistency (Cronbach alpha) of the 
questionnaire in the current sample was .85. This parameter measures the reliability of 
the scale. A set of questionnaire items with a reliability of .70 or higher is considered 
acceptable. Face validity (10 cardiologists, 10 heart failure nurses) was assessed by 
analyzing the feedback received on the total questionnaire.
Statistical Analysis
Descriptive statistics were used to present the data. For some parts of the analysis, 
we subdivided the respondents into current telemonitoring users (n=31) and intended 
telemonitoring users (n=12), because some research questions are related to actual 
experiences of working with telemonitoring and other are more exploratory (eg, which 
patients do you think are suitable for applying telemonitoring?). Paired samples t tests 
were used to examine possible differences between expectations of and experiences with 
using telemonitoring. Analyses were performed using PASW, version 18.0 for Windows.
Results
Basic Characteristics of the Study Population
Of the 109 heart failure clinics who received a survey, 86 clinics responded (79%). Their 
responses were included in the analysis. Respondents had a mean age of 48 ± 8 years, 
and 68% were female. The mean years of work experience in the current position was 
14 ± 9 years, and the respondents worked with heart failure patients for an average of 
19 ± 10 hours a week. Of the 86 responding clinics, 31 reported using telemonitoring 
in their current patient care (36 %), and 12 clinics (14%) planned to use telemonitoring 
within one year. Further analysis was therefore restricted to the clinics that actually used 
telemonitoring and those that planned to use telemonitoring within one year (total n=43).
Availability of Telemonitoring
The three systems most frequently used for telemonitoring were commercially available 
systems (Motiva, Health Buddy, and IPT Telemedicine),15-17 and one clinic had developed 
its own telemonitoring system. The systems used in this study are generally similar to 
each other based on functionality. They transfer measurements generated at home and 
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Table 1: characteristics of the commercial available telemonitoring systems used in this study
Motiva 27 Health Buddy 28 IPT-Telemedicine 29
Monitoring
Blood pressure yes yes yes
Weight yes yes yes
Heart frequency yes yes yes
Electrocardiography no yes yes
Questions
Symptoms yes yes yes
Knowledge heart failure yes yes yes
Change of behavior yes yes yes
Informing of patient about
Symptoms yes yes yes
Knowledge about heart failure yes yes yes
Change of behavior yes yes yes
Communication
Datacenter yes yes yes
Medical service Center yes no yes





Direct feedback of healthcare 
provider to patient
yes, by phone yes, by phone yes, by phone
Continue feedback to healthcare 
provider
yes,  through software 
on desktop
yes,  through software 
on desktop
yes,  through portal
Alerts in case of deviation of 
predefined measurements
yes,  through software 
on desktop
yes, risk profile’s 
(low-middle-high)
yes,  through  portal
Patient requirements
Ability to read yes yes yes
Active input yes yes yes
Cognitive functional yes yes yes
Manual extensive simple simple
Television yes no no
Source: Inventarisatie eHealthNu Expertgroep Hartfalen 2010; authors: TNO Kwaliteit van Leven, Ton 
Rövekamp, Pim Valentijn). For specific product information see references 27-29.
answers to questions to a health care environment via the Internet. The Health Buddy 
system differs, however, because it transfers the data directly to the health care provider 
instead of a data center. This means that the heart failure nurses are directly responsible for 
the handling of data and measurements. However, the consequence of directly receiving 
data and measurements is the need for a 24/7 shift of health care providers.
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The feedback from the health care provider to the patient in all three systems is given 
by telephone. For the specific characteristics of the commercially available systems used 
in this study,18 see Table 1.
The clinics that intended to use telemonitoring within a year mostly reported (42%, 
n=5) that they planned to use the Motiva system (Table 2). The number of patients using 
telemonitoring in a clinic varied between 10 and 50, but in two clinics more than 75 
patients used telemonitoring.
The following main goals for implementing telemonitoring were reported: “monitoring 
physical condition”, “monitoring signs of deterioration” (91%, n=39), “monitoring 
treatment” (74%, n=32), “adjusting medication” (56%, n=24), and “educating patients” 
(77%, n=33) (see Table 3). Beside these goals, most clinics also used this as a practical 
reason to start telemonitoring.
Experience With Telemonitoring
Patient Profile
The criteria for using telemonitoring for a specific patient were reported to be based on 
“needing education” (68 %, n=29), “increasing self management” (63%, n=27), “having 
complaints of heart failure symptoms” (60%, n=26), and “being (re) admitted due to 
heart failure” (60%, n=26). See Table 4.
Respondents from 8 clinics reported that the current use or amount of medication 
were reasons for using telemonitoring. The majority of respondents (85%, n=36) stated 
that the New York Heart Association (NYHA) functional class was not a reason to start 
telemonitoring (see Table 5).
In order to determine the best course of therapy, heart failure professionals assess the 
stage of heart failure according to the New York Heart Association (NYHA) functional 
classification system (see Table 6). This classification system relates symptoms to everyday 
Table 2: Availability and use of telemonitoring (TM) system by actual users (n=31) and planned users (n=12)
TM systems Actually used system
(31 clinics)
System of choice in case 
of a new decision
(31 clinics)
No current user but 
expecting to make a 
choice within 1 year
(12 clinics)
Health Buddy 7 (28%) 2 (8%) -
Motiva  14 (46%)  4 (12%) 5 (42%)
IPT Telemedicine 6 (15%) 2 (6%) -
Other systems 4 (11%)  3 (10%) 2 (16%)
No choice yet -   4 (12%) 2 (16%)
Unsure -   16 (52%) 3 (26%)
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activities and the patient’s quality of life. The NYHA class is not a determined factor for 
the application of telemonitoring according to the guidelines.
Nevertheless, patients in NYHA class II and III were most often reported to be enrolled 
for telemonitoring, whereas no patients in NYHA class I used telemonitoring. In total, 
15% of patients in NYHA class IV used telemonitoring.
Length of Time of Telemonitoring
Most respondents stated that they monitor their patients with telemonitoring “as long 
as needed” or without a time limit. Six clinics noted a maximum time period for using 
telemonitoring per patient between 3 and 6 months respectively. In response to the 
question on whether clinics (n=43) could estimate which of the total percentage of all 
patients in heart failure care were suitable for telemonitoring, the mean percentage was 
10%.
Telemonitoring System
Fifteen of the 31 clinics that actually used telemonitoring stated that if a new selection 
process were to be put in place, they would choose a different system compared to the 
Table 3: General descriptive data of heart failure centers using (31) and plan to use (12) telemonitoring (TM)
Number of patients in TM care N= 31 clinics
None   2 (6%)
0-10   5 (16%)
10-20   8 (26%)
20-50 11 (35%)
50-75   3 (11%)
>75   2 (6%)
Main goal of using TM (31 + 12  clinics, more answers possible) N= 43 clinics
Monitoring physical conditioning, signs of deterioration 39 (91%)
Monitoring and adjustment of treatment 32 (74%)
Titration of medication 24 (56%)
Patient education 33 (77%)
Other goals   3 (7%)
Duration of applying TM in patient care N= 31 clinics
Between 3 and 6 months   6 (19%)
Between 6 and 12 months   6 (19%)
No limit   9 (30%)
As long as necessary 10 (32%)
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Table 4: Criteria for applying telemonitoring (TM) in heart failure (HF) patients, more answers possible
Criteria for applying TM N= 43 clinics
Education 29 (68%)
Patient management 27 (63%)
HF Re-admission 26 (60%)
Complaints HF symptoms 26 (60%)
Based on actual NYHA class 13 (30%)
Medication status   8 (19%)
Different   2 (4%)
Table 6: NYHA: New York Heart Association classification for heart failure
Class Patient symptoms
Class I (Mild) No limitation of physical activity. Ordinary physical activity does not cause 
undue fatigue, palpitation, or dyspnea (shortness of breath).
Class II (Mild) Slight limitation of physical activity. Comfortable at rest, but ordinary physical 
activity results in fatigue, palpitation, or dyspnea.
Class III (Moderate) Marked limitation of physical activity. Comfortable at rest, but less than 
ordinary activity causes fatigue, palpitation, or dyspnea.
Class IV (Severe) Unable to carry out any physical activity without discomfort. Symptoms of 
cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is 
increased.
Table 5: NYHA class in telemonitoring (NYHA: New York Heart Association classification for heart failure), 
more answers possible
Actually NYHA class of patients currently using 
telemonitoring  
N= 31 clinics
NYHA I 0 (0%)
NYHA II 19 (61%)
NYHA III 27 (87%)
NYHA IV 5 (15%)
Which NYHA class in your patient population is suitable for 
applying telemonitoring? 
N= 43 clinics
NYHA I 3 (6%)
NYHA II 14 (32%)
NYHA III 18 (41%)
NYHA IV 10 (23%)




system they currently used. Sixteen clinics indicated that they were not sure which system 
they would choose (see Table 2). Of the 31 clinics, 14 reported that they were satisfied 
with their current telemonitoring system. The other 16 clinics took a neutral stance, and 
one user reported to be dissatisfied with the telemonitoring equipment.
Expectations Versus Experienced Outcomes
In Figure 1, the expectations of applying telemonitoring are compared with the 
experienced outcomes after implementation of telemonitoring. The combined 3 groups 
of aspects of working with telemonitoring (direct patient-related care, telemonitoring 
system aspects, and organizational aspects) and 10 of the 11 separate items showed that 
the actual experiences did not meet the prior expectations. The results showed that users 
had high expectations of the benefits of using telemonitoring, in particular with respect 
to direct patient-care aspects (mean 7.4).
Expectations of the system-related aspects (mean 6.8) and organizational aspects (mean 
6.0) were also high. However, these high expectations of the use of telemonitoring were 
not reflected in the actual experiences after implementation. The largest difference was 
Figure 1: Expectations of applying telemonitoring and experienced differences after applying telemonitoring 
(31 clinics) y-axis: 0=’not important’, 10 = ‘very important’.  * =P<.0001, # innovation = P.003, # better 
guideline adherence  = P.005, ns (non-significant)=P.146 (paired sample T-test).
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found in the group of organizational aspects (reduction of workload score, 5.9 versus 3.5, 
P<.001) and lowering heart failure–related costs, score 5.8 versus 3.2, P<.001). The aspect 
“keeping up with current developments” was the only one in which a reduction was not 
significant (score, 7.2 versus 6.8, P=.15).
Organizing and Financing Telemonitoring
A total of 12 clinics (39%) reported to be in a “start-up” period; whereas the other 19 
clinics stated that they had fully integrated telemonitoring in their daily care routine. 
Rules and protocols on the implementation of the system and responsibility for 
incoming data were available in 70% of the clinics. Protocols on the acceptable length 
of time between the moment of incoming patient data and the response of the caregiver 
(response-reaction time) were available in 60% of the clinics. With respect to financing, 
54% of telemonitoring systems were financed by health care insurance companies, 13% 
by project financing, and 7% by the hospital itself or the cardiology department. The 
other 26% of the clinics did not give insight into their financing of telemonitoring.
Discussion
The most prominent result of our study was that, although the respondents had high 
perceptions and expectations of working with telemonitoring, these were not positively 
reflected in the actual experiences.
The trade-offs directly related to the telemonitoring system were most often addressed, but 
important trade-offs of telemonitoring concerning direct patient care and organizational 
aspects were only briefly mentioned or not reported at all. A striking finding is that the 
majority of responding heart failure clinics stated they were considering the use of a 
different system than the system currently used. Furthermore, aspects of direct patient 
care (like monitoring and education) were reported as main goals for implementing 
telemonitoring.
The dominant criteria for using telemonitoring for a specific patient included 
“education”, “heart failure (re) admission”, and “complaints of heart failure symptoms”. 
Thirty percent of the respondents mentioned that the actual NYHA class is a criterion 
for applying telemonitoring, but at the same time only 15% stated that the NYHA class 
was decisive for applying telemonitoring. In actual practice, the majority of the patients 
showed to be in NYHA class II and III. Finally, although 1 out of 10 patients was suitable 
for telemonitoring, the actual number of patients using telemonitoring was limited in 
general and the duration of the use of telemonitoring unknown. Despite the increased 
introduction and use of telemonitoring in heart failure, there has been little research 
regarding user-related aspects of working with telemonitoring. Therefore, it is unknown 
to what extent expectations, experiences, and possible difficulties in the implementation 
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process of telemonitoring are present in health care providers working with telemonitoring. 
In this first study to focus specifically on the application of telemonitoring in heart failure 
clinics, we showed that heart failure clinics have high expectations of patient care, system, 
and organizational outcomes of working with telemonitoring.
In an earlier study on the expectations of telemonitoring of caregivers in nursing homes, 
Chang et al19 reported that respondents expected the benefits of improved efficiency and 
quality of care, reduction of medical costs, and a reduced workload. However, experiences 
of telemonitoring were not measured in the study of Chang et al. Although the evidence 
for the use of telemonitoring in heart failure patients is still growing,5-8 gaps in knowledge 
about the use of telemonitoring in heart failure remain.3,20,21 These gaps in knowledge are 
mainly caused by the absence of data on adequate patient profiling and the overall cost-
effectiveness of telemonitoring.
Despite the presence of conflicting evidence on the usefulness of telemonitoring for 
heart failure and the lack of data regarding the implementation of telemonitoring, the 
consequences for health care providers, and the logistic processes in daily practice, more 
than one-third of all heart failure clinics in the Netherlands have implemented this 
new technology for some of their heart failure patients. This indicates that health care 
providers have high expectations of working with telemonitoring and are even willing 
to start working with telemonitoring in the absence of guidelines, protocols, and solid 
evidence for its usefulness. The use of telemonitoring, however, is still in its infancy, 
and many clinics are still searching for a way to provide telemonitoring efficiently and 
effectively. A similar experience was reported with respect to the selection processes for 
electronic patient records and other technology tools in health care.22-24 Users were either 
extremely positive or negative about their system, and this had a “wait-and-see” effect 
on potential future users. Negative experiences were reflected in the fact that some users 
were considering looking for a different system than the system currently used. The need 
for a different system seems to be primarily driven by the practical usage of the system, 
which falls short of expectations. Our findings indicate that the actual functionalities 
of the telemonitoring system itself are of great importance to the respondents. Hence, 
it is questionable if the feeling of overall disappointment is indeed the result of a 
failing telemonitoring system or is due to a lack of efficient organization around the 
implementation of telemonitoring systems.
For future success it is very important to create an efficient organization around a 
system.13 In the case of telemonitoring, this means that a system should be integrated in 
a heart failure clinic in which heart failure nurses11,25 have a coordinating role and have 
insight in all aspects of patient care (eg, health care professionals involved, situation at 
home). Within this setting, the heart failure nurse can take appropriate action on the 
data received from the telemonitoring system.26,27 Furthermore, additional training is 
required in which insight and understanding of receiving data, data handling, evaluating 
expectations, and effect monitoring are vital.28
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Our data showed that in 61% of the heart failure clinics that actually worked with 
telemonitoring, it was used only in small cohorts with numbers of 10 to 50 patients. 
Although this concerns only a limited number of patients, it is important to realize that 
monitoring 50 heart failure patients (next to the treatment of other heart failure patients) 
might cause a substantial amount of additional work with respect to logistic adjustment, 
training on using the system, and the development of protocols on data handling, response 
time, and treatment. We could therefore predict that implementing telemonitoring will 
not automatically decrease workload.
In this first study on user-related aspects of telemonitoring, we demonstrated that the 
optimal use of telemonitoring remains a challenge. The main finding of our research 
is that a substantial difference exists between prior expectations of telemonitoring and 
the actual use of telemonitoring in daily practice. The focus on, for instance, optimizing 
medication by using telemonitoring, however, has been shown to be a promising and cost-
effective future application.29,30 While the use of telemonitoring is still in its infancy, it is 
important to learn from current experiences, even if it currently concerns only a limited 
number of telemonitoring systems and patients. Ongoing studies such as the IN TOUCH 
trial14 in the Netherlands should provide more evidence about cost-effectiveness and the 
effects of telemonitoring in combination with different types of disease management in 
heart failure.
A finding that has to be specifically addressed is that most of the respondents indicated 
that telemonitoring will be applied as long as needed or can even be used indefinitely. This 
approach should be critically evaluated. First, it might not be the most cost effective in 
terms of using equipment and staff. Most intervention studies on the use of telemonitoring 
were short in follow-up, and therefore there are no data available that support the choice 
for (life) long use of telemonitoring. Second, ethical issues can be raised about whether 
or not patients would benefit from lifelong monitoring, regardless of the burden on their 
personal lives. Other notable findings were that 85% of the respondents indicated that 
the NYHA functional class was not decisive for the application of telemonitoring and 
that most patients who received telemonitoring were in NYHA functional classes II and 
III. Although the optimal patient profile for successful use of telemonitoring has not yet 
been described, it can be expected that specifically patients with severe and more unstable 
heart failure are suitable for telemonitoring and would benefit in terms of preventing 
re-admissions. Considering this, it is remarkable that in daily practice telemonitoring is 
increasingly used for patient education and for optimizing medication in patients with 
less severe heart failure.
Limitations
For this study, we used a self-developed questionnaire that was not designed to test 
the feasibility of a telemonitoring system, but rather to examine both the general 
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considerations and reasons for applying telemonitoring in Dutch heart failure clinics, 
as well as the organizational aspects these systems address. In this study, we did not 
focus on possible differences in the perception of working with telemonitoring of heart 
failure nurses and cardiologists, because the main goal of this study was to explore 
the expectations and experiences of a heart failure team working with telemonitoring. 
However, one might predict that the comments of the two separate groups would relate to 
their characteristics. Although we are aware of the limitations of asking about experiences 
with telemonitoring retrospectively, the design of this study could not correct for this. To 
account for this limitation, we have focused in the discussion on the learning aspects of 
the experiences instead of giving clear-cut conclusions.
Conclusion
This representative study (86 of 109 surveyed Dutch heart failure clinics) showed that 
one- third of heart failure clinics were using or planned to use telemonitoring as part 
of their care, albeit in a limited number of patients only. Our survey also showed that 
telemonitoring is not a success story yet. Respondents did not experience a decreased 
workload while working with telemonitoring, and prior expectations of introducing 
telemonitoring were not reflected in actual experiences, possibly leading to disappointment. 
Criteria for both the optimal duration period of using the telemonitoring system and the 
targeted patient groups were not established, and the choice for a telemonitoring system 
seemed to be made on the specifications of the system itself, rather than on organizational 
issues such as protocols or education of staff. All the suppliers of telemonitoring devices 
observed in this study provide the services of generating and transferring data from a 
home environment to a health care environment. Telemonitoring is not a “one size fits all” 
solution. From a patient point of view9,10 and supported by the recent European Society 
of Cardiology heart failure guidelines (2012), we conclude that the optimal profile of 
patients who might benefit from telemonitoring needs to be further explored. Long-term 
experiences are necessary to discover the most effective use of telemonitoring in terms of 
reduction of mortality, re-admissions, and improvement of quality of life.
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Clinical Decision Support Systems (CDSSs) can support guideline adherence in heart 
failure (HF) patients. However, the use of CDSSs is limited and barriers in working with 
CDSSs have been described as a major obstacle. It is unknown if barriers to CDSSs are 
present and differ between HF nurses and cardiologists. Therefore the aims of this study 
are; 1. Explore the type and number of perceived barriers of HF nurses and cardiologists 
to use a CDSS in the treatment of HF patients. 2. Explore possible differences in perceived 
barriers between two groups. 3. Assess the relevance and influence of knowledge 
management (KM) on Responsibility/Trust (R&T) and Barriers/Threats (B&T).
Methods
A questionnaire was developed including; B&T, R&T, and KM. For analyses, descriptive 
techniques, 2-tailed Pearson correlation tests, and multiple regression analyses were 
performed.
Results
The response- rate of 220 questionnaires was 74%. Barriers were found for cardiologists 
and HF nurses in all the constructs. Sixty-five percent did not want to be dependent on 
a CDSS. Nevertheless thirty-six percent of HF nurses and 50% of cardiologists stated 
that a CDSS can optimize HF medication. No relationship between constructs and age; 
gender; years of work experience; general computer experience and email/internet were 
observed. In the group of HF nurses a positive correlation (r .33, P<.01) between years 
of using the internet and R&T was found. In both groups KM was associated with the 
constructs B&T (B=.55, P=<.01) and R&T (B=.50, P=<.01).
Conclusions
Both cardiologists and HF-nurses perceived barriers in working with a CDSS in all of 
the examined constructs. KM has a strong positive correlation with perceived barriers, 
indicating that increasing knowledge about CDSSs can decrease their barriers.
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Introduction 
With a growing elderly population and improved survival after myocardial infarction, 
the number of patients with heart failure (HF) is increasing. HF is associated with a high 
re-admission and mortality rate.1 In order to reduce these rates, many strategies have been 
developed over the years. The structural application of disease management programs 
is one such important strategy, and proven to be an important contributor.2-5 Disease 
management programs can be effective in improving the outcomes of HF patients and are 
therefore advised in recent HF guidelines.5,6 Since the introduction of those guidelines for 
both pharmacological and non-pharmacological treatment of HF patients, more patients 
have been treated with evidence based medication,7-9 and clinical outcomes of fewer 
cardiovascular hospitalizations have been observed.10 However, healthcare providers 
still experience difficulties when implementing those guidelines in daily practice.11 The 
ESC HF pilot survey12 showed that the rate of prescribed medication that adheres to 
the guidelines is satisfactory, but the number of patients that receive the optimal dose 
of ACE-inhibitors, beta blockers, and aldosteron antagonists nevertheless still remains 
suboptimal. To improve guideline adherence, clinical decision support systems (CDSSs) 
could, for instance provide advice and support in prescribing the optimal doses of 
medication,13 help with managing the complex care process of HF patients, and improve 
guideline implementation.14 There are many definitions of a CDSS15 but the core principle 
remains the same throughout. Based on the literature, a CDSS can be said to provide 
software-based healthcare-related advice to assist doctors and nurses in making decisions 
and developing solutions, and is often used in complex or non-routine situations.
There is evidence that when using a CDSS, the performance of healthcare providers 
on clinical outcomes in general improves the quality of care significantly.14,16-18 Despite 
this evidence for the effectiveness of CDSS, a widespread development, evaluation and 
implementation of CDSSs, especially in HF clinics, is lacking.19,20 One of the reasons for 
this underutilization seems to be a certain level of mistrust or user resistance to CDSSs,21,22 
which has been described as a major barrier for implementing and using CDSSs.22-25
Theoretical background
In general, barriers to guideline adherence consist of a lack of awareness, a lack of 
agreement or perceived self-efficacy to change, minimal outcome expectancy, and inertia 
associated with a lack of faith in existing treatment practices.26 For this study a practical 
working definition of barriers was defined as: ‘’a barrier is the HF healthcare worker’s 
perception or estimation of the level of (objectively or subjectively) experienced obstacles’’. 
This indicates that a (perceived) barrier is the result of a complex mental process, in which 
earlier experiences, beliefs, social environment, and education influence the number of 
experienced barriers, both in facilitators and in perceived barriers. 
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Varonen et al.21 identified potential barriers and facilitators of general physicians to 
using CDSSs such as earlier experience with dysfunctional computer systems, potential 
harms to the doctor-patient relationship, unclear responsibilities, threats to clinicians’ 
autonomy, and extra workload due to excessive reminders. Poor computer skills can 
also be a barrier to the implementation of a CDSS.27 The next generation of healthcare 
providers, however might bring with them a higher level of computer literacy, thus 
possibly helping the implementation of a CDSS. 
Knowledge of a CDSS and the management of knowledge itself28 (i.e., understanding the 
underlying process of dataflow, the establishment of decisions made by a CDSS, and the 
assessment of the value of automatically conducted advices by self-generated data input) 
have been described in earlier research as strong influencers (positive facilitators), for 
reducing barriers. At this moment however there is limited knowledge about the type and 
number of barriers experienced in working with CDSSs by healthcare providers caring 
for HF patients. The justification for our study is that CDSSs are increasingly considered 
to be very effective instruments for improving guideline implementation.14,29,30 Therefore 
we decided to perform this study to increase knowledge about barriers to the adaption 
of CDSSs.
The aims of the present study are:
1: To explore the type and number of perceived barriers of HF nurses and cardiologists 
to using a CDSS in the treatment of HF patients. 
2: To explore possible differences in perceived barriers between two groups of 
respondents (cardiologists / HF nurses).
3: To explore whether characteristics such as age, gender, education, profession and 
computer skills are related to the number of perceived barriers. 
4: To assess the relevance and influence of Knowledge Management on Responsibility/
Trust (R&T) and Barriers/Threats (B&T). 
Methods
Development of the questionnaire
The term “barrier” is often used as an umbrella term for covering a whole range of 
differently and subjectively perceived concepts. This heterogeneity makes it difficult to 
actually measure a barrier itself. Previously described barriers have been classified in 
five constructs; trust, responsibilities, threats, resistance, and knowledge management. 
These constructs were used as indicators of perceived barriers in our study. Since no 
valid instruments have been developed to measure barriers concerning CDSSs in the 
domain of HF, a questionnaire based on earlier findings of Varonen21 Leslie,27 Short,22 and 
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Toth-Pal23 was developed. In all of these studies, the reported barriers met the criteria 
of the aforementioned constructs, (i.e., trust, responsibilities, threats, resistance, and 
knowledge management). In this study, the various items to be used in the five constructs 
were first defined (Table 1), and later reduced by means of interviews and pilot-testing 
with pilot responders (10 cardiologists and 20 HF nurses) to a set of item groups. The 
final questionnaire consists of 49 items, focusing on perceived barriers using a 5-point 
Likert type rating scale. (Table 5, questions of perceived barriers on CDSS questionnaire).
Validation process of the questionnaire
To test the questionnaire, a group of 30 pilot responders, representing the future research 
population, completed the questionnaire. Face validity was assessed by analyzing the 
feedback received on the total questionnaire. 
As a result of the pilot, and based on remarks of the pilot responders,  the original 
two constructs, ‘responsibility’ and ‘trust’ could be pooled together to form one scale 
(Responsibility and Trust; R&T). The items belonging to the original constructs ‘threats’ 
and ‘resistance’, could similarly be grouped together in a single scale, named  Barriers 
and Threats (B&T). The items of the fifth construct formed the scale of Knowledge 
Management (KM). Since a lower score on each separate item (1 = totally agree to 5 = 
totally disagree), indicates more knowledge, a lower score on this construct also indicates 
more knowledge about a CDSS. After all responders filled in the questionnaire (N=162), 
reliability of the questionnaire in terms of Cronbach’s alpha was .85 for the total scale. 
This parameter measures the reliability of the scale. A set of questionnaire items with 
a reliability of .70 or higher is considered to be acceptable. Cronbach’s alpha for the 
subscales ranged from .67 to .79. To identify possibly non-observed variables, or new 
combinations of variables which could indicate another new construct, a factor analysis 
was performed. However, no new insights for combining items differently were found. 
The factor analysis thus supported the decision to combine the original five constructs 
into three (new) main constructs. 
Table 1: Definition of constructs
Construct Definition
Responsibility The extent to which the user can take accountability for their (professional) actions and its 
consequences for the (professional) actions by others.
Trust The expectation of the user that the offered CDSS is doing what is promised and that you 
can rely on it.
Barrier A user objectively or subjectively experienced obstacles to the use of a CDSS








Descriptive statistics were used to characterize the study population (mean and 
SD) and to describe the results of the 49 questions. To examine a possible correlation 
between characteristics of the respondents and the three constructs, ‘R&T’, ‘B&T’, and 
‘KM’, 2-tailed Pearson correlation tests were used. To assess an association of R&T and 
B&T with KM and the effect of four other theoretically relevant variables (age, years 
of experiences in current position, years of experience in working with computers, 
and the use of telemonitoring), multiple regression analyses were performed using the 
“Forward” selection method.31  All analyses were conducted for both the whole group 
and the separate healthcare providers (cardiologists, HF nurses). Missing values (3%) 
in the questionnaires were corrected by replacing them with mean values per construct. 
Statistical analyses were performed using PASW version 18.0 for Windows.
Results
Study population
In March 2011, 220 questionnaires were sent out to all 110 HF clinics in the 
Netherlands. Because most HF teams consisted of one cardiologist and two HF nurses 
we can estimate that there are approximately 110 HF dedicated cardiologists and 220 HF 
nurses (distribution 1/3-2/3) in the Netherlands. The questionnaire was addressed to the 
cardiologists and HF nurses working as a team in a HF outpatient clinic. Participants were 
requested to return the questionnaire within 12 weeks, and two reminders were sent out. 
In June 2011 the response period ended, bringing the total response-rate to 74% (total 
162 questionnaires, 36 questionnaires from cardiologists;  = 32% of the 110 estimated 
HF dedicated cardiologists and 126 questionnaires from HF nurses;  = 57% of the 220 
estimated HF nurses). Compared to the responders, the non-responders were equally 
divided among working region and in professional position. All baseline characteristics 
of the study population had a normal distribution; there were no extreme outliers (Table 
II). Thirty-five percent of the responders had experience in working with telemonitoring 
systems.
Basic characteristics of the study population (Table 2)
Respondents had a mean age of 48 ± 8 year, and 68% ± 45 were female. Of the 
respondents, 22% were cardiologists and 78% were HF nurses. The mean years of work 
experience in the current position was 14 ± 9 years, and the respondents worked with 
HF patients for an average of 19 ± 10 hours a week. The mean experience in years of 
working with computers was 17 ± 6 years. Cardiologists have more experiences in years 
of working with computers in general (p = 0.01) as in more complex computer routine 
as working with operating systems (p = 0.02) and working with software applications 
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(p = <0.01). No differences were found between cardiologists and HF nurses regarding 
the use of email and the internet (p=ns). Respondents reported no experience with 
programming language, but did have 13 years of experiences using email and the internet. 
It is known from earlier experiences and field research that specific CDSS systems for HF 
in the Netherlands are seldom used. However, one third of the total respondents had 
experience in using telemonitoring. (Table 2) Because most of the telemonitoring systems 
that are used in the Netherlands have some CDSS functionality incorporated (e.g. advice 
to take action based on incoming alerts) it seems justified to assume that 30% of the 
responders have more or less experiences in using CDSS and therefore responded to the 
questionnaire based on practical experiences. For the score of all respondents and the 
separate scores of cardiologist and HF nurses we refer to Table 5. All single items of the 
CDSS questionnaire were normally distributed. 
Table 2: Summary of Baseline Characteristics Perceived Barriers in CDSS (N=162)
Cardiologist HF nurse Total
(N=36) SD (N=126) SD (N=162) SD
Characteristic
Age (mean),y 50 8 47 9 48 8
Female sex (%) 9(25) 45 102(82) 36 111(68) 45
Work region       
     North 9  27  36  
     Middle 13  45  58  
     South 12  53  65  
 Education       
    University 34  5  39  
     Master  40  40  
     Applied science  86  86  
Years of experience in current position (mean) 16 9 6 3 8 6
Working hours per week with HF patients (mean) 11 10 21 8 19 10
 Experience with computers (y) 19 7 16 5 17 6
    Operating systems 16 7 13 5 14 6
    Software applications 16 6 12 5 13 6
    Programming language 
    Email 13 5 13 4 13 5
    Internet 13 4 13 4 13 5
    Use of telemonitoring systems (%) 49  32  35  
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Responsibility and trust (R&T)
Towards more barriers; sixty-five percent of the respondents indicated they believe 
that a CDSS can make mistakes. The “clinical expertise” of the healthcare provider was 
rated as more important and not easily replaced by a computer.  The human factor in 
interpreting clinical patient data and making decisions on treatments was estimated as 
more important than an advice from a CDSS (98%). Ninety percent stated that advices of 
a CDSS should always be checked.  Seventy-nine percent stated that they are responsible 
for the treatment of “their” patients and not a CDSS. Sixty-five percent of the respondents 
stated that they did not want to depend on a CDSS and 50% reported that they still felt 
responsible for an advice given by a CDSS. Forty-nine percent of the respondents stated 
that they always checked an advice given by a CDSS and 87% stated that they will always 
check how a CDSS generates an advice.
Towards less barriers; most respondents stated that a CDSS can give useful advice about 
the treatment they should implement (80%). Thirty-five percent reported that in their 
opinion a CDSS is able to assess patient data, and 18% of the respondents reported that 
they would easily heed to an advice given by a CDSS. 
Barriers and threats (B&T)
Towards more barriers; one third (32%) reported that advice given by a CDSS complicates 
the treatment process. Also, one third (30%) stated that if they have to adapt advices of a 
CDSS this would costs them time. Sixty-five percent was uncertain about whether advices 
of a CDSS would improve their care. 
Nearly 75% of the respondents were uncertain about the time it will take to work with 
a CDSS during their patient contact. Twenty percent found it confusing that a CDSS 
gives advice about their treatment, and 70% were uncertain whether such an advice 
should be adapted or not. More than 80% of the respondents did not know whether a 
CDSS especially designed for HF patients would be convenient. Seventy percent stated 
that they would always notice if deviations or shortcomings in data, such as laboratory 
tests, physical examinations, and medication appear or are present. Forty-nine percent 
of the respondents asserted that the development of a CDSS is still in its infancy, and 
25% indicated that they need complementary computer skills to work in a satisfactory 
way with a CDSS. Seventy percent were not sure or disagreed that following a treatment 
advice given by a CDSS has no influence on whether or not the patient takes a doctor or 
a nurse seriously.  Thirty-nine percent reported that a “normal/standard” patient record 
provides sufficient information. Ninety percent disagreed with the statement that anyone 
can treat a HF patient with the help of a CDSS.
Towards less barriers; sixty-two percent of the respondents reported that advice of a 
CDSS on how to treat a HF patient is a welcome supplement to their own expertise, 
whereas another 30% reported that a CDSS that works with guidelines can be adapted 
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quickly. A total of 46% of the respondents stated that the use of a CDSS will not influence 
the relationship with their patients and 55% stated that a CDSS supplements their 
independency as a HF care expert. 
Knowledge management (KM)
Towards less barriers; sixty percent of the respondents declared that a CDSS can give 
advice about treatment and gives insight in the treatment process of a HF patient and 
thus has additional value for the treatment. Fifty percent stated that a CDSS especially 
designed for HF has added value for their work, and 50% believed that it can give useful 
information about the treatment. Eighty percent proclaimed that information supplied 
Table 3: Differences found in response to a selection of the questions between HF nurses (HF) and 
cardiologists (cardio). 
% agree % not agree
HF cardio diff. HF cardio diff.
Knowledge management
A CDSS gives me useful information about the 
treatment.
68 43 26 0 3 3
A warning from a CDSS about the course of 
treatment is very welcome.
36 62 26 21 6 15
I can determine the optimal dose of heart failure 
medication much faster with the help of a CDSS.
36 50 14 21 12 9
Responsibility and Trust (R&T)
The treatment I prescribe to my patients could 
depend on a CDSS.
36 65 29 23 27 4
A CDSS can give advice about the treatment I should 
implement.
81 67 14 6 6 0.2
The Healthcare Inspectorate should stimulate the use 
of a CDSS that can provide treatment advice.
21 18 4 18 32 14
Barriers and Tread  (B&T)
When I use a computer during patient contacts, this 
does not influence my relationship with the patient.
45 32 13 29 55 26
A CDSS could play a dominant role during a 
consultation.
20 9 11 38 53 15
A CDSS reduces my work load. 10 0 10 37 49 12
The application of guidelines by a CDSS is still in its 
infancy.
36 64 28 2 0 2
A CDSS that works with guidelines can be adapted 
quickly.
27 44 17 2 10 8
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by a CDSS adds (additional) value to their own knowledge of treating HF patients.  Fifty 
percent reported that a CDSS makes it easy to use HF guidelines and that it can update 
protocols, and sixty percent reported that they could learn from a CDSS. The respondents 
stated that their ability to apply guidelines improved and they felt positive about a warning 
or alert given by a CDSS about the course of the treatment. Forty percent reported that 
with the help of a CDSS they are better able to adjust optimal dosages of medication. 
Sixty-five percent were of the opinion that other healthcare providers involved in care for 
HF patients should all work with the same CDSS system.
Towards more barriers; Twenty percent stated that they are not better able to adjust 
optimal dosages of medication with the help of an CDSS. Another 10%  stated that  a 
CDSS that provides advice about treating heart failure gives no insight into their treatment 
process.
Differences between cardiologists and HF nurses (Table 3)
In the descriptive analyses of the constructs, differences were found between the groups 
of respondents (cardiologists versus HF nurses). In the 2-tailed Pearson correlation 
tests of the total group, no significant correlation between age, gender, years of work 
experience, general computer experience or experience with operating systems, computer 
programs, and email/internet within the three constructs (B&T, R&T and KM) were 
found for the total group. This means that there is no significant relation between the 
baseline characteristics and B&T, R&T, and KM. The most prominent differences with 
respect to the three constructs are described in Table III. In the subgroup of HF nurses 
there was a significant positive correlation between years of using the internet (r= .33, 
P<0.01), years of using email (r= .23, P<0.05), and years of computer experience (r= 
.29, P<0.01) in relation to R&T. There was also a positive correlation between years of 
computer experience and the construct KM (r= .22, P<0.05). 
In the multiple regression analyses the variables age, years of experience in current 
function, years of experience in working with computers, the use of telemonitoring, 
and the construct of KM itself were tested on their possible association with B&T and 
R&T (Table IV).  These variables were chosen for their relevance and strong presence 
in the baseline characteristics. Only KM had a strong, independent association with the 
constructs B&T (B= .55, P=<.01) and R&T (B=.50, P=<.01). Respondents who reported 
that they were currently using telemonitoring systems tended to experience less B&T (B= 
-.13, P=.06) In summery we found that warnings, alerts, and advices given by a CDSS 
to enable better guideline adherence seem to be less adopted by the group of HF nurses. 
Cardiologists find the use of a CDSS a negative interfering source in their patient 
contact and are not convinced of reduction in work but are in comparison to HF nurses 
more aware of the value of a CDSS in terms of medication adherence. In the group of HF 
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nurses, a significant positive correlation between variables related to computer experience 
and the examined construct (R&T and KM) were found, which indicate reduced barriers 
towards CDSS. 
Discussion
In this first study to examine the number of perceived barriers on working with a CDSSs 
by cardiologists and nurses, we found a substantial number of perceived barriers in using 
a CDSS in two of the three constructs (R&T and B&T). The results of the construct KM 
in general showed that most respondents do see the added value of a CDSS in terms 
of learning, being better informed about the treatment, and a possibly better guideline 
adherence.  Our study explored whether demographic factors, education, and/or computer 
experience are related to the number of perceived barriers in using a CDSS. Insight into 
and understanding of these barriers is important because the implementation of CDSSs 
in HF care can play a significant role in optimizing the management of HF medication 
according to the guidelines. 
It is generally known that optimizing medication management in HF patients reduces 
readmission and mortality rates. The respondents of this study were both highly 
Table 4: Multi variate regression analyses; association of B&T and R&T with independent variables (all 
respondents)
Barriers and Threats (B&T)
95% CI   
B (SE) Lower Upper P-value
Age -.02 (.05) -.10 .07 .74
Knowledge management .55 (.09) .57 .92 <.01
Years of experience in current function .09 (.06) -.05 .19 .24
Years of experience in working with computers -.03 (.06) -.14 .09 .63
Use of telemonitoring -.13 (.05) -2.08 .06 .06
Responsibility and Trust (R&T)
95% CI   
B (SE) Lower Upper P-value
Age -.01 (.04) -.09 .08 .91
Knowledge management .50 (.09) .46 .82 <.01
Years of experience in current function .11 (.06) -.03 .20 .16
Years of experience in working with computers -.03 (.06) -.09 .14 .65







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































experienced in working with HF patients, and in working with computers, email, the 
internet, and software programs. However, contrary to results reported in earlier studies,21,27 
in the subgroup of cardiologists (N=36) no correlation was shown between age; gender; 
experiences in working with computers, programs, and software on perceived barriers. 
The often heard presumption that “working with computers” positively influences the 
capability to work with CDSSs and hence causes fewer barriers was therefore not proven 
for the group of cardiologists in this study. This is an important finding because previous 
results from other studies suggest that there might be a relationship between poor 
computer skills, age, and computer literacy in physicians, which in turn might facilitate 
or hinder the implementation of CDSSs. However, in the subgroup of HF nurses (N=126) 
different types of experience in working with computers strongly influenced the number 
of perceived barriers, in particular with respect to responsibility and trust (R&T). More 
experience in working with computers was related to higher scores on R&T and therefore 
to a lower number of perceived barriers. This dissimilarity between cardiologists and 
HF nurses might be explained by differences in professional position and the amount 
of autonomy and/or final responsibility in treatment decisions. It is imaginable that HF 
nurses experience more support from a CDSS as a ‘helper’ in making important treatment 
decisions instead of experiencing a loss of autonomy. 
Interestingly, a high percentage of respondents who already worked with telemonitoring 
were found. This could have influenced the number of perceived barriers, because the 
telemonitoring systems used in the Netherlands have CDSS functionality incorporated 
(e.g. advice to take action based on incoming alerts). Beside these experiences in working 
with CDSS’s, working with this new technology probably indicates a certain preference 
for technology. For this reason we corrected by using telemonitoring as a covariate in the 
multivariate regression analyses. However, no significant relation between the constructs 
and the use of telemonitoring itself was found.  It is remarkable that when a CDSS is 
less informative and instead gives more direct and stringent advice (alerts, warnings, 
and request for additional information), respondents seem to have more hesitations or 
reserves towards a CDSS. This is interesting because this functionality in particular marks 
the main difference between ‘regular’ software and a CDSS.  A possible explanation for 
this finding could be that this specific functionality of a CDSS is seen as causing a loss of 
professional autonomy. 
In general, the barriers to the adaptation of a CDSS are similar in both the groups of 
HF nurses and the group of cardiologists, although some differences were found between 
the two groups. It is difficult to interpretate these differences because the scores on the 
constructs towards a greater or lesser number of barriers fluctuated as much in the group 
of HF nurses as in the group of cardiologists. However, warnings, alerts, and advices 
given by a CDSS to enable better guideline adherence seem to be less adopted by the 
group of HF nurses. This could be a result of who is actually performing the HF care in 
daily practice. A perceived feeling of lost autonomy can therefore be more present in the 
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young profession of HF nursing. 
There were some known prejudices about CDSSs found in this study. We have seen 
statements confirmed or reject such as ‘CDSS is still in its infancy’, ‘CDSS can reduce my 
workload’, and ‘CDSS can play a dominant role during a consult’.  These are important 
factors to consider when introducing and implementing a CDSS in daily HF practice. 
These prejudices or presumptions can be seen as barriers and are associated with a lower 
adoption level of a CDSS, and can therefore possibly result in a decrease of adherence to 
guidelines. The construct Knowledge Management itself was, as expected, not a barrier 
and was associated with the constructs B&T and R&T. This indicates that a higher level 
of knowledge in understanding the underlying mechanism of a CDSS leads to a decrease 
in barriers. This is understandable, because comprehension of how a CDSS works gives a 
more realistic view of the possibilities and impossibilities of a CDSS. The fact that a CDSS 
is not a magic black box, but will only generate advice by means of predefined formulas 
and data provided by the HF professionals themselves, will give more attention to the 
system’s capabilities. This could prevent disillusions and lead to a more positive attitude 
towards CDSSs. 
Limitations
This study has some potential limitations. First of all, we are aware of the disadvantages 
of using data based on self-reports. Unfortunately, in the Netherlands we do not have a 
long history of experience in working with CDSSs in the field of HF.  Second, the following 
two questions were central when developing the questionnaire: ‘Did we identify the right 
constructs and independent variables to measure the strength of perceived barriers’, and 
‘Are the constructs representative enough to determine the perceived barriers’? In our 
pilot we found that four of the five defined constructs (responsibility with trust, and 
barriers with threats), are strongly aligned to each other and exist in a continuum as it 
were. Because of this continuum, it was difficult to measure these constructs separately. 
Combining these related constructs therefore seemed a logical and explainable action. 
Finally, although the overall response rate of this questionnaire was more than reasonable 
(74%) and the distribution is in line with the distribution of HF- dedicated cardiologists 
and HF nurses working in the Netherlands, the actual response of the cardiologists was 36 
questionnaires, making the sample of cardiologist rather small with consequently effect 
for the power of the study. The identified constructs used in this research were based 
on the available literature on barriers to the adoption of CDSSs. Therefore, we believe 
that we have sufficient reasons to acknowledge that the identified constructs indeed give 
information on barriers to using CDSS, although further research should be conducted 
to give more insights in this specific field.
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Conclusion
The first and second aim of our study was to explore the type and number of perceived 
barriers of cardiologist and HF nurses in using a CDSS in the treatment of HF patients. 
This study showed that HF nurses and cardiologists working in HF clinics in the 
Netherlands - while taking into account differences between the groups - indeed have 
substantial perceived barriers in all three examined constructs when working with a 
CDSS.  The third aim was to explore whether characteristics such as age, gender, and 
experience in working with computers influenced the strength of the perceived barrier. 
In the group of cardiologists this was not the case. However, in the group of HF nurses, 
experience in working with computers and with email and the internet, had a strong 
effect on B&T and R&T. 
These are therefore factors that should be taken into consideration, as described in earlier 
studies. Our fourth aim was to assess the influence of Knowledge Management on R&T 
and B&T. Knowledge Management has a strong, significant association with perceived 
barriers, indicating that users who find the CDSS useful experienced less percieved 
barriers and that suggests that increasing knowledge will decrease barriers. Teaching 
future users about the underlying mechanism behind CDSSs can probably decrease 
the strength and number of perceived barriers. Though it is important to highlight the 
possibilities of a CDSS, it is perhaps even more important to discuss the impossibilities 
of a CDSS so as to adequately manage the expectations and presumptions of users about 
this kind of software support.  In spite of the presumption that telemonitoring devices are 
‘smart devices’ and require a higher level of computer literacy, no significant association 
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Despite clear guidelines, patients often do not receive maximum doses of heart failure 
(HF) medication. Disease management programs (DMPs) are known to increase 
guideline driven prescriber adherence, but it is not known what differences exist in 
prescriber adherence between programs. Objective: 1: To explore the differences in 
prescriber adherence of three different HF-DMPs. 2: Explore if the severity of HF is 
related to the (sub)- maximum dose of HF medication in the three DMPs. 3: To explore 
possible differences in all cause mortality between the three HF DMP models. 
Methods
Data from the Martini Hospital (MZH, computer-based decision support driven), the 
COACH study (nurse led basic and intensive patient education),  and the DEAL study 
(an HF nurse with a dedicated HF physician) was used. Total percentages and (sub)-
maximum dosage (75%-100% of the target dose) of angiotensin- converting enzyme 
(ACE) inhibitors, angiotensin receptor blockers (ARB), combined ACE and ARB, beta-
blockers and Aldosterone antagonists were assessed. Multivariate logistic regression 
analyses were used to assess differences in prescriber adherence between the three DMP 
models and to analyze any relation to severity of HF. To gain insight in all-cause mortality 
and account for differences between the three groups we used propensity score analyses. 
Results
Data from 1564 patients were analyzed (426 MZH, 898 COACH, 240 DEAL). The 
total percentages of the maximum dose of prescribed HF medication, except for 
Aldosterone antagonists stayed below 50%. There is a significant relationship between 
variables associated with the severity of HF and the maximum dose of HF medication. 
The (sub)-maximum dose of prescribed medication (75 and 100% of the target dose) 
was significant higher in patients in the DEAL group and MZH group compared to the 
COACH DMP group for ACE, the combination of ACE and ARB, and beta-blockers and 
for Aldosteron in the COACH group versus the MZH. For the (sub)-maximum dose of 
ARB no differences were found between the three groups. The survival of patients in the 
MZH and the intervention group of DEAL were both  higher when compared with the 
patients of the COACH and the control group of DEAL patients.
Conclusion
The results showed that less than 50% of all patients received the maximum dosage HF 
medication as advised by guidelines, with the exception of Aldosteron blockers, even in 
DMPs that have medication uptitration as a specific component of DMP. 
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Variables that are an indicator of the severity of HF are related to the (sub)-maximum 
dose of prescribed HF medication. Adjusted for these variables, this study showed that 
HF DMPs that have a focus on optimization of medication significantly more often 
prescribe (sub)-maximum dosages of medication compared to a DMP that is focused on 
counseling. It is reasonable to assume that a higher prescriber adherence of medication 
results in better outcome in terms of survival.
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Introduction 
With a growing elderly population and improved survival after myocardial infarction, 
the prevalence of heart failure (HF) is increasing. HF is associated with high mortality and 
re-admission rates.1 In order to manage the burden of HF, disease management programs 
(DMPs) are implemented.2-5 DMPs can improve the outcomes of HF patients6 and are 
recommended in the recent HF European Society of Cardiology (ESC) guidelines (Class 
I recommendation, Level of evidence A).7 In these guidelines, a set of HF management 
components is recommended, such as optimization of HF medication, targeting to the 
maximum dosage. The ESC developed clear guidelines of starting up and up-titrating 
drug therapy in daily practice, and the HF pilot survey showed that adherence to these 
guidelines is satisfactory. However the number of patients who receive maximum doses 
of Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers 
(ARB), beta blockers and Aldosterone antagonists still remains suboptimal.8,9 Barriers 
related to optimal guideline adherence include deficits in knowledge, skills and attitude 
of healthcare providers.10-13 A possible helpful tool to overcoming these barriers is the use 
of a computer decision support system (CDSS).14-17 Through repeatable alerts to start the 
right medication and reminders for up-titration under safe and controlled conditions, a 
CDSS can help in achieving a better prescriber adherence, resulting in a higher dose of 
evidence-based HF medication.18,19 For the definition of prescriber adherence, we have 
adopted the description used by the National Institute for Health and Clinical Excellence 
(NICE) 2009 clinical guidelines:20 “The extent of which the prescriber’s action matches 
the agreed recommendations”. 
With respect to practical implications this indicates that the dosage of HF medication 
(ACE-inhibitor, ARB, beta blocker and Aldosterone antagonist) should be uptitrated to 
the recommended target dosage as pointed out in the HF guidelines. In these ESC HF 
guidelines, optimizing medical therapy is described as an important component of HF 
DMP programs. 
In the Netherlands at least three HF DMP models have been used; The first is a model 
in which a combination with a CDSS in standard HF care is used in an HF outpatient 
clinic of the Martini Hospital (MZH) in the Netherlands.21,22 The effects of this model 
were not studied until recent involvement in a clinical trial.23 The second model is the 
DMP used in the COACH study.24 COACH was designed to explore a possible difference 
between HF care provided by cardiologists, compared to two levels of an intensive nurse-
led HF DMP. Data from this trial showed that this model was not effective in reducing 
the primary endpoint of time to first HF readmission and all cause mortality. The third 
model is the DEAL model, which tested the effects of collaboration between an HF nurse 
and a dedicated HF physician compared to standard medical care. The primary outcome 
in the DEAL was a reduction of hospitalization for HF and/or all-cause mortality and 
an improved functional NYHA class and quality of life. This model had a strong focus 
on guideline prescriber adherence, and one important outcome in this study was a 
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significantly higher dose of prescribed HF medication in the intervention group.25 Since 
optimal HF medication therapy is directly related to a better outcome, we aimed to gain 
more insight into the possible beneficial effects in terms of clinical outcome of these three 
different HF DMPs in relation to the extent of prescriber adherence.
The aims of the present analysis therefore are (1) to explore differences in prescriber 
adherence of HF medication (ACE-inhibitors, ARB, beta-blocker and Aldosterone 
antagonist) in total percentages and (sub) maximum doses of medication in three 
different HF DMPs: a CDSS-driven intervention (MZH), a nurse-led basic and intensive 
patient education (COACH),  and an HF nurse and physician-directed model (DEAL); 
(2) to explore the relationship between severity of HF and the maximum dose of HF 
medication in the three different HF DMPs; (3) to explore possible differences in all-
cause mortality between the three HF DMP.
Methods
Patient data from the Martini Hospital’s HF outpatient clinic in Groningen, from the 
COACH study (Coordinating study evaluating Outcomes of Advising and Counseling 
in Heart Failure) and from the DEAL HF study (Deventer-Alkmaar HF project) were 
pooled in this analysis. Details on the design of the COACH and DEAL study and the 
CDSS model used at the MZH have been published elsewhere.14,25,26 Patients with systolic 
HF (LVEF <45) were followed for a period of 12, respectively 18 months in the three 
different DMPs and included in this analysis. For this study, we consider the maximum 
dose of medication (100% of the target dose) as the highest adherence. However, since the 
HF guidelines are based on medication trials such as MERIT,27 SOLVD28 and RALES29 and 
the majority of patients in these studies received 75% of the target dose, with significantly 
positive effects on mortality and readmission outcomes, we also consider 75% of the 
target dose as optimal adherence to the guidelines and clinical relevant. Therefore we 
observed the total percentages of HF medication (e.g. the number of patients that use a 
beta-blocker) and the maximum and sub-maximum target dosage (100% and 75%) of the 
separate HF medications in individual patients prescribed. 
We observed this for the HF medications; ACE-inhibitor, ARB, combined use of 
ACE and ARB, beta blocker and Aldosterone antagonist. Although the ESC HF 2001 
guidelines recommended that 50 mg of Aldosterone antagonist was indicated for patients 
in NYHA class III/IV, we adhered to 25 mg as the maximum dose because first, the DEAL 
study started in 2000 and in that specific period, 25 mg Aldosterone antagonist was set as 
the maximum dose, and second in the 2001-2005 HF guideline, Aldosterone antagonists 
were also frequently prescribed as an additive diuretic, besides being intervention therapy 
in the renin angiotensin Aldosterone (RAAS) system. Because there is no maximum or 
“optimum” dose for diuretics and the use or dose of diuretics is not related to a better 
outcome, we present only the total percentages of  diuretics in the descriptive analyses. 
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To calculate the percentages of prescribed doses of medication in quartiles at the end 
of the DM program, we assumed that patients who were on 100% of the target dose also 
were on the at least 75%, 50% and 25% of the target dose criteria. Patients who were on 
the at least 75%  criterion of the target dose also were on the at least 50% criterion and 
25% of the target dose criterion. 
Intervention models
       Martini Hospital (MZH)
Martini Hospital’s DMP14,21 consists of a CDSS that included patient records and data 
collected during standard care. For this study, we collected data from a theoretically 
ascertained baseline and 18 months of follow-up (similar to the period in which patients 
in the COACH were included. i.e., October 2002 to August 2006). Permission to access 
this hospital record was granted by the local Ethics Committee (M12.112063). Although 
written informed consent was not necessary for use of the MZH group data according 
to the local Ethics Committee, we asked the 429 patients if they had any objection to our 
use of their files. Three patients did not give their permission and were therefore excluded 
from m this analysis. 
HF patients with a reduced ejection fraction and NYHA functional class II- IV were 
referred to the HF DMP after admission for HF or a visit to the outpatient clinic, within 
a 4 week period. The treatment, both pharmacological and non-pharmacological 
were  controlled by and integrated into a CDSS, based on the ESC HF guidelines. The 
software for this CDSS was specifically developed for the treatment of patients with HF 
and uses algorithms for starting and up-titrating HF medication to maximum tolerated 
dosage. The CDSS is linked to the hospital laboratory and electrocardiography database 
to provide the titration algorithms with the necessary data. History and actual use of 
medication was introduced manually into the CDSS, due to a lack of integration of the 
pharmacological database. The treatment and number of visits are structured through 
automatically generated advice from the CDSS. Patients’ education and development 
of self-management are important issues, but there is a strong focus on optimization of 
HF medication. This model is defined by the users as an “ICT-guided medical-nursing” 
model, with no interference of a cardiologist in the pharmacological treatment of HF. 
However, in the case of a new (or other  cardiovascular) diagnosis, persistent complaints 
or the need for supervision, consultation by a cardiologist was optional. If the HF 
medication was optimal and patients were aware of signs and symptoms of deterioration 
and know how to respond adequately, they were discharged from the HF outpatient clinic 
and referred to regular follow-up by the cardiologist. Follow-up by telephone was used 
frequently for the adjustment of treatment and evaluating interventions, as well as for 
the up-titration of medication at a distance, without seeing the patient at the outpatient 
clinic. The mean visit rate of patients in the MZH DMP (face-to-face visits ) was 5 visits 
in a period of 18 months, excluding telephone calls (Table 1).
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       COACH
The COACH study was a multicenter, randomized controlled trial, designed to evaluate 
the effects of education and counseling by a HF nurse on clinical outcome. For our study, 
we pooled and used the data from the basic and intensive support groups. Because the 
COACH study did not differentiate between HF patients with reduced or preserved 
ejection fraction, for this analysis, we excluded the patients with a left ventricular ejection 
fraction above 45%. Patients in NYHA functional class II-IV were referred within 2 weeks 
after an admission for HF to the HF DMP, in addition to usual routine management by 
their cardiologist. This routine management included an outpatient visit after hospital 
discharge and then every 6 months afterwards. Patients were scheduled for additional 
visits to the HF nurse at the outpatient clinic and had monthly contact with the nurse 
(intensive treatment). Patients were educated using a protocol, and behavioral strategies 
were used to improve patient compliance. In addition, patients were instructed to contact 
the HF nurse if there was any change in their condition. In the first month after hospital 
discharge, weekly telephone contact was made and patients were visited at home by the 
HF nurse. Furthermore, telephone calls, 2 home visits, and multidisciplinary advice 
given by a physiotherapist, dietician and social worker were part of the intensive support 
intervention. The main focus of the COACH DMP was education, counseling and 
motivation. The designers of this study classified the treatment as “counseling intensive”. 
Although starting and uptitration of HF medication by HF nurses within the time window 
of the protocol was allowed, the majority of the patients were pharmacologically treated 
by their cardiologists. Patients received at least 13 or 26 visits in an 18-month follow-up 
period (depending on the study protocol), including telephone calls (Table 1).
       DEAL
The DEAL-HF study was a parallel group, randomized controlled trial designed to 
compare standard (usual) HF care to an intensive intervention by a combination of visits 
from an HF physician and a HF nurse. For this study, we used the data from the intensive 
treatment and control group. Patients in NYHA class III or IV after an admission or 
visit to the outpatient HF clinic were referred to the HF DMP. The patients received 
an intensive follow-up with 10 visits, performed at increasing intervals by both an 
experienced HF nurse and an HF physician. Comprehensive education and counseling 
was given to increase knowledge, skills and motivation. In the DEAL intervention, there 
was a strong focus on optimization of HF medication, facilitated by the presence of a 
physician, including the assessment of electrocardiography and laboratory results. The 
physician interpreted signs and symptoms, collected possible side effects of the prescribed 
medication and performed physical examination used clinical judgment and optimized 
pharmacological therapy. In addition there was emphasis on recognizing and how to 
anticipate adequately signs of deterioration. Increased access to healthcare, including 
extra visits or intervention by a cardiologist whenever needed, was optional. The total 
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follow-up period was 12 months with a total number of nine face-to-face instances of 
contact with the HF nurse and HF physician, excluding telephone contacts and extra 
visits when needed (Table 1). 
Statistical analyses
Descriptive statistics were used to characterize the sample; data are presented as mean 
± standard deviation when normally distributed, as median and interquartile range when 
non-normally distributed, and as frequencies and percentages for categorical variables. 
Differences between baseline variables were evaluated by Student’s t test, Kruskal-Wallis 
test, Mann-Whitney U, Wilcoxon, chi-square or Fisher exact tests, as appropriate. 
Data on medication at entry to the MZH HF DMP were not available. Therefore the 
differences in total percentage of medication at entry can be assessed only between the 
COACH and the DEAL group. To assess associations between the maximum dose of HF 
medication and the severity of HF, we performed multivariate logistic regression analyses 
with both variables associated with the severity of HF7 and with variables that were 
univariate associated (P=< 0.01) with maximum dose of HF medication, resulting in: 
age, sex, LVEF, previous hospitalization, days of hospitalization, hospitalizations during 
treatment, ischemic etiology, NYHA functional class, laboratory values (eGFR, sodium, 
hemoglobin), heart-rate, and blood pressure. As pointed out in the methods section we 
performed analysis with patients who were on (sub)-maximum recommended dose 
(100% and 75% of the target dose) of ACE-inhibitor, ARB, the combined ACE and ARB, 
beta blocker and Aldosterone antagonist. We performed these analyses on the composite 
of all HF medication as well on the separate medication To assess whether a DMP had an 
independent effect on the maximum and sub-maximum dose of prescribed medication, 
we introduced each DMP into our multivariate model. In order to gain insight into the 
observed survival, associated with the different DMPs we combined the care as usual 
groups of COACH and DEAL and tested them against the groups of patients allocated 
to the different DMP models.  Because patients were not randomly assigned to the DMP 
models, we matched patients based on their probability or propensity to receive the 
model at study entry.30,31 The Propensity Score is the conditional probability of receiving 
an exposure (e.g. a DMP model) given a vector of measured covariates, and can be used 
to adjust for selection bias when assessing causal effects in observational studies. The 
estimated propensity score was obtained from the fit of a multinominal logistic regression 
model for which we considered the following variables: age, gender, etiology, LVEF and 
NYHA class, co-morbidities, prior admission for HF, laboratory (hemoglobin, eGFR, 
sodium, creatinine), blood pressure and heart rate. We used caliper matching, restricting 
propensity score matches to be within 0.05. P-value was set at 0.05. Analysis were 
performed using PASW version 18.0, R version 2.15.1. and STATA 11.0.
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Table 1: Characteristics of the three different heart  failure disease management models
MZH COACH DEAL
Intensive treatment yes yes yes
Follow-up 18 months (regular 
care)
18 months (protocol) 12 months (protocol)
Visit rate 5 (mean) excluding 
telephone contacts
13-26, depending on 
the protocol, including 
telephone contacts
9, excluding telephone 
contacts
Inclusion in DSM After readmission or 
outpatient clinic
After readmission After readmission or 
outpatient clinic
HF nurse yes yes yes
Physician no yes yes
Assessment of physical condition, 
  ECG and lab results
yes yes yes
Home visits no yes no
Treatment plan yes yes yes
Education/Counseling yes yes yes
Compliance yes yes yes
Monitoring signs and symptoms 
  of deterioration
yes yes yes
Telemonitoring yes (telephone) yes (telephone) yes (telephone)
Telephone access for patients yes yes yes
Easy access to care yes yes yes
Fulltime accessible (24/7) yes yes no (working hours)
Focus optimalisation of 
medication
yes no yes
Multidisciplinary advice yes yes yes
Multidisciplinary team no yes no
ICT-guided DSM/CDSS yes no no


















































































































































































































































































































































































































































































































































































































































































































































































































In total, 1564 patients were included in our analyses: 426 from the MZH group, 898 
from the COACH group (560 intervention, 338 control) and 240 from the DEAL group 
(118 intervention, 122 control). No differences in age and gender (mean age 70 years, 
female 35%) between the three DMPs were found. The mean LVEF was lower in  the 
COACH group (28%), compared to the MZH (34%, p=<0.001) and DEAL groups (31%, 
p=0.008). The COACH group had a significantly lower percentage of patients with 
ischemic HF (42% versus 60-63%, p=<0.001) and the COACH and DEAL group had a 
lower percentage of prior hospitalizations before inclusion, compared to the MZH group 
(31%-48% versus 66%, p=<0.001). The majority of patients (70%) in the MZH group 
were in NYHA functional class II, whereas patients in the DEAL group were primarily in 
NYHA class III (96%, p=<0.001), a direct result of the different inclusion criteria. In the 
COACH group the distribution between NYHA class II and III was equal (48% vs. 48%) 
and also significantly lower than the DEAL group (p=<0.001). eGFR and mean systolic 
blood pressure were significant higher in the MZH group compared to the COACH and 
DEAL. Other baseline characteristics are presented in Table 2.
Total percentage of HF medication at entry and after follow-up period
At the point of patients’ enrollment in the DMPs, the total percentages of ACE-inhibitors 
and beta blockers between the COACH and the DEAL groups were numerically not 
similar but did not differ significantly (ACE: 75% versus 83%, ACE/ARB: 84% versus 
97%, beta blocker: 67% versus 60%) with the exception of a lower amount of prescribed 
Aldosterone antagonist for the DEAL population (36% versus 55%, p=<0.001) and a 
higher amount of prescribed diuretics (74% versus 93%, p=<0.001) for the DEAL group.
After the DMP follow-up period, the total percentage for ACE-inhibitor in the MZH 
group was 75%, COACH was 71%  and  DEAL was 83%, (no significant differences 
between the three groups). ARB in the MZH group was 22%, COACH 18% and DEAL 
21% (no significant differences between the three groups). The combination of ACE and/
or ARB in the MZH group was 96%, COACH 86% and DEAL 96%. (MZH versus COACH 
p=ns, MZH vs. DEAL p=ns, COACH vs. DEAL p=0.01). For B-blocker this is MZH: 
82%, COACH 75% and DEAL 81%. (MZH versus COACH p=0.02). For Aldosterone 
antagonist MZH was 49%, COACH 51% and DEAL 60% (MZH versus DEAL p=0.05). 
Finally for diuretics the percentages were: MZH 75%, COACH 64% and DEAL 97% 
(DEAL versus MZH and COACH p=<0.001); see Table 3.
(Sub)-maximum doses of medication (100% and 75% of the prescribed target dose)
For the maximum doses of the separate HF medications (=100%) we observed that for 
all the DMP groups less than 50% of all patients had the maximum dose of HF medication 
(Table 3), with the exception of Aldosterone antagonist (25 mg), where we observed the 
highest percentage in the DEAL group (73%): MZH 56% and COACH 58%. (DEAL 
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P- v a l u e 
MZH vs. 
COACH
P- v a l u e 
MZH vs. 
DEAL
P- v a l u e 
COACH 
vs. DEAL
Medication at entry DMP-program
ACE Unknown 75% 83% 88% 69% ns ns ns
ARB Unknown 10% 14% 7% 15% ns ns ns
ACE /ARB Unknown 84% 97% 95% 84% ns ns ns
B-blocker Unknown 67% 60% 69% 65% ns ns ns
Aldosterone Unknown 55% 36% 29% 54% ns ns <0.001
Diuretics 74% 95% 77% 96% ns ns <0.001
Medication at end of DMP-program
ACE 75% 71% 83% 91% 48% ns ns ns
ARB 22% 18% 25% 12% 12% ns ns ns
ACE /ARB 96% 86% 108% 102% 60% ns ns 0.01
B-blocker 82% 75% 81% 79% 54% 0.02 ns ns
Aldosterone 49% 51% 60% 41% 59% ns 0.05 ns
Diuretics 75% 64% 97% 99% 93% ns <0.001 <0.001
Percentage of prescribed dose at end of DM program
ACE- inhibitor
≥ 25% 75% 50% 77% 77% 42%
≥ 50% 60% 33% 63% 64% 30%
≥ 75% 32% 15% 36% 37% 12% <0.001 0.46 <0.001
100% 31% 14% 35% 30% 11%
ARB
≥ 25% 23% 11% 20% 13% 12%
≥ 50% 14% 8% 16% 12% 10%
≥ 75% 3% 2% 6% 8% 4% 0.78 0.18 0.07
100% 3% 2% 6% 2% 3%
ACE/ARB
≥ 75% 34% 17% 41% <0.001 0.24 <0.001
B-blocker
≥ 25% 84% 48% 74% 53% 45%
≥ 50% 60% 29% 59% 25% 30%
≥ 75% 33% 13% 40% 1% 11% <0.001 0.18 <0.001
100% 30% 11% 34% 1% 11%
Aldosterone antagonist
12,5 mg. 41% 17% 20% 16% 12%
25 mg. 56% 58% 73% 68% 61% ns 0.02 0.03
50 mg. 3% 24% 7% 16% 27%
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Table 4: Multivariate logistic regression analyses on the combination of (sub)-maximum dosage of HF 
medication (≥ 75% of the target dose), all groups; MZH, COACH, DEAL) adjusted for; age, sex, LVEF, 
previous hospitalization¹, days of hospitalization², hospitalizations during treatment³, etiology (ischemic/non 
ischemic), co-morbidities, NYHA class II-III, laboratory, heart rate and blood pressure.
OR 95% CI P value
ACE-inhibitor (ACE)
Age (years) 0.98 0.97-0.99 <0.001
Hospitalization³ 0.68 0.51-0.92 0.012
NYHA III 1.01 1.00-1.02 0.002
Diast BP (mmHg) 1.02 1.01-1.04 0.005
Syst BP (mmHg) 1.01 1.00-1.02 0.008
Creatinine 0.99 0.99-1.00 0.027
eGFR 1.01 1.01-1.02 <0.001
Angiotensin- receptor blocker (ARB)
Syst BP (mmHg) 1.02 1.00-1.03 0.079
Combination of ACE and ARB
Hospitalization³ 0.71 0.53-0.94 0.017
Diast BP (mmHg) 1.02 1.00-1.03 0.016
Syst BP (mmHg) 1.01 1.01-1.02 <0.001
Creatinine 0.99 0.99-1.00 0.03
eGFR 1.01 1.00-1.02 0.001
Beta-blocker
Age 0.98 0.97-0.99 0.003
Syst BP (mmHg) 1.01 1.00-1.02 0.026
History of MI 1.33 1.06-1.67 0.015
History of hypertension 1.5 1.22-1.84 <0.001
History of AF 1.54 1.25-1.92 <0.001
History of DM 1.37 1.1-1.71 0.005
History of stroke 1.4 1.09-1.81 0.009
History of PCI 1.49 1.17-1.89 0.001
History of CABG 1.47 1.15-1.88 0.002
Aldosteron antagonist
Syst BP (mmHg) 0.99 0.98-1.00 <0.001
Sodium 0.95 0.92-0.98 <0.001
Creatinine 0.99 0.99-1.00 0.012
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Table 5: Multivariate logistic regression analyses on the combination of (sub)-maximum dosage of HF 
medication (≥ 75%of the target dose), adjusted for; age, sex, LVEF, previous hospitalization, hospitalizations 
during treatment, days of hospitalization, etiology (ischemic/non ischemic), NYHA class II-III,  sodium, 
eGFR, heart rate, blood pressure and HF disease management model MZH, COACH, DEAL.
OR 95% CI P value
ACE-inhibitor (ACE)
COACH-v-MZH 0.57 0.38-0.85 0.006
DEAL-v-MZH 1.93 1.0-3.78 0.05
DEAL-v-COACH 3.15 1.72-5.82 <0.001
Angiotensin- receptor blocker (ARB)
COACH-v-MZH 1.31 0.48-3.68 0.60
DEAL-v-MZH 1.94 0.46-9.66 0.38
DEAL-v-COACH 2.22 0.63-7.76 0.20
Combination of ACE and ARB
COACH-v-MZH 0.6 0.41-0.88 0.009
DEAL-v-MZH 1.94 1.03-3.69 0.04
DEAL-v-COACH 3.07 1.73-5.49 <0.001
Beta-blocker
COACH-v-MZH 0.36 0.24-0.54 <0.001
DEAL-v-MZH 1.75 0.94-3.27 0.078
DEAL-v-COACH 4.63 2.55-8.56 <0.001
Aldosteron antagonist
COACH-v-MZH 1.43 1.03-1.99 0.03
DEAL-v-MZH 0.86 0.47-1.56 0.62
DEAL-v-COACH 0.98 0.6-1.61 0.94
versus MZH p=0.02, DEAL versus COACH p=0.03) The percentage of (sub)-maximum 
dose of prescribed ACE-inhibitors, the combination of ACE/ARB and beta blockers at 
the end of the DMP were significantly higher in the DEAL and MZH group compared to 
the COACH (p=<0.001) (Table 3). A higher percentages of ARB tended to be prescribed 
in the DEAL group (p=0.07). The (sub)-maximum dose of Aldosteron antagonists was 
significant higher in the COACH and DEAL group compared to the MZH. 
Relationship between severity of HF and (sub)-maximum dose of medication 
Analyzing the relationship between the (sub)-maximum dose of separate HF 
medication and demographic and clinical variables, a significant relationship was found 
for ACE-inhibitors on age, hospitalizations for HF during treatment, NYHA class III, 
clinical variables co-morbidities and laboratory values. For ARB we found no significant 
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Figure 1: Kaplan Meier: survival curve of the three different HF  DSM models at 365 days. (MZH vs. control 
. p=0.03, OR: 0.46, CI [95%] 0.22-0.92; COACH vs. control p=0.48, OR: 0.85, CI [95%} 0.55-1.29; DEAL vs. 
control p=0.15, OR: 0.55, CI [95%] 0.24-1.20). 
relationship between the sub-maximum dose demographic and clinical variables. For the 
combination of ACE and ARB we found a significant  relationship with hospitalization 
for HF during treatment, blood pressure and laboratory values . For beta blockers we 
found a significant relationship with age, systolic blood pressure and co morbidities and 
for Aldosteron antagonist we found a significant relationship with the systolic blood 
pressure and laboratory values. (Table 4). 
Effect of the DMPs on the maximum and (sub)-maximum dose of HF medication
Looking at the effect of the three different DMPs on (sub)-maximum dose of medication, 
adjusted for demographic (age, sex) and clinical variables indicating severity of HF LVEF, 
previous hospitalization, hospitalizations during treatment, days of hospitalization, 
etiology (ischemic/non ischemic), NYHA class II-III,  sodium, eGFR, heart-rate, blood 
pressure) there was a significant difference between the MZH and DEAL versus the 
COACH on ACE, the combination of ACE/ARB, and beta blocker. The maximum dosage 
of ACE and the combination of ACE/ARB in the DEAL group was higher than in the 
MZH group (ACE: p=0.05, OR:1.93 CI[95%] 1.0-3.78, ACE/ARB: p=0.04, OR:1.94 CI 
[95%] 1.03-3.69). For Aldosterone antagonist we found a significant higher percentage 
of prescribed dosage in favor for the COACH versus the MZH group (p=0.03 OR:1.43 
CI[95%] 1.03-1.99) Table 5.
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All cause mortality
For survival in the three groups, according to the propensity score analysis, we observed 
a better survival for the MZH and DEAL group compared to the control groups than for 
the COACH group versus the control groups. i.e., MZH: OR:0.46, CI [95%]  0.22-0.92, 
p=0.03,. COACH group versus control OR:0.85, CI [95%] 0.55-1.29, p=0.48,  and DEAL 
group versus controlOR:0.55, CI [95%] 0.24-1.20, p=0.15,. (Figure 1). 
Discussion 
The main finding of this study is that the total percentage of medication of the DMPs 
at the end of follow-up were all considered quite acceptable. In examining the total 
percentages of prescriber adherence in the three different HF DMPs we found the DEAL 
to have the highest total percentages when compared to the other two models for ACE-
inhibitors, Aldosterone antagonists and diuretics, although it had included, when looked 
at NYHA and eGFR, more compromised HF patients. For beta blockers we found a 
(slightly) higher prescription in the MZH model. It is therefore interesting to observe 
that the DEAL model had the highest prescriber adherence in terms of total percentages 
for almost all HF medications. However, total percentage of prescribed HF medication 
is different than the (sub)-maximum dose of prescribed HF medication. Because HF 
guidelines advise uptitrating to maximum dosage, it seems therefore better to focus on 
(sub)-maximum dosage of medication rather than total percentages alone. We found that 
less than 50% of all patients received the 100% of the target dose medication as advised 
by guidelines, with the exception of Aldosterone antagonists, even in DMPs that have 
medication uptitration as a specific component of DMP.  
Many studies have pointed out that HF DMPs improve outcome in terms of mortality, 
readmissions and quality of life. Although the most effective DMP has not yet to be 
discovered,32,33 patients are increasingly treated with evidence-based medication.34,35 The 
MAHLER study showed a clear relationship between adherence to pharmacological 
guidelines (the actual use of the maximum dose of medication) and a lower rate of 
cardiovascular hospitalizations in HF patients.11 Nevertheless, healthcare providers still 
experience difficulties when implementing those guidelines in daily practice.36-39 On the 
other hand, it is important to realize that in most studies upon which the guidelines are 
based, patients did not achieve more than 75% of the target dose as advised.27,28,42,43 
In the multivariate regression analyses, we observed that variables that significantly 
influenced the maximum dose of HF medication were pre dominantly present (age, re-
hospitalization for HF, NYHA class, blood pressure and renal function). These variables 
are known for their negative influence on the dose of prescribed HF medication.40 For 
example, age, frequent readmissions, and a lower NYHA class are challenging factors in 
targeting to maximum dosage of medication. Therefore, despite lacking data on reasons 
why patients in the DMP groups were not targeted to maximum dosage of medication, 
it seems plausible that the severity of HF in patients in terms of re-hospitalization for 
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HF, NYHA class, blood pressure and renal function in all the DMPs might explain why 
“only” 50% were titrated to a maximum dosage.9,41 The exception was the prescribed 
dose of Aldosterone antagonist. Current HF guidelines do not give advice on how to 
deal (pharmacologically) with patients regarding co-morbidities, aging and frequent 
readmissions. 
An important issue to address is that the COACH intervention was primarily designed 
to determine a possible effect of patient education and self-management provided by 
an HF nurse and optimizing medication was not part of the treatment protocol. The 
MZH and DEAL interventions were primarily aimed to optimize medication, although 
the way this was performed was essentially different. In the DEAL intervention this was 
performed by the intensive cooperation of an HF dedicated physician and HF nurse. 
In the MZH intervention, this was done by an HF nurse, supported by a CDSS system, 
which had the potential to help in start and uptitration of medication.14-17  One of the 
advantages of working with a CDSS is the absolute certainty of data registration (e.g., side 
effects, maximum dosage in combination with clinical data) due to the simple fact that 
a CDSS does not work without constant data import. It follows exactly the predefined 
rules, often an exact copy of the guidelines. A CDSS can lead to faster therapeutic control 
because human-related factors (e.g., not up titrating medication because the patient is 
“feeling well and have no complaints”, or not uptitrating immediately after a readmission) 
are much less influential when working with a CDSS.44 This is mainly due to the alerts 
and reminders of the CDSS in the case of suboptimal HF medication. If there are updated 
therapeutic guidelines, changes can easily be incorporated into the CDSS and will 
immediately help the healthcare provider with advice based on most recent guidelines. 
A randomized controlled study was published recently with a similar DMP as the MZH, 
for patients with atrial fibrillation, with a positive outcome.16  In terms of the costs of 
the different models, it is in our study not possible to identify the most cost-effective HF 
DMP because this requires data specifically collected for cost effectiveness analyses. 
Although we are very aware of the limitations of this study, mainly caused by the 
different study designs  (observational versus randomized controlled trials), baseline 
character differences at baseline, different treatment protocols and focus of the HF 
DM models, we still believe that it is valuable to compare HF DMPs on their degree of 
prescriber adherence because, the guidelines recommend that optimizing medication is 
an important component for an HF DMP. Therefore, based on our findings we conclude 
that HF DMP models with a focus on optimizing medication, regardless of whether 
this is via a CDSS or a dedicated physician, are an important contributor to the degree 
of prescriber adherence. It is well known  that higher prescriber adherence is related 
to better survival and although using a propensity score analysis for this purpose has 
limitations, we assume that the observed higher prescriber adherence is reflected in the 
survival analysis. The fact that the DEAL survival, compared to the control groups in 
the propensity score analysis is not significant is probably caused by a small sample size. 
In the original DEAL study, the intervention group of the DEAL did show significant 
differences with respect to hospitalizations and all cause mortality compared to the 
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control group of the DEAL. This study explored the extent of prescriber adherence in 
terms of (sub) maximum dosage HF medication in different HF DM models. To obtain 
a better insight in the way optimal prescriber adherence can be achieved, more research 
is needed.
Conclusion
Prescriber adherence of HF medication in the three HF DMPs is high in terms of total 
percentages, but the number of patients that received a maximum dosage, as advised by the 
guidelines, was no more than 50%, with the exception of Aldosterone antagonists in the 
DEAL and COACH population. There is a significant association between the severity of 
HF and the maximum dosage medication, possibly indicating that a substantial number 
of the other 50% of the patients in the DMP models received medication up titrated 
to their optimum dosage. The HF DMP models in this analysis, that have a focus on 
optimization of medication, are more successful in accomplishing prescriber adherence, 
in terms of (sub)-maximum dosage medication, than the examined HF DM model with 
a focus on counseling alone.  
Limitations
This study has some potential limitations that need to be addressed. First, the MZH 
data are not study data in terms of data collected through a study protocol. We collected 
these data from standard care by extracting them from electronic patient records with 
permission from the hospital and patients. Unfortunaly, the data on total percentage of 
medication at baseline of the MZH group were not available because of the transition of 
(paper) patients files to an electronic patient record. It might therefore be questionable 
whether the results obtained at the end of the follow-up period were solely achieved by 
the effort  of the HF DMP alone. However, we believe that patients in the MZH, referred 
by the cardiologists to the HF DMP from 2003-2005, were not initially treated differently 
with respect to medication compared to the patients included in the two other models. 
Secondly, there were substantial differences in baseline characteristics of the three 
treatment groups. The most important one is that in the DEAL group more sicker patients 
were included and maximal adherence is more difficult to achieve in patients in NYHA-
class III. To account for this we used multivariate and propensity score analysis. Thirdly, 
the outcome of this study could be influenced if data were available about why caregivers 
did not uptitrate to maximum dosage. It is conceivable that patients did not receive the 
maximum dosage of medication because their individual optimum dosage had been 
reached. Fourthly, the data of the three HF DMPs were assembled over a time period 
from 2000-2005. In this 5-year timeframe it became clear that a higher dosage of HF 
medication was associated with a better outcome and a shift toward a higher prescription 
in time could be expected. Finally, even though propensity score matching can balance 
observed baseline differences between exposure groups, they do nothing to balance 
unmeasured characteristics and confounders and remaining unmeasured confounding 
may still be present.
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The prevalence of heart failure (HF) is progressively increasing due to ageing and 
can result from unhealthy lifestyle of individuals. Although there is some discrepancy 
betweeen national and international studies regarding the prevalence, incidence and costs 
of HF, the overall conclusion is that the disease is associated with a high hospitalization 
and mortality rate. This imposes a significant economic burden on our healthcare system. 
To maintain accessible and affordable healthcare for HF patients and a consistent standard 
of quality, it is important to search for new and innovative ways to challenge this major 
health problem. This thesis concerns patient-related health outcomes and user-related 
expectations, experiences, barriers and guideline adherence of using telemonitoring in 
combination with computer decision support systems (CDSS) in HF care. The application 
of health information technology such as telemonitoring (TM) and CDSS, as part of 
disease management, can make a positive contribution to this challenge. 
Aims of this thesis
To describe the benefit, practical use, and consequences, of using telemonitoring and 
computer decision support systems in heart failure care, the following aims have been 
formulated:
1. Explore the effects of telemonitoring combined with a CDSS on clinical outcome, 
adherence to guidelines, cost effectiveness and quality of life. 
2. To explore the expectations, experiences, barriers and usability of telemonitoring 
and CDSS, used by HF nurses and cardiologists in the treatment of HF patients. 
3. To gain insight into different heart failure disease management models (one 




To describe the effects of telemonitoring combined with a CDSS on clinical outcomes, 
adherence to guidelines, cost effectiveness and quality of life.
What is already known?
1. In the last decade, nine systematic reviews have been published concerning the use 
of telemonitoring in heart failure.1 Eight of these reviews reported positively on 
outcome as mortality and/or readmission for telemonitoring. There are two recent 
randomized controlled trials that gave opposite (negative) results.2,3
2. CDSS in healthcare can improve guideline adherence,4,5 however the current use of 
CDSS is limited.6,7
139Summary and discussion
3. There is conflicting evidence about the cost effectiveness of telemonitoring.8
What this thesis adds: 
First experience:
In the case study (Chapter 2), it was found that TM in combination with CDSS could 
be helpful in preventing HF readmissions and could have had a possible positive effect 
on the adherence of patients’ experienced quality of life and the use of medication. An 
important finding was that, with the help of the CDSS in combination with TM, it was 
possible to up-titrate HF medication under safe conditions without contacting the patient 
at the outpatient clinic. Frequent contact between caregivers and the patient at a distance 
was possible without any problem and the technology at home facilitated the patient’ 
education and caused a better understanding in terms of recognition of deterioration 
of the disease. With the help of TM and a CDSS, it was assumed that at least two HF 
readmissions were prevented for in a period of ten months. 
The experiences with this model, described in the case study9 were the rationale for the 
IN TOUCH study (the value of INnovative ICT-guided Disease Management combined 
with Telemonitoring in OUt patient clinics for Chronic Heart failure patients). IN 
TOUCH is a multicentre randomized intervention trial in 10 hospitals in the Netherlands, 
investigating the effects of ICT-guided disease management, versus ICT-guided disease 
management combined with TM in HF patients, including 179 patients for a 9-month 
follow-up period.10 CDSS was a substantial part of the ICT-guided disease management 
system.
Outcome of the IN TOUCH study
Regarding the outcome of the IN TOUCH (Chapter 4) it was found that ICT-guided 
disease management in combination with TM, used in the management of HF patients 
did not affect the primary (composite) endpoint of mortality, HF readmission and 
quality of life, nor the separated parts of this composite endpoint. However, a significant 
reduction of HF-related visits to the outpatient HF clinic in the TM group was found. 
Because there was no difference between the two group on mortality and readmission 
this indicates that TM is safe to use and can reduce visits to the outpatient clinic, keeping 
HF care accessible. The adherence of using devices as a weighing scale and blood pressure 
measurement for patients in the TM group was extremely high (95%), which indicates 
that the devices used for this study, in combination with daily measurements, were well 
accepted and therefore applicable in regular care. Healthcare providers had a positive 
perception and experience with the ‘ease of use’ of TM.  However using an ICT-guided 
disease management system (DMS) was rather difficult, specifically regarding the use of 
CDSS functionality for starting and titrating HF medication. This CDSS functionality 
was barely used, resulting in only a slightly higher percentage of medication use at the 
end of the study, compared to baseline. 
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Cost effectiveness 
Because there was no effect on the primary (composite) endpoint of mortality, HF 
readmission and quality of life, nor on the separated individual outcomes of this 
composite endpoint, no cost effectiveness analysis was performed. Instead a Cost 
Minimization Analyses (CMA), was performed which gave insight into the actual costs 
of the interventions. Incremental costs for TM were calculated for a period of 9 months 
of 1360 Euro. Initially one might conclude that these higher costs for an intervention, 
without any profit in terms of effect are a waste of money. However, the cost of 1360 Euro 
might be of value for decision makers in the case of situations where patients do not have 
direct access to an HF outpatient clinic (e.g., primary care, long distance to travel, the 
inability to visit an HF outpatient clinic) or in the case of minimizing regular visits to 
the outpatient clinic that are only for uptitration of medication or assessment of physical 
condition. The cost of the intervention could be important in cases of reorganizing the 
care of HF patients to be efficient by reducing visits to the HF outpatient clinic and 
therefore keeping treatment for patients accessible. 
In the descriptive study on usability and acceptability of heart failure related computer 
decision support (Chapter 5) it was found that the  CDSS and the usability and 
acceptability were considered poor, mainly due to personal, organizational and system-
related barriers. These findings were partly attributed to the fact that the CDSS was not 
integrated into the existing electronic patient record and therefore caused additional 
work. Besides this, the offered CDSS functionality was perceived as ‘immature’ and in 
need for further development. Another reason was that in some participating hospitals 
HF nurses were not allowed to titrate medication themselves because of cardiologists’ 
doubts  about the validity of the CDSS.
In conclusion 
The outcome of the IN TOUCH study did not show an additional effect in HF patients 
who received TM and CDSS; however, there are some positive findings in this study. The 
two most important ones are that TM and CDSS are safe to use for HF patients and that 
the number of HF-related visits to the outpatient HF clinic was significant lower (partly 
protocol-driven) compared to the group that did not use TM. Therefore, the IN TOUCH 
contributed dually to the existing evidence. First, it remains questionable if TM in 
combination with CDSS can reduce mortality and readmissions in HF patients. Second, 
TM in combination with CDSS can be used to reduce visits to the HF outpatient clinic 
and therefore keep care accessible for patients who need treatment in outpatient clinics. 
TM in combination with CDSS can certainly contribute positively to HF care in terms 
of improvement of accessibility of care and the desire of patients to communicate with 
their care providers at a distance, a natural consequence of information technology in our 
society. The major challenge for the up-coming years is to find the right patients who will 
benefit most from this new technology and to get and keep it accessible and affordable.
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What this study adds to the existing evidence:
1. ICT-guided DMS with telemonitoring in HF is safe to use and significantly reduces 
visits to the outpatient HF clinic. 
2. The costs of using ICT-guided DMS with telemonitoring in the IN TOUCH study 
are relatively low and can be of value for decision makers in the case of situations 
where patients do not have direct access to an HF outpatient clinic or for re-
organizing HF care.
3. Patients’ adherence with telemonitoring is high, which indicates that the used 
protocol and devices are acceptable in regular HF care.
4. Using a CDSS for a better pharmacological guideline adherence remains difficult, 
mainly because of personal, organizational and system-related barriers.
5. Patients and healthcare providers are satisfied about the ease-of-use of 
telemonitoring but healthcare providers are less satisfied in working with a CDSS
Aim 2
Explore the expectations, experiences, barriers and usability of telemonitoring and CDSS, 
used by HF nurses and cardiologists in the treatment of HF patients. 
What is already known?
1. In contrast to research about patients’ experiences and expectations of 
telemonitoring, there is very limited research and knowledge about the expectations 
and experiences of telemonitoring by HF healthcare providers. It is unknown how 
many HF clinics actually uses telemonitoring and if the use of telemonitoring is 
based on protocols and/or patient profiles.
2. CDSS can significantly improve pharmacological guideline adherence.5,11 Barriers 
by general practitioners in using CDSS are related to personal and demographic 
characteristics including a ‘feeling of lost autonomy’, a higher age and lower 
computer literacy, which result in a lower implementation rate.12-14
What this thesis adds:
Telemonitoring
TM has been seen as a promising new technology by workers in the field of HF care and 
the expectations of its effects are high. This high expectations has already led to its use in 
about 35% of all HF clinics in the Netherlands, without clear, predefined criteria of user 
requirements.15 
The recent HF guidelines (2012) did not find sufficient evidence to  recommend TM 
in HF care16 and it is therefore questionable that, without solid evidence on patient 
outcome, TM is used on such a large scale. HF clinics may have other motives for 
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using TM in patient care than reduction of mortality and readmission. In the study on 
expectations and experiences of TM (Chapter 6) specific reasons and motives to use TM 
were: monitoring physical condition, signs of deterioration and treatment, adjusting 
medication and educating patients in self-management. All these motives seem realistic, 
even without evidence of preventing readmissions and the reduction of mortality. 
Another reason to start TM was to ‘go with current developments and innovation’s, 
showing that reasons other than ‘evidence based medicine’ alone are important to start 
TM. This is comparable to the introduction of other health information technology, 
partly driven by “high-tech” possibilities, marketing of the commercial industry and the 
desire of using state of the art technologies, being excellent and distinguished.17 This is a 
serious threat to a solid use and implementation. Despite high expectations on working 
with TM, users did not experience reduction in re-admissions, reduction in workload, 
treating more patients or improving quality of care, possibly leading to disappointment 
in users. This disappointment is reflected in the fact that some users were already 
considering purchasing another TM system. Hence, it is questionable if the overall 
feeling of disappointment indeed is the result of a failing TM system or is due to a lack of 
efficient organization around the implementation of TM systems. It is expected that with 
the initial introduction of TM, workload will increase and this might be disappointing. 
To prevent TM being a potentially interesting health technology that becomes “another 
failed health technology”, implementation should be addressed carefully, learning from 
the experiences (positive and negative) of other clinics, including monitoring of patients, 
providing education and improvement of self-management in other chronic diseases, 
and so work toward best practices and structural applications. 
The implementation phase should start by defining and stating expectations, making 
clear agreements about who is responsible for the incoming data, the time for the care 
provider to respond on deviating data, the type of intervention, patient profiling to 
find out which are most suitable/beneficial for TM, the duration of TM and finally the 
determination of (predefined) markers in order to evaluate if treading a specific group 
of patients with TM is successful. Because these aspects of patient care lies within the 
working field of HF nurses, it seems reasonable that HF nurses should claim a central, 
coordinating role in working with TM.18,19 
Barriers in using CDSS 
In Chapter 7, we described the perceived barriers of HF nurses and cardiologists in using 
CDSSs. Other studies, focused on the barriers of using CDSS by general practitioners 
showed that earlier experiences with dysfunctional computer systems, potential harm 
the doctor-patient relationship, lead to unclear responsibilities and threats to clinicians’ 
autonomy, resulting in major barriers in working with CDSSs. Aging of healthcare 
providers and a lack of computer experience were also pointed out as barriers. In our 
study, a strong similarity to some of these earlier findings in HF nurses and cardiologists 
was found. These barriers were categorized as: ‘barriers and threats’, ‘responsibility and 
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trust’ and ‘knowledge management’. Both HF nurses and cardiologists perceived barriers 
in working with CDSSs in all the examined areas, which would be counterproductive for 
implementation. 
However, a positive finding was that knowledge management has a strong correlation 
with the perceived barriers, indicating that increasing knowledge by specific training and 
education for users can decrease barriers. It is important to offer future users insight into 
the possibilities, but perhaps even more important, the impossibilities of a CDSS. 
The fact that a CDSS is not a magic black box, but something that generates advice only 
by means of predefined formulas and data provided by the HF professionals themselves, 
will give more attention to and information about the system’s capabilities. Future 
policymakers and managers that are involved in the introduction of CDSS should be 
aware of the risk of perceived barriers towards CDSS and should introduce education, 
additional and extended training, and the use of “super-users” as a constant element in 
their implementation strategy. In contrast to other studies, we did not find that a higher 
age and a lack of computer experience is a barrier towards working with a CDSS. In 
Chapter 5 we showed how important the findings of the described barriers are in case of 
using CDSSs in daily practice. In the study on usability and acceptability of CDSS, we have 
made the transition from theoretically expected barriers into real experienced barriers. 
All the users of a CDSS in the IN TOUCH study experienced a very low acceptability and 
usability of the offered CDSS. This resulted in a prescriber adherence to HF medication, 
which was lower than the observed percentage in the Euro Heart Survey II of 200520 
Because better prescriber adherence directly results in a better outcome21, this stresses 
the importance of a successful implementation of CDSS.
Conclusion
Barriers towards working with a CDSS are a real threat in the actual use of CDSSs. In the 
analyses of the low acceptability and usability, we found again that barriers towards using 
a CDSS in HF care are relevant in a successful use. CDSS should be user friendly, not 
too time-consuming to work with, and sophisticated enough to give the required advice. 
Only if these primary characteristics are fulfilled in advance, can the implementation 
phase start and it must be monitored intensively, with respect to all the known barriers. 
To gain insight into possible barriers, a pre-inventory of barriers is recommended. The 
questionnaire, developed for the study in Chapter 7 can be valuable for this purpose. 
Along with constant education and regular evaluation, successful use of a CDSS in terms 
of better guideline adherence can be expected.
What this study adds to the existing evidence:
1. HF nurses and cardiologists have high expectations about the effect and use of 
telemonitoring in heart failure care, but these high expectations are not reflected in 
their actual experiences.
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2. Despite conflicting evidence, almost 35% of all Dutch HF clinics already use 
telemonitoring for regular care in the absence of pre-defined protocols and/or 
guidelines.
3. Both HF nurses and cardiologists have perceived practical barriers towards 
working with CDSS, and these barriers are an actual threat to successfully using 
CDSS. Knowledge management is significantly related to barriers, implying that 
increasing knowledge might be a tool to decrease barriers. 
Aim 3
To gain insight into 3 different heart failure disease management models (one of which is 
CDSS-driven) regarding their rate of prescriber adherence of medication.
What is already known:
1. According to the recent HF guidelines, patients with a reduced left ventricular 
ejection fraction should receive optimal medication, titrated to target dosage, in 
order to reduce mortality and readmissions.22 However it is known that the number 
of patients that receive this target medication is suboptimal.20,21
2. Optimizing medication is an important component of HF disease management23 
and should be an essential part of the tasks and responsibilities of  HF clinics22
3. Differences are known in prescriber adherence of heart failure medication between 
HF clinics related to the applied disease management model.20,24-26
What this thesis adds:
Prescriber adherence
Optimal HF medication is related to the improvement of outcome in terms of mortality, 
readmissions and quality of life.21 In search for the most optimal HF disease management 
model, prescriber adherence, according to the HF guidelines, is an important component 
and often used as an indicator for the successfulness of a HF disease management 
model. HF nurses and cardiologists still experience difficulties when implementing these 
guidelines into daily practice.24,27 As described in chapter 8, the prescriber adherence to 
medication of the three examined models, in terms of maximum dosage of medication 
is suboptimal. 
In chapter 8 it is reported that less than 50% of all patients in the 3 included models 
received the maximum dosage of HF medication, with an exception for the combination 
of ACE-inhibitors and Angiotensin receptor blockers. As expected, and confirmed in 
earlier studies,24,28,29 characteristics of patients that indicate the ‘severity of the disease’ 
HF, is significantly related to the maximum dose of prescribed HF medication. These 
characteristics are present in our study as in other studies20,21,27 and are thus a plausible 
explanation for the results. The two HF disease management models that focus on 
optimalization of medication more often prescribe maximum dosage of medication. 
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One of these models uses a CDSS, operated by a HF nurse and is a even effective in 
prescriber adherence than the model with a dedicated HF physician. Using a propensity 
score for analyzing groups of patients, with differences at baseline characteristics and 
different study protocols, has several and potential limitations as addressed in Chapter 8. 
Taking into consideration this limitations, the patients treated in the disease management 
models that focus on optimal medication have a better outcome in terms of survival, 
which is in line with the existing evidence30-35 as described in the HF guidelines22 
However, there are still some unanswered questions from the study described in chapter 
8. Besides the influence of characteristics such as co-morbidities and clinical variables, it 
remains unclear why HF patients overall do not receive more than 50% of the maximum 
doses. It could be possible that 50% of the target dosage is the individual optimum, or 
perhaps healthcare providers just stop targeting to a higher dose. If this latter is the case, 
it is important to understand why. It might be caused by an acceptable ‘steady state’ of 
a patient who claimed no complaints at the time of the consultation, or the prescriber 
might experience a feeling of lost autonomy, caused by the advice of a CDSS. It is also 
possible that patients’ experience undesirable side-effects of higher doses, or they are not 
willing to take higher doses. These are some important issues that need to be addressed 
to obtain more insight in the concept of prescriber adherence. This information is often 
not available in the patient record. A CDSS can help in answering these questions due to 
its repeatable alarms and reminders36 when patients do not receive maximum dosages 
and the obligation for the precriber to describe why a patient did not received 100% of 
the target dose. With the gathering of this precriber data of a CDSS, together with other 
important clinical information such as laboratory and physical parameters, it is possible 
to gain more insight into factors that influence the prescribed dose of medication in HF 
patients.
Conclusion
Even in HF disease management models that focus on optimizing medication, the 
actual dose of medication for patients is overall not higher than 50% of the target dose. 
Patient characteristics like age and co-morbidities and the severity of the disease (leading 
to frequent readmissions) are important ‘negative’ contributors. Working with a CDSS 
that is specially built for starting and uptitrating medication can be an important and 
effective contributor to prescriber adherence.11 It is safe to use and it will fit perfectly in 
the scope of HF nurses, in terms of responsibility for optimal pharmacological therapy as 
part of a disease management program. 
What this study adds to the existing evidence:
1. Prescribed medication is high in all of the examined HF DMS models. However, 
less than 50% of all patients were prescribed the maximum medication, despite the 
fact that two HF clinic models had a focus on optimizing medication.
146 Chapter 9
2. Age, co-morbidities and clinical variables as blood pressure and eGFR influence the 
prescription of the maximum dosage of medication. Readmissions and the physical 
condition of the patient, reflected in the NYHA class, are negatively influencing the 
maximum dose of medication.
3. A disease management model with a CDSS is as effective in terms of prescription 
of HF medication as a model with a dedicated physician, with differences observed 
in ACE-inhibitors and beta-blockers. This CDSS-driven outcome on prescriber 
adherence of maximum HF medication is reflected in better survival according to 
a propensity score analysis.
Telemonitoring and CDSS:  the holy grail for (future) clinical 
practice?
Currently there is conflicting evidence on the effectiveness of TM and CDSS on clinical 
outcomes like mortality and readmissions for HF patients.37 In the past 5 years, many 
studies, in which TM was the main intervention, were published.1,38-41 These studies 
provided as many positive as negative outcomes2,3 The most important reason for this 
conflicting evidence seems the absolute absence of comparable study designs: different 
technology used, different follow-up time (mostly short for a chronic disease), different 
interventions and different patient-profiles. This is a major concern in the recent 
published meta-analysis in which all these studies with different designs were combined. 
Richard Wootton, editor in chief of the Journal of Telemedicine and Telecare concluded 
in his review “Twenty years of telemedicine in chronic disease management”, that the 
evidence base for the value of telemedicine in managing chronic diseases on the whole is 
weak and contradictory37 So how is it possible that the majority of healthcare providers 
are still positive about telemedicine?  And why should we use it?
Although not confirmed in the IN TOUCH study, the overall common positive finding 
in most studies is an increased quality of life for patients as a result of TM. Patients 
performed better self-management and had a feeling for a sense of control. The fact 
that patients are able to directly contact their healthcare providers in case of emergency 
probably plays an important role in this feeling. We did not find any publication that 
described negative effects in terms of worsening of outcome. With the help of TM, it 
is possible to keep care (especially for outpatient clinics) accessible. One might wonder 
why we should we ask patients to visit the outpatient clinic for a visit of 10 minutes in the 
company of their relatives, which may cost them half a day of time, for only a blood pressure 
measurement and adjustment of medication, instead of aggregating that information 
at home with TM. Important physical variables like weight, blood pressure, heart rate, 
glucose, peak flow, temperature, EKG and even the actual health status, delivered by 
digital questions are already available through TM and more applications will be available 
in future developments. Companies are actually developing technology to gain a fluid 
147Summary and discussion
status of a patient and laboratory values with the help of a camera (smart)phone. Because 
of the growing computerization level of our society, patients themselves already ask for 
using health information technology. Healthcare insurance companies are reacting to 
this demand with the inclusion of TM in their insurance policies and policymakers in 
the government/Ministry of Health believe strongly in the implementation of eHealth. 
In the end it seems unrealistic to wait for new evidence in terms of lower mortality and 
reduction of readmission. TM and CDSS have much more to offer from a point of view of 
the patient, healthcare provider and policymakers.
Recommendation for clinical practice:
1. Implementing telemonitoring and CDSS in clinical practice does not automatically 
decrease patient outcomes like mortality or readmissions. It can contribute to 
keeping HF care accessible in terms by decreasing visits to the outpatient HF clinic, 
and it can help in monitoring physical condition, monitoring signs of deterioration, 
monitoring treatment, adjusting medication and educating patients. The costs of 
using telemonitoring and CDSS are relative low and could be a factor re-organizing 
HF care.
2. Using telemonitoring and CDSS requires a careful look at users in terms of patient-
profiling. It is obvious that telemonitoring is not a “one size fits all” solution. It is 
advisable to start and monitor a pre-defined group of patients, for example new 
diagnosed patients who had a recent (re)admission and who experienced difficulties 
in recognizing signs and symptoms of deterioration.
3. Using telemonitoring and CDSS will lead initially to an increased workload 
for healthcare providers. This requires intense monitoring by management of 
the implementation phase and the need for agreement/protocols about data 
management, responsibilities and accessibility of staff.
4. For successful implementation of telemonitoring and CDSS, it is important to 
focus on existing barriers and thresholds. Implementation should be monitored 
intensively, with respect to all known barriers and only with constant education and 
regular evaluation can successful use of telemonitoring and CDSS in terms of better 
guideline adherence be expected. We must be aware of high and/or unrealistic 
expectations of health care providers. 
5. CDSS should be user friendly, not too time consuming to work with, and 
sophisticated enough for the required tasks. Only if these primary characteristics 
are fulfilled in advance, the implementation phase can start. Using a CDSS lacking 
these primary characteristics is a serious threat to its usability and acceptability.
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Implications for further research 
This thesis demonstrates that health oriented information technology, such as TM and 
CDSS, is a promising tool to help healthcare providers improve care and performance, 
but only if implementation and use are monitored under strict and predefined conditions. 
It is questionable whether further research will contribute to the existing evidence about 
readmissions and mortality. This will be successful only if future studies are comparable 
in terms of interventions and patients. We need a consensus of endpoints in new studies 
such as costs to society, the number of visits to the emergency room and outpatient clinic, 
the way we measure quality of life and the added value of focusing on ‘only’ readmission/
mortality.
Because HF is a chronic disease it is questionable if studies with a short follow-up (< 1 
year) will contribute to the known evidence. Currently it is unclear which patients will 
benefit most from these new interventions. Therefore, it is necessary to focus on patient 
profiling. Besides the fact that new studies might provide new evidence, it is important to 
learn from experiences to gain “best practices”. The evidence for using a CDSS to improve 
prescriber adherence is growing. However, in the case of practical applications of CDSSs 
we often do not know why healthcare providers stopped targeting to a higher dose of 
medication. Because this could be behavioral, clinical or patient determined we need to 
gain more insight into reasons for this, which could be partly helped by using a CDSS. 
With the help of a CDSS we can possibly titrate more patients to optimal medication, 
leading to a better outcome. Future CDSS studies should focus on this specific reasons or 
motives why patients do not receive the target dose of HF medication as advised. 
Limitations/critical reflection
An important limitation concerns the generalizability of this thesis. Most of the studies 
have been performed in Dutch HF clinics with only one type of TM and one type of 
CDSS. Despite of the fact that at this moment there are no other HF CDSSs on the Dutch 
market available, the overall comments of the users, described in Chapter 6, are explicit; 
they experienced the offered CDSS as immature and not sophisticated enough to use in 
their daily HF care at this moment. This is important information because it is known 
that a low experienced usability and acceptability of CDSSs results in barely using it and 
thus the absent of an in potential helping instrument to improve guideline adherence 
(Chapter 6). However, at this moment it is unclear if the user’s attitude on CDSS, which 
is defined as a personal related barrier, influenced patient outcomes. This should be the 
focus of future research. 
In Chapter 8 it was described that using a CDSS was at least as effective in terms of 
prescriber adherence than a dedicated physician. However, this was examined in a 
retrospective study and performed in HF patients with different profiles and study 
protocols. This consequently affects the generizability of this study. It is important to 
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know if the observed outcomes of the study described in Chapter 8, are as present in 
comparable HF patients and with a specific focus on the reasons why prescribers do 
not prescribe to maximum dose and/or patients do not take the maximum dose of  HF 
medication, this requires further research.
 In general, there are two different ways of looking at the present TM evidence. One is 
that there still is a lack of solid evidence in terms of lowering mortality and readmissions, 
making the implementation of TM as a new intervention too premature and therefore 
not accountable. The other way of interpreting the present evidence is that TM as an 
intervention alone, might not bring a better patient outcome but maybe the intervention 
should be considered as a helping tool, together and integrated with other components 
of disease management, which in the end might lead to an improvement of patient 
outcomes. In designing a new TM study we should more focus on the value of TM as 
a substantial part of disease management and not as an intervention alone, in order 
to improve education, self management/empowerment of patients and health-related 
quality of life. To find a cohort of patients who will benefit most this might be done 
by selecting different patient profiles; immediately after a first readmission for HF in 
new diagnosed patients,  after worsening of HF  caused by not acting appropriately on 
signs and symptoms, or after several readmissions in a short period of time. Beside this 
different profiles it is important to explore the edit value of different time intervals in 
using TM (e.g., 3, 6, 12, or 24 months).
Conclusion
This thesis shows that TM as well as CDSS are capable of transferring patient data from 
a home environment to a healthcare provider and with this data, the healthcare provider 
is able to interpret data and to act. TM is not a “one size fits all” solution and in contrast to 
the of use ‘new’ TM, the development, use and evidence of CDSSs is different. We do not 
have a long tradition of CDSSs in healthcare, but with the introduction of evidence-based 
healthcare and guidelines, CDSS can help in making clinical decisions, preventing medical 
errors and improving prescriber adherence. This thesis shows that the difficulty in using 
CDSSs lies not in the absence of evidence of accomplishing higher dosage of medication 
as integrated part of disease management, but in the number of barriers and risk of low 
usability and acceptability. To turn this risk into a positive implementation, we must not 
only monitor patients, but also healthcare providers regarding the implementation-phase 
and use of TM and CDSS. Realizing the potential of TM and CDSS and the need for 
innovation in the healthcare system, especially for HF, leads us to an interesting challenge, 
which will force change in many different aspects of healthcare delivery.
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Het ontstaan van hartfalen en de toename van het aantal mensen dat er aan lijdt, 
worden in hoge mate bepaald door leeftijd en een ongezonde leefstijl. Deze factoren 
zijn gerelateerd aan het optreden van hoge bloeddruk, overgewicht of een hartinfarct, 
en daarmee op de lange termijn met hartfalen. De diagnose hartfalen is voor patiënten 
een sterke last. Het veroorzaakt veelvuldige ziekenhuisopnames, een sterk verminderde 
kwaliteit van leven en een hoog sterftecijfer. Daarnaast wordt hartfalen ook geassocieerd 
met aanzienlijke kosten voor onze gezondheidszorg. 
Om het gezondheidsprobleem van hartfalen in de nabije toekomst beheersbaar te 
houden, moet de zorg voor patiënten  toegankelijk,  kwalitatief hoogstaand en betaalbaar 
blijven. Daarom is het belangrijk naar nieuwe en innovatieve manieren van zorgverlening 
te zoeken.
Dit proefschrift gaat over twee voorbeelden van innovatieve ICT ontwikkelingen 
die ingezet worden bij de zorg voor patiënten met hartfalen: telemonitoring (TM) en 
computer beslissingsondersteunende systemen (CDSS). In wetenschappelijke literatuur 
is beschreven dat de toepassing van deze ICT technologiën, als onderdeel van disease 
management, een positieve bijdrage kan leveren aan het beheersbaar houden van de 
gezondheidsproblemen rond hartfalen. Disease management wordt omschreven als 
een gecoördineerde aanpak van zorg voor patiënten met een chronische ziekte die 
onder andere de doelmatigheid, de kwaliteit van zorg en de zelfzorg van patiënten moet 
verbeteren. 
Er zijn vele vormen van TM. Het gebruik van de telefoon tussen hulpverlener en de 
patiënt of het per e-mail sturen van een digitale foto van een afwijking door een huisarts 
naar een specialist zijn de oudste en meest simpele vormen. In het afgelopen decennium 
zijn er vele ontwikkelingen geweest op het gebied van nieuwe vormen van TM. Voor 
dit proefschrift is de volgende definitie van TM gebruikt: ‘Het meten, monitoren, 
verzamelen en versturen van gegevens over de gezondheidsstatus van de patiënt in 
zijn eigen omgeving, door gebruik van informatie- en communicatietechnologie’. Voor 
TM bij hartfalen gebruikt men tegenwoordig vaak gegevens als gewicht, bloeddruk, 
hartfrequentie en eventuele klachten van de patiënt. Deze gegevens geven een goed beeld 
van de situatie van de patiënt op afstand. Met behulp van TM kunnen patiënten nu op 
een veilige manier thuis geobserveerd worden, waardoor eerder kan worden ingegrepen 
bij verslechtering en (her)opnames kunnen worden voorkomen. Daarnaast kunnen 
patiënten door TM beter leren omgaan met hun ziekte, onder andere door verbetering 
van hun zelfmanagement. Nog een andere toepassing van TM is het op afstand instellen 
van medicatie, zonder dat patiënten daarvoor naar de polikliniek hoeven te komen. 
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CDSS systemen zijn computerprogramma’s die met behulp van ingevoerde gegevens de 
gebruiker kunnen adviseren om bepaalde (behandel) beslissingen te nemen, gebaseerd op 
richtlijnen en protocollen. Deze systemen blijken vooral waardevol in complexe situaties 
waarbij een CDSS bijvoorbeeld prioriteiten kan aangeven in de behandeling. CDSS 
systemen kunnen onder andere het proces van veilig medicatie voorschrijven, bewaken 
en bevorderen. De behandelaar kan zo herinnerd worden aan het feit dat de medicatie 
nog niet in een optimale dosering is voorgeschreven aan de patiënt. In het geval van dit 
proefschrift is de behandelaar de hartfalen verpleegkundige en/of de cardioloog. 
Daarnaast kan een CDSS ook de loop van de behandeling volgen en daar advies over 
geven. Een voorbeeld hiervan is wanneer met behulp van TM het gewicht van een patiënt 
wordt gemeten.  Het CDSS kan vervolgens beoordelen of dit gewicht te hoog is als gevolg 
van het vasthouden van vocht, en kan de behandelaar adviseren om contact met de 
patiënt op te nemen en de dosering plastabletten te verhogen. Op deze manier  is het 
voor de behandelaar mogelijk om op een relatief eenvoudige manier veel patiënten veilig 
op afstand te volgen. 
Doelen 
In hoofdstuk 1 worden de doelen van het proefschrift beschreven. Het algemene doel 
van dit proefschrift is:
1. Het beschrijven van de mogelijke voordelen, het praktisch gebruik en de gevolgen 
van  telemonitoring (TM) en computer beslissingsondersteunende systemen 
(CDSS) bij hartfalen (HF).
Specifieke subdoelen zijn:
1. Het beschrijven van de effecten van het gebruik van TM in combinatie met CDSS 
bij de naleving van richtlijnen door behandelaars, bij kosteneffectiviteit en bij de 
kwaliteit van leven van patiënten. 
2. Het beschrijven van de verwachtingen, ervaringen, belemmeringen en de 
bruikbaarheid van TM en CDSS door hartfalen verpleegkundigen en cardiologen 
bij de behandeling van patiënten.
3. Inzicht verkrijgen in het voorschrijfgedrag en de mate van opvolgen van richtlijnen 
binnen verschillende hartfalen disease management modellen (waarvan 1 model 
met behulp van CDSS) 
In hoofdstuk 2  is in een case studie beschreven dat TM in combinatie met CDSS 
heropnames kan voorkomen. In deze case studie is beargumenteerd dat bij hartfalen een 
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dergelijk systeem een positief effect kan hebben op de ervaren kwaliteit van leven en het 
gebruik van geneesmiddelen. Een belangrijke bevinding was dat het met de combinatie 
van TM en CDSS mogelijk bleek om zonder contact op de polikliniek de HF-medicatie 
van de patiënt onder veilige omstandigheden te optimaliseren. De toegepaste technologie 
bij de patiënt thuis zorgde voor een beter inzicht van de patiënt op het gebied van het 
herkennen van tekenen van verslechtering van de ziekte. Met behulp van TM en CDSS 
zijn in de case studie bij de patiënt in een periode van tien maanden ten minste twee HF-
heropnames voorkomen. 
Deze positieve ervaring met de toegepaste technologie was aanleiding om de  IN 
TOUCH studie te starten. IN TOUCH staat voor de waarde van ICT-gestuurd disease 
management in combinatie met telemonitoring op poliklinieken voor patiënten 
met chronisch hartfalen. Het ontwerp van deze IN TOUCH studie is beschreven in 
hoofdstuk 3.
Uitkomsten van de IN TOUCH studie: effecten van het gebruik 
van TM en CDSS
Effecten voor HF-patiënten
De uitkomst van de IN TOUCH studie (hoofdstuk 4) liet zien dat ICT-gestuurd disease 
management in combinatie met TM de mortaliteit en HF-opnames niet kon verminderen 
en dat de ervaren kwaliteit van leven niet verbeterde. Wel was er in de TM groep een 
significante vermindering van het bezoeken van patiënten aan de HF-polikliniek. Omdat 
er geen verschil bestond tussen de twee groepen (met en zonder TM) op mortaliteit en 
(her)opnames, gaf dit aan dat TM veilig in gebruik is en het de bezoeken aan de HF-
polikliniek kan reduceren. Dit is in termen van beheersbaarheid en het anders inrichten 
van zorg voor HF-patiënten een belangrijke bevinding. Het onderzoek liet ook zien dat 
het niet voor iedere patiënt noodzakelijk is om voor controle naar de HF-polikliniek te 
komen.
Daarnaast bleek dat het gebruik van de apparatuur, zoals een weegschaal en een 
bloeddrukmeter, voor patiënten in de TM-groep hoog was (95%). Dit bevestigde dat – in 
combinatie met dagelijkse metingen -  in de praktijk de apparaten die werden gebruikt 
voor dit onderzoek goed toepasbaar waren. Het gebruik van het CDSS werd door de 
hulpverleners daarentegen als lastig en omslachtig ervaren, met name voor gebruik 
bij het starten en optimaliseren van HF-medicatie. Deze functionaliteit van het CDSS 
is gedurende de IN TOUCH studie nauwelijks gebruikt. Dit resulteerde in slechts iets 
hogere percentages voorgeschreven medicijnen aan het eind van de studie vergeleken 
met de start van de studie.
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Kosteneffectiviteit   
Omdat er geen effect is gevonden op het primaire, samengestelde eindpunt van mortaliteit, 
hartfalen heropnames en de kwaliteit van leven, leek een  kosteneffectiviteit analyse niet 
zinvol. In plaats daarvan is een kosten minimalisatie analyse (CMA) uitgevoerd die inzicht 
gaf in de werkelijke kosten van de interventies. De kosten voor TM bedroegen 1360 Euro 
per patiënt en werden berekend voor een periode van negen maanden. In eerste instantie 
zou men kunnen concluderen dat deze hogere kosten voor een interventie, zonder enige 
winst in termen van effect als reductie van mortaliteit en heropnames een verspilling 
van geld is. Echter, deze extra investering kan van doorslaggevende betekenis zijn voor 
behandelaars in situaties waarbij patiënten geen directe toegang tot een HF-polikliniek 
hebben. Bijvoorbeeld in de eerstelijnszorg bij lange reisafstanden, of bij het onvermogen 
om een HF-polikliniek te bezoeken. Ook kan deze investering van belang zijn bij een 
wens om regelmatige bezoeken aan de HF-polikliniek te minimaliseren, bijvoorbeeld in 
het geval van het op afstand optimaliseren van medicatie.
Bruikbaarheid en acceptatie door behandelaars:
In de studie over de bruikbaarheid en acceptatie van CDSS bij hartfalen (hoofdstuk5) 
bleek dat vooral persoonsgebonden, organisatorische en systeemgerelateerde barrières 
een rol speelden bij het niet gebruiken van het CDSS.  Een veel voorkomende 
persoonsgebonden barrière was dat gebruikers aangaven zelf voldoende kennis te hebben 
om de medicamenteuze behandeling te starten en uit te voeren en daarvoor geen CDSS 
nodig hadden. Daarnaast bestond er gebrek aan vertrouwen in de juistheid van het 
systeem. Een organisatorische barrière was het feit dat het CDSS niet geïntegreerd was 
in de bestaande elektronische patiëntendossiers en daarom extra werk veroorzaakte. Een 
systeemgerelateerde barrière was dat het te veel tijd kostte om goed met het systeem te 
werken en dat de gebruikers het systeem niet voldoende doorontwikkeld vonden. 
Het gebruik van telemonitoring door Nederlandse hartfalen poliklinieken 
Telemonitoring (TM) wordt gezien als een veelbelovende nieuwe technologie en de 
verwachtingen van de effecten ervan zijn hoog gespannen. Dit heeft er toe geleid dat 
in ongeveer 35% van alle HF-poliklinieken in Nederland TM al wordt ingezet, zonder 
dat er duidelijke, vooraf bepaalde criteria of protocollen zijn vastgelegd. Recente HF-
richtlijnen (2012) geven aan dat er nu nog onvoldoende bewijs is van de toegevoegde 
waarde van TM. Het is dan ook opmerkelijk dat zonder duidelijk bewijs TM nu al op een 
dergelijk grote schaal wordt ingezet. Het aantal patiënten dat met TM behandeld wordt is 
overigens nog relatief laag. HF-klinieken lijken dus andere motieven te hebben voor het 
gebruik van TM in de directe patiëntenzorg dan alleen het verminderen van mortaliteit 
en heropnames.
In hoofdstuk 6 werden specifieke redenen en motieven van Nederlandse HF-poliklinieken 
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onderzocht om TM te gebruiken. Veel genoemde redenen waren het bewaken van 
de fysieke conditie van de patiënt, het monitoren van tekenen van verslechtering, het 
aanpassen van de medicatie en het begeleiden/instrueren van patiënten wat moet leiden 
tot een beter zelfmanagement. Ondanks de hoge verwachtingen over het effect van TM 
bij HF-patiënten ervoeren de gebruikers ervan geen vermindering van heropnames of 
vermindering van de werklast en ondervonden ze evenmin dat ze meer patiënten konden 
behandelen. Ook zagen ze (nog) geen verbetering van de kwaliteit van de zorg. 
Deze tegenvallende ervaringen zouden kunnen leiden tot teleurstelling. Deze 
teleurstelling werd zichtbaar in het feit dat sommige gebruikers in de studie overwogen 
om bij een nieuwe keuze van een TM systeem een ander systeem te kiezen. Het is echter 
maar zeer de vraag of dit algemene gevoel van teleurstelling een direct gevolg was van het 
gebruik van het specifieke TM systeem of dat de teleurstelling veroorzaakt werd door een 
gebrek aan efficiënte organisatie rondom de uitvoering van TM. 
Uit de studie bleek verder dat behandelaren diverse patiëntenprofielen hanteerden 
om TM in te zetten. Veel genoemde redenen om TM in te zetten waren: ‘eerdere HF-
opname’, ‘op basis van de mate van ziektelast’, ‘voor educatiedoeleinden’ en ‘op basis van 
klachten’. Uit dezelfde studie bleek ook dat behandelaren nog niet goed konden aangeven 
welk profiel nu het best geschikt was om TM in te zetten en vooral waarmee de meeste 
‘patiëntenwinst’ te behalen was.
Aanbevelingen voor succesvolle implementatie van TM 
Om TM succesvol te implementeren is het belangrijk dat de introductie, implementatie 
en uitvoering zorgvuldig worden aangepakt. Het leren van ervaringen - zowel positief 
als negatief - van andere HF-klinieken is een essentieel onderdeel  in het leren werken 
met TM. Een ander onderdeel van zorgvuldige implementatie is het vooraf vaststellen 
van succescriteria waardoor men kan bepalen of een behandeling met TM succesvol 
is geweest. Een voorbeeld van een vooraf vastgesteld doel kan zijn: ‘geen enkele 
verslechtering mag leiden tot een (her)opname’ of  ‘met behulp van drie contacten op 
afstand moet het probleem bij de patiënt afgehandeld zijn’. Daarnaast is het van belang 
te weten waardoor de behandeling bij een patiënt succesvol is geweest. Het is daarom 
belangrijk om in de implementatiefase van het werken met TM  regelmatig te evalueren 
en beleid en afspraken bij te stellen op basis van de opgedane ervaringen. 
Voorafgaand aan de praktische uitvoering is het aan te bevelen dat het behandelteam 
de verwachtingen over het toepassen van TM, ook die van de patiënt, gaat inventariseren 
en vaststellen. Zo kan worden voorkomen dat er onrealistische verwachtingen ontstaan. 
Daarnaast is het zinvol dat er heldere afspraken worden gemaakt over: 
•	 wie verantwoordelijk is voor de binnenkomende gegevens;
•	 de maximale responstijd;
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•	 hoe en wanneer te reageren op (afwijkende) data;
•	 het type interventie dat wordt toegepast bij de afwijkende data;
•	 de wijze waarop de effecten van de interventie gevolgd moet worden.
Het is ook van belang vast te stellen hoe lang een TM interventie zinvol is bij een patiënt 
en of er door de kliniek invulling gegeven moet worden aan een full continue bewaking 
(24/7) of alleen tijdens kantooruren. Tenslotte is het belangrijk dat er getest gaat worden 
met de inzet van TM bij verschillende patiëntprofielen om te achterhalen welke patiënten 
nu het meest baat hebben bij de inzet van TM. Omdat veel van bovengenoemde aspecten 
in het werken met TM binnen het werkveld van HF-verpleegkundigen ligt, lijkt het 
logisch dat zij dan ook een centrale, coördinerende rol kunnen gaan vervullen in de 
behandeling met TM.
Wat draagt dit proefschrift bij aan de al bestaande onderzoeken over TM: 
1. ICT-gestuurd  disease management met telemonitoring in hartfalen is veilig en 
creëert mogelijkheden om bezoeken aan de HF-polikliniek te verminderen.
2. De kosten van het gebruik van ICT-gestuurd disease management met 
telemonitoring in de IN TOUCH studie zijn relatief laag. Bovendien kan 
telemonitoring van waarde zijn voor behandelaars in situaties waarbij patiënten 
geen directe toegang hebben tot een HF-polikliniek of om de bestaande zorg voor 
HF-patiënten te herorganiseren.
3. De therapietrouw van patiënten in het gebruik van telemonitoring apparatuur is 
hoog, wat aangeeft dat het gebruikte protocol en de apparatuur acceptabel zijn.
4. Een betere naleving van de bestaande richtlijnen voor hartfalen met behulp 
van een CDSS blijft moeilijk, voornamelijk als gevolg van persoonsgebonden, 
organisatorische en systeemgerelateerde barrières.
Belemmeringen en barrières bij behandelaren in het gebruik van 
CDSS
In hoofdstuk 7 zijn de barrières van HF-verpleegkundigen en cardiologen bij het gebruik 
van een CDSS beschreven. Uit eerdere onderzoeken, gericht op de belemmeringen van 
het gebruik van een CDSS door huisartsen, bleek dat ervaringen met disfunctionerende 
computersystemen en het gevoel van verstoring van de arts-patiënt relatie door een 
computer resulteerde in barrières. Voor deze studie definieerden we een barrière als 
de mate van -subjectief of objectief - ervaren belemmeringen in het werken met een 
CDSS. Daarnaast speelden onduidelijke verantwoordelijkheden en bedreigingen in de 
autonomie van een behandelaar een negatieve rol in het werken met een CDSS. Een 
hogere leeftijd van zorgverleners, al dan niet in combinatie met een gebrek aan ervaring 
in het werken met computers, werden ook opgemerkt als belangrijke barrières.
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In het onderzoek uit hoofdstuk 7 werd een sterke gelijkenis met een aantal van 
deze eerdere bevindingen bij HF-verpleegkundigen en cardiologen gevonden. Deze 
barrières werden gecategoriseerd als: ‘barrières en bedreigingen’, ‘verantwoordelijkheid 
en vertrouwen’ en ‘kennismanagement’. Zowel HF-verpleegkundigen en cardiologen 
ervoeren barrières in het werken met een CDSS in alle onderzochte categorieën. Deze 
barrières kunnen contraproductief zijn voor het werkelijke gebruik van een CDSS. 
In tegenstelling tot andere onderzoeken hebben we bij cardiologen  niet kunnen 
vaststellen dat een hogere leeftijd of een gebrek aan ervaring in het werken met computers 
leidde tot een barrière bij het werken van een CDSS. 
Aanbevelingen voor vermindering van ervaren barrières
Het vergroten van kennis door middel van specifieke opleidingen en onderwijs kan de 
ervaren barrières verminderen. Het is daarom belangrijk om de toekomstige gebruikers 
van een CDSS  inzicht te geven in de mogelijkheden, maar misschien nog belangrijker, 
de onmogelijkheden van een CDSS. Het gegeven dat een CDSS  geen magische zwarte 
doos is maar een systeem dat alleen maar advies kan genereren door middel van vooraf 
gedefinieerde richtlijnen en gegevens die door de HF professionals zelf zijn ingevoerd, 
zal meer begrip geven over hoe een advies van een CDSS tot stand komt. Toekomstige 
beleidsmakers en zorgmanagers die betrokken zijn bij de introductie van een CDSS 
moeten zich bewust zijn van het risico van aanwezige barrières bij gebruikers omdat 
deze een goede implementatie en daarmee dus goed gebruik in de weg staan. Onderwijs, 
aanvullende scholing en de introductie  van zogenaamde ‘super-users’ zouden een vast 
onderdeel kunnen uitmaken van de implementatiestrategie. Met ‘super-users’ worden 
personen bedoeld  die extra opleiding en scholing krijgen en andere gebruikers kunnen 
helpen in de praktische uitvoering.
Wat draagt dit proefschrift bij aan de al bestaande onderzoeken over het gebruik van 
TM en CDSS:
1. HF-verpleegkundigen en cardiologen hebben hoge verwachtingen van 
telemonitoring maar deze hoge verwachtingen worden niet gereflecteerd in hun 
feitelijke ervaringen.
2. Ondanks het gebrek aan solide bewijs van effectiviteit van TM gebruiken bijna 35% 
van alle Nederlandse HF-poliklinieken telemonitoring voor hun reguliere zorg, 
zonder vooraf gedefinieerde protocollen en /of richtlijnen.
3.  Zowel HF-verpleegkundigen als cardiologen ervaren barrières in het werken 
met CDSS. Deze barrières zijn een actuele bedreiging voor een succesvol gebruik. 
Kennismanagement is significant gerelateerd aan deze barrières, hetgeen impliceert 
dat het vergroten van kennis een hulpmiddel kan zijn om deze barrières te verlagen.
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Voorschrijfgedrag van behandelaars bij het gebruik van TM en 
CDSS
Het voorschrijfgedrag van de behandelaar (in het proefschrift: prescriber adherence) 
is de mate waarin een voorschrijver zijn gedrag afstemt op aanbevelingen zoals de 
standaarden voor zijn of haar vakgebied. Één van deze standaarden bij hartfalen is het 
zorgdragen bij patiënten voor optimale medicatie. Optimale (hartfalen) medicatie geeft 
een verbetering in uitkomst op het gebied van sterfte, heropnames en kwaliteit van leven. 
Het streven naar maximale doseringen medicatie is daarom opgenomen in de richtlijnen 
voor het behandelen van HF-patiënten en vormt een belangrijk onderdeel van disease 
management. De mate van voorschrijfgedrag van de behandelaar is al in de EuroHeart 
failure Survey 2003 beschreven als een voorspeller op het gebied van mortaliteit en 
heropnames en is een indicator voor het succes van een HF-disease management model. 
HF-verpleegkundigen en cardiologen ondervinden bij het toepassen van deze 
richtlijn in de  praktijk echter nog steeds moeilijkheden. In hoofdstuk 8 is de mate van 
voorschrijfgedrag van de behandelaar in drie verschillende HF-disease management 
modellen onderzocht. Namelijk in een model waarbij een HF-verpleegkundige een 
centrale rol speelt, in een model waarbij een CDSS is gebruikt voor de behandeling, en 
in een model met een combinatie van een arts en een HF-verpleegkundige. In alle drie 
de onderzochte modellen blijkt dat de individuele dosis medicatie niet meer dan 50% 
bedraagt van wat maximaal kan worden voorgeschreven en wordt geadviseerd door de 
richtlijn. Patiëntkenmerken zoals leeftijd, co-morbiditeit en de ernst van de ziekte  leiden 
niet alleen tot frequente heropnames, maar zijn ook de factoren die ervoor zorgen dat de 
patiënt niet de maximale dosering medicatie krijgt. Het werken met een CDSS dat speciaal 
ontworpen is voor het starten en het optitreren van medicatie kan een bijdrage leveren aan 
het voorschrijven van maximale doseringen medicatie. Het is veilig te gebruiken en kan 
worden toegepast door HF-verpleegkundigen die een belangrijke verantwoordelijkheid 
hebben in het zorgen voor een optimale medicamenteuze behandeling, als onderdeel van 
een HF- disease management programma.
Wat draagt dit proefschrift bij aan de al bestaande onderzoeken over voorschrijfgedrag van 
de behandelaar (prescriber adherence):
1. De totale percentages voorgeschreven medicatie (ACE-remmers, bètablokkers, 
aldosteron antagonisten) zijn hoog in alle onderzochte hartfalen disease 
management modellen. Echter, minder dan 50% van alle patiënten gebruiken een 
maximale dosering ondanks het feit dat twee hartfalen-modellen gericht zijn op het 
optimaliseren van medicatie.
2. Er is een significante relatie tussen de ernst van de ziekte hartfalen (onder andere in 
heropnames en de fysieke conditie van de patiënt) en de voorgeschreven dosering 
medicatie in individuele patiënten. Dit betekent dat een substantieel deel van de 
onderzochte patiënten de voor hun optimale dosering gebruikt. 
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3. Een disease management model met een CDSS blijkt net zo effectief te zijn in 
termen van voorschrijfgedrag van de behandelaar, als een model met een arts, op 
enkele waargenomen verschillen in doseringen ACE-remmers en bètablokkers na. 
Conclusie
Dit proefschrift toont aan dat innovatieve  informatie- en communicatietechnologieën 
zoals telemonitoring (TM) en computer beslissingsondersteunende systemen (CDSS) 
veelbelovende instrumenten zijn die kunnen helpen om zorgverleners te ondersteunen in 
het verbeteren van zorg voor hartfalen patiënten. TM en CDSS kunnen patiëntgegevens 
overbrengen vanuit de thuissituatie van patiënten naar een zorgverlener. Met behulp 
van deze patiëntendata is de zorgverlener in staat gegevens te interpreteren en daarop te 
handelen. 
In de praktische toepassing van evidence based richtlijnen kan een CDSS helpen bij het 
maken van de juiste klinische beslissingen. TM en CDSS zijn echter geen ‘one size fits 
all’ oplossingen. Dit proefschrift laat zien dat het inzetten van TM niet automatisch leidt 
tot vermindering van heropnames, sterfte en verbetering van kwaliteit van leven. Het 
ontbreken van specifieke profielen van patiënten die het meest baat hebben bij TM speelt 
hierbij een rol. De moeilijkheid in het gebruik van CDSS ligt voornamelijk in de praktische 
ervaren barrières, die weer leiden tot het risico van een laag gebruik en een slechte 
acceptatie. Om dit risico om te buigen naar een positieve en succesvolle  implementatie 
moeten we niet alleen onze zorgvragers/patiënten monitoren en behandelen maar ook 
de zorgverleners. Hierbij essentieel zijn goede afspraken over het praktische gebruik van 
TM en CDSS, het vaststellen van patiëntenprofielen, behandeldoelen, interventies en 
continue evaluatie en zo nodig het bijstellen van de behandeldoelen. 
Het besef van het potentieel van TM en CDSS en de noodzaak tot innovatie in de 
Nederlandse gezondheidszorg, in het bijzonder voor hartfalen, leidt tot een interessante 
uitdaging die ons zal dwingen tot verandering in vele verschillende aspecten van onze 
gezondheidszorg.
Dankwoord
Arjen E. de Vries
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‘Geen Promotie zonder hulp van en samenwerking met anderen’
Gedurende mijn aanstelling als promovendus in de periode van mei 2009 tot mei 
2013 hebben vele personen substantieel bijgedragen aan het tot stand komen van dit 
proefschrift. Graag wil ik ze daarom hier persoonlijk bedanken.
Prof. dr. Hillege, beste Hans. Ik heb onze samenwerking als zeer constructief en plezierig 
ervaren. Je ‘open-door-policy’ gaf mij letterlijk de ruimte om regelmatig even met je 
te overleggen of te sparren. Je begeleiding is in alle opzichten professioneel en vooral 
leerzaam geweest. Dankzij jou is het mij gelukt om deze thesis binnen de gestelde termijn 
af te ronden. Daarvoor ben ik je veel dank verschuldigd. Ik wens je veel succes met je 
nieuwe baan en hoop van harte dat we in de toekomst contact houden. In antwoord op je 
vraag of ik het weer opnieuw zou doen, zeg ik: ‘Ja, mits jij weer mijn promotor zou zijn’. 
Prof. dr. Jaarsma, beste Tiny. We kenden elkaar al lang voordat ik in 2009 onder je 
deskundige begeleiding mocht starten met mijn promotietraject. Tijdens mijn sollicitatie 
gesprek wierp je als eerste een eerdere uitspraak van mij (‘Ik ga nooit promoveren’; 
CCNAP, Glasgow 2001) voor mijn voeten. Toen wist ik al dat ik het met jou zou gaan 
redden. Met jou mogen samenwerken is voor iedere promovendus een plezier, zelfs op 
afstand! Je heldere blik op situaties waarbij ik dacht vast te zitten, je analytisch vermogen 
en vooral je gevoel voor humor hebben mij erg geholpen. Mijn dank!
Prof. dr. Jorna, beste Rene, Wij hebben elkaar ontmoet nadat ik al een jaar op weg was. 
Op zoek naar expertise op het gebied van CDSS en het menselijk gedrag kwamen we 
al snel bij jou terecht. Zoek niet ver wat dicht bij huis is! Je hebt mij op verschillende 
gebieden erg geholpen. Je aandacht voor methodiek en theoretisch kader hebben ervoor 
gezorgd dat ik onze artikelen kon submitten. Naast je deskundigheid heb je een warme 
persoonlijkheid met aandacht voor de menselijke kant van het leven die ik zeer op prijs 
heb gesteld. Ik ben zeer vereerd dat je mijn derde promotor wilde zijn en ik wens je het 
allerbeste toe. 
Dr. van der Wal, beste Martje. Als Co-promotor sta je meestal wat dichter bij de 
promovendus. Dat was ook zo in ons geval. Zo hebben we het meest samengewerkt in 
de praktische uitvoering van mijn onderzoeken en het tot stand komen van publicabel 
waardige artikelen. In dit proces hebben we ook lastige momenten gekend maar onze 
samenwerking is altijd constructief gebleven. Mede dankzij jouw hulp ben ik in staat 
geweest om een aantal fraaie artikelen te produceren en mijn promotietraject succesvol 
af te ronden. Daarvoor wil ik je hartelijk danken. “Het wordt er altijd beter van”, en dat 
is waar!
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Ook de Beoordelingscommissie, bestaande uit prof. dr. Crijns, Prof. dr. Bilo en Prof. dr. 
Schrijvers, wil ik hartelijk bedanken voor het zorgvuldig lezen van mijn thesis en hun 
waardevolle commentaren. Ik ben zeer vereerd met uw goedkeuring.
Prof. dr. van Veldhuisen, beste Dirk Jan, graag wil ik je bedanken voor de gelegenheid te 
mogen promoveren onder jouw leiding op de afdeling cardiologie van het Thoraxcentrum 
van het Universitair Medisch Centrum Groningen. 
Dr. de Jong, beste Richard. Als Co-promotor in de beginfase van mijn promotie heb 
je me vaak geholpen met praktische oplossingen en ideeën om onderzoek op te zetten. 
Helaas moest je na een jaar het co- promotorschap opgeven vanwege het aanvaarden van 
een nieuwe baan elders.
Dr. van Dijk, beste Rene, wij hebben samen al langer een bijzondere band. Mede dankzij 
jou ben ik op deze promotieplek terecht gekomen, zelfs na een eerdere poging van jou 
daartoe in Amsterdam. Kennelijk had je voldoende vertrouwen in me dat ik ooit een 
goede doctor zou worden! We hebben in het verleden samen interessante projecten 
gedaan en ik hoop dat in de toekomst nog vaker met je te mogen doen, Bedankt!
Dr. Johansson, dear Peter, we met in my first year, where you kept us promovendi 
company on the fourth floor and learned us all about Swedish coffee breaks. Later it 
turned out that we had more in common than we initially thought. Our passion for 
nocturnal discussions in company of a bottle of Southern Comfort brought me, beside a 
major hangover, new insight in my telemonitoring article and at the end led to successful 
visit to the Medical University of Linkoping, Sweden. I wish you success in your career to 
a full professorship and hope to keep in touch.
Vincent van Deursen en Meint Roosjen, mijn paranimfen. Beste Vincent, jij bent voor 
mij van onschatbare waarde geweest gedurende mijn promotietraject. Je kennis van 
statistische toetsen en data-analyse is ongekend. Deze kennis - samen met je gave om 
moeilijke zaken tot iets heel simpels te reduceren en dat vervolgens ook nog eens goed 
uit te leggen - geeft je een schat in handen. Je moet het alleen zelf nog leren zien! Jij zult 
een prima cardioloog worden maar behoud je aandacht voor de menselijke aspecten van 
een ziekte. Beste Meint, onze loopbanen kruisen elkaar al sinds de jaren ‘90 telkens weer. 
Samen in de Heart Beats voor een volle zaal op het Millennium:, jij op de gitaar en ik 
Franse kaasjes kauwend op de basgitaar. Op de racefiets naar het Teutoburgerwald, en 
nu onze nieuwe hobby: het brouwen van bier. Je bent de afgelopen jaren een grote steun 
voor me geweest, als een baken in onrustige wateren. Ik ben er trots op dat jullie mijn 
paranimfen zijn.
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Mijn collega’s in het ‘zorgonderzoek’; beste Maurice, Thialda, Imke en Maaike en Marie-
Louise. Inmiddels zijn we bijna allemaal uitgevlogen. Imke, mijn kamergenoot in de 
afgelopen vier jaren: ik hoop dat je een mooie nieuwe arbeidsplek krijgt, die verdien je! 
Thialda, Maaike en Marie-Louise, dank voor jullie hulp en gezelligheid. Maurice, voor 
jou een speciaal dankwoord: Als medeauteur bij vier van mijn zeven artikelen heb je een 
meer dan substantiële bijdrage geleverd aan het tot stand komen van mijn thesis. Het is 
grappig te zien dat jij het werkveld in bent gerold waar ik uit kwam toen ik begon; de EPD 
wereld. Ik wens je veel succes met je verdere carrière en geloof me: ooit zal Feyenoord 
weer landskampioen worden.
Graag wil ik ook mijn collega-onderzoekers van de eerste verdieping bedanken die 
hebben bijgedragen aan een gezellige promotietijd. Ontspanning en gezelligheid is 
onontbeerlijk tijdens een promotieonderzoek. Bart, Wouter, IJsbrand, Frank, Nicolas, 
Lennaert, Sven, Mattia, Licette, Chris, Marieke, Marlies, Ernaldo, Rob, Marjolein, 
Ymkje, Hendrik, Rosanne, Rogier, Wouter. Jullie waren geweldig! Ook de mensen van de 
Cardio Research wil ik bedanken voor hun prettige samenwerking: Geert, Peter, Trienke, 
Margriet, Carolien, Carlien, Maaike, Karin, Saphirah, Anja, Carla, Greetje en Bernard.
Tenslotte wil ik van het Trial Coördination Centre (TCC) graag in het bijzonder 
Janneke, Olga, Marco, Suzette, Hedde, Anne-rixt, Diana en Petra bedanken voor hun 
inzet en hulp rondom de IN TOUCH en TRIUMPH studie. Beste Ivonne, jij hebt mij in 
vele opzichten erg geholpen. Ik kijk met veel plezier terug op onze samenwerking en zal 
onze laboratoriumbezoeken missen.
Beste Alma en Audrey, hartelijk dank voor jullie hulp en advies in de laatste maar zeker 
niet onbelangrijkste fase van het afronden van mijn proefschrift
Lieve ouders en broer, Ger, Adri en Geerhard. Nu is mijn promotietraject ten einde en 
begin ik weer aan een nieuwe fase. Jullie steun, hulp en onvoorwaardelijk vertrouwen in 
een goede afloop hebben ervoor gezorgd dat ik er ook vertrouwen in hield. Dat is in de 
vele fasen van mijn onderzoek een enorme steun geweest. Geen standbeeld zonder een 
solide fundament! 
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Lieve Elisa en Carmen, nu is jullie vader bijna doktor maar geen dokter. Het blijft lastig 
hé? Ik hoop dat jullie je met net zoveel warme en behulpzame mensen mogen omringen 
als dat ik dat heb mogen ervaren bij het schrijven van dit boek. Dan krijgen jullie nog een 
mooie toekomst, ik ben trots op jullie!
Tenslotte, lieve Monique. Wat moet ik zeggen? Elke letter op papier doet tekort aan wat 
wij samen hebben en woorden drukken dat dus al helemaal niet uit. Jij leerde me: 
wat overbodig is; niet doen. 
en ja, vanaf aanstaande maandag zal ik de vuilnis weer buiten zetten.
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Deelnemende patiënten en Ziekenhuizen 
Medisch wetenschappelijk onderzoek is niet mogelijk zonder patiënten die bereid zijn 
om hun tijd en energie te geven aan onderzoek. Dankzij deze patiënten hebben we een 
klein stukje van het vraagstuk telemonitoring kunnen verhelderen. Ik wil daarom in het 
bijzonder alle patiënten hartelijk danken die volstrekt belangeloos hebben meegewerkt 
aan de IN TOUCH studie. Daarnaast wil ik graag alle Nederlandse hartfalen klinieken 
bedanken welke hebben meegewerkt aan 1 of meerdere onderzoeken van dit proefschrift, 
in het bijzonder: het Antonius Ziekenhuis Sneek, Catharina Ziekenhuis Eindhoven, 
Canisius-Wilhelmina Ziekenhuis Nijmegen, het Deventer Ziekenhuis,  Diakonessen 
Ziekenhuis Utrecht, HAGA Ziekenhuis Den Haag, Martini Ziekenhuis Groningen, 
Medisch Centrum Leeuwarden,  Rijnland ziekenhuis Leiderdorp en  het UMC Groningen.
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Arjen de Vries is geboren op 7 augustus 1968 in Groningen, Nederland. In 1986 behaalde 
hij zijn middelbare school diploma, waarna hij zijn militaire dienstplicht  vervulde op de 
polikliniek Geneeskundige Dienst van de luchtmachtbasis Leeuwarden.
In 1988 ging hij als verpleegkundige in opleiding werken op verschillende afdelingen van 
het Diaconessen Ziekenhuis Groningen (nu Martini Ziekenhuis). In zijn laatste studiejaar 
volgde hij tevens de Coronary Care (CCU) opleiding op de afdeling Cardiologie, waar hij 
tot 1996 bleef werken. Na een uitstapje naar onderwijs en de ondernemingsraad ging hij 
in 1998 naar de Polikliniek Cardiologie, waar hij verantwoordelijk was voor het opzetten 
en uitvoeren van een ‘nieuwe stijl’ Hartfalen en Preventie Polikliniek voor patiënten met 
hart en vaatziekten. Daar ontstond ook zijn interesse voor reorganisatie van zorgprocessen 
met ondersteuning van ICT in combinatie met taakherschikking. In 2001 volgde hij de 
Master Advanced Nursing Practice te Groningen.
In de periode 2006 tot 2009 werkte hij als consultant bij Pink Roccade, Getronics, Kader 
Software en Curit B.V., waarbij hij verschillende toepassingen van ‘Health Information 
Technology’ implementeerde in Nederlandse ziekenhuizen.  In 2007 was hij direct 
betrokken bij de oprichting van Cavari Clinics, een centrum voor cardiovasculaire 
aandoeningen. In de jaren daarna bleef hij bij Cavari Clinics werkzaam, waarbij het zijn 
uitdaging was om - samen met dr. Rene van Dijk, cardioloog - vorm te geven aan het 
inzicht dat het verlenen van (cardiologische) zorg veel beter en efficiënter kan met behulp 
van ICT. Een belangrijke component van deze efficiëntere zorg was de inzet van computer 
decision support systemen en telemonitoring. Voor de ontwikkeling en toepassing van 
‘slimme’ ICT in combinatie met taakherschikking ontvingen Arjen de Vries en Rene van 
Dijk meerdere onderscheidingen en Awards.
Van 2001 tot 2008 was Arjen de Vries tevens voorzitter van de Nederlandse Vereniging 
van Nurse Practitioners en hij liet zich in 2009, na invoering van de nieuwe BIG wetgeving 
voor Verpleegkundig Specialisten, als één van de eerste Nurse Practitioners registreren 
als Verpleegkundig Specialist preventieve zorg.  In 2012 volgde een tweede registratie 
voor intensieve zorg.
In Mei 2009 startte hij zijn promotietraject aan de Faculteit der Medische Wetenschappen 
van de Rijksuniversiteit Groningen met dit proefschrift als resultaat. De promotie  is 
uitgevoerd op de Afdeling cardiologie van het Thoraxcentrum van het Universitair 
Medisch Centrum Groningen, onder leiding van Professor dr. D.J. van Veldhuisen. 
Momenteel is Arjen de Vries werkzaam als Verpleegkundig Specialist cardiologie in 
het Centrum voor Revalidatie ‘Beatrixoord’ in Haren en is hij vicevoorzitter van het 
Nederlands Netwerk voor Verpleegkundig Specialisten cardiologie.


